,ticker,content
0,PKI,welcome move perkinelmer pki see relative strength rating improve thursday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price performance worst best score rating show stock price behavior last week hold other stock database decade market research reveal best perform stock often have better rs rating launch largest price move see perkinelmer continue show renew price strength hit benchmark see ibd help make more money be build consolidation entry see clear price heavy volume keep mind later stage consolidation be riskier earlier stage pattern company bottom line growth decline last quarter top line rise previous report perkinelmer earn rank peer medical research equipment service industry group medpace medp illumina ilmn icon iclr be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
1,PKI,important metric look stock be higher relative strength rating perkinelmer pki just hit mark jump wednesday unique rating measure technical performance used worst best score identify stock price action trail week match rest market decade market research reveal market biggest winner often have rs rating early stage move look winning stock try simple be still buy range climb entry cup handle proper buy range extend initial entry once stock hit benchmark best hold investing set buy opportunity perkinelmer see earning sale growth rise last quarter earning share increase revenue rise company earn rank peer medical research equipment service industry group pra health science prah quintile im illumina ilmn be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
2,PKI,bean counter keep book man green eyeshade make investment grow cpa trained jim tringas co lead manager well fargo special small cap value fund espax sure diversify stock mutual fund business entire decade end dec track morningstar inc only manage beat past year fund be ibd best mutual fund award winner special small cap value be fund be just year date go thursday be run ahead small cap value peer stock market environment now favore large cap growth stock tringas co manager know count such slack time have proven way handle key success be not try hit home run tringas say just try get base maybe hit single maybe draw walk then just try get second base then third then home not give lot run tringas say fund focus winning do lot little thing right stem training fellow co lead manager bryant vancronkhite share start certify public accountant cpa background have more conservative cautious approach most fund manager tringas say so don take lot risk don take shareholder harrowing ride aim performance time do way beat peer benchmark less volatility many other fund get end point nicer ride co manager robert rifkin share approach not have cpa background take look top performer top holding novanta novt make photonic motion control system be dst system dst make software financial service industry be container manufacturer silgan holding slgn be tringas be turn have manage well fargo special small cap value talk ibd investment approach office boston ibd do special fund name refer tringas get question lot fund be set word be used lot be originally part evergreen fund family get acquire first union acquire company already have fund name small cap value so couldn drop special well fargo then acquire now speak ask special stock re consider buy code competitive advantage special sauce second thing look be recur free cash flow third thing look be flexible balance sheet mean re underleveraged look company low debt use financial flexibility create value create shareholder return invest organically new plant technology platform enable improve work capital increase margin time ibd be key fund consistent outperformance tringas come focuse thing ve discuss portfolio construction pay attention risk risky environment distinguish have portfolio company be high quality generate lot free cash flow carry little debt be company investor want buy market sell company hold much better market sell operate position strength usually outperform market ibd let talk thesis interesting holding latest disclosure ve be build share count central garden pet cent several disclosure attraction tringas turnaround year go nowhere management team come go have excited be be not capital intensive end market have seasonality be attractive management today have improve distribution rationalized number product bring potential barely make money year make share company fix inefficiency have more ability create value not say current price awesome have lower cost basis ibd ve also add stake novanta be tringas make laser laser base system machine cut tool high precision surgical application work customer create tool customer so be essentially sole source supplier thing wear get follow order also top management come perkinelmer pki medical research equipment company so novanta begin tilt medical care market be less cyclical nonmedical care market now revenue be medical end market other end market model show be still substantial opportunity continue value create strategy ibd executive headhunter korn ferry kfy be yet name ve add do tringas have great relationship executive ve help place fortune company natural serve now ve do smart job diversify consult type business provide more recur revenue core executive recruit more stable cash flow get more access cheaper borrow so have more opportunity create value flexible balance sheet risk be get recession executive recruit business be hard hit ibd take korn ferry rank ibd commercial service staffing industry group top notch smr rating ibd mean be top stock term sale growth profit margin return equity ratio see additional easy understand fundamental technical datum stack rival ibd stock checkup ibd dsp group dspg be small designer wireless chipset be play overlooked gem tringas re not anyone radar screen re run israeli management team have phenomenal balance sheet have lot new product believe be target mobile phone wearable device include speech recognition audio technology be unique valuable re profitable now extent monetize new market be even more interesting ibd mueller industry mli make copper brass tube hvac refrigeration plumbing market sex appeal tringas re not sexy just make money product go residential nonresidential end market economy grow give take good enough let grow earning paid special dividend share march so re good steward capital reward long term shareholder be infrastructure create demand thing sell ibd earning share growth associate banc asb have accelerate quarters row else do tringas ceo be phil flynn sell union bank own believe know turn franchise come company be verge failure do better believe company be sell have idea likely buyer be canadian bank associate be upper midwest give foothold ibd atkore international group atkr construction product maker be newcomer portfolio play tringas have similar end market mueller also have mechanical product service division generate enormous amount cash flow company come private equity generally be well run go public still have discipline company don have flexible balance sheet have enough free cash flow continue deliver add value shareholder time be reasonably price ibd hancock hold hbhc ep grow past quarters be rebound story bank expose energy company tringas be southeastern bank exposure energy oil go barrel have issue risky nonperforming loan oil have come back nonperforming loan book be lot lot company shore balance sheet equity offering ibd jim often do talk buy sell team tringas be ad conversation initiate analyst come say stock be get rich risk reward ratio be tell need cut weight doesn mean ll do talk have regular weekly meeting thursday discuss buy sell amazing much macro conversation happen bottom guy related blue chip tech name help fuel red hot fundfidelity talk super bowl super stock
3,PKI,high tech instrument maker dhr report soft guidance early thursday send stock tumble nearly morning trading stock market today earning share rise year earlier quarter cent include cent tax gain sale security analyst consensus call cent sale rise
4,PKI,share perkinelmer pki jump year high morning trading friday day scientific equipment maker beat expectation late thursday company report make cent share quarter year earlier quarter beating analyst consensus cent sale rise estimate
5,PKI,stock remain mixed narrowing tighter range quiet trade midday friday market track healthy gain week
6,PKI,dow jone industrial average trade be nasdaq improve loss volume be nasdaq lower nyse
7,PKI,stock market today receive mixed send first quarter gdp growth improve much less expect final read april consumer sentiment improve sharply initial estimate industry group track ibd be trading lower midday
8,PKI,stock penney jcp horton dhi lead morning session respectively medical scientific equipment maker perkinelmer pki drop score index worst loss deliver weak first quarter report
9,PKI,ibd list rental car competitor avis budget group car hertz global holding htz catch fire avis more hertz grab gain
10,PKI,move drive avis just april high thick trade rebound support day move average hertz be also just april high hasn come day line february
11,PKI,new issue drugmaker abbvie abbv jump new high putt share january open price spinoff abbott laboratory narrowly top sale earning expectation quarter reiterate full year guidance be low end analyst consensus view
12,PKI,baidu bidu stumble loss result miss analyst consensus forecast
13,PKI,chipmaker maxim integrate product mxim shed report fiscal third quarter result late thursday earning rise better expect sale growth top projection fourth quarter sale earning guidance be line consensus estimate
14,PKI,stock have be shallow consolidation struggle hold week support mid march stock remain mixed narrowing tighter range quiet trade midday friday market track healthy gain week dow jone industrial average trade be nasdaq improve loss volume be nasdaq lower nyse stock market today receive mixed send first quarter gdp growth improve much less expect final read april consumer sentiment improve sharply initial estimate industry group track ibd be trading lower midday stock penney jcp horton dhi lead morning session respectively medical scientific equipment maker perkinelmer pki drop score index worst loss deliver weak first quarter report ibd list rental car competitor avis budget group car hertz global holding htz catch fire avis more hertz grab gain move drive avis just april high thick trade rebound support day move average hertz be also just april high hasn come day line february new issue drugmaker abbvie abbv jump new high putt share january open price spinoff abbott laboratory narrowly top sale earning expectation quarter reiterate full year guidance be low end analyst consensus view baidu bidu stumble loss result miss analyst consensus forecast chipmaker maxim integrate product mxim shed report fiscal third quarter result late thursday earning rise better expect sale growth top projection fourth quarter sale earning guidance be line consensus estimate stock have be shallow consolidation struggle hold week support mid march
15,PKI,share illumina ilmn gap month high stock market tuesday gene sequence firm beat estimate late monday lead several analyst hike price target
16,PKI,company say profit rise year quarter cent share beating analyst consensus cent exclude time legal charge sale climb more consensus do not however raise full year guidance
17,PKI,credit suisse cantor fitzgerald isi group raise price target stock tuesday move blow past illumina share be late morning trading
18,PKI,isi ross muken write be maintain hold rating await better entry point call quarter impressive note growth manifest variety product line geography
19,PKI,muken also note upcoming catalyst year be resolution budget battle austerity measure europe well impact illumina recent buyout prenatal testing firm verinata lead partnership perkinelmer pki
20,PKI,illumina be first several maker life science instrument report earning week early tuesday water corp miss profit estimate stock rise more anyway miss be mainly due weak japanese yen accord muken
21,PKI,thermo fisher scientific tmo be process buy illumina competitor life technology life be schedule report early wednesday analyst be expect steady unspectacular growth new ibd member profit share sale rise share illumina ilmn gap month high stock market tuesday gene sequence firm beat estimate late monday lead several analyst hike price target company say profit rise year quarter cent share beating analyst consensus cent exclude time legal charge sale climb more consensus do not however raise full year guidance credit suisse cantor fitzgerald isi group raise price target stock tuesday move blow past illumina share be late morning trading isi ross muken write be maintain hold rating await better entry point call quarter impressive note growth manifest variety product line geography muken also note upcoming catalyst year be resolution budget battle austerity measure europe well impact illumina recent buyout prenatal testing firm verinata lead partnership perkinelmer pki illumina be first several maker life science instrument report earning week early tuesday water corp miss profit estimate stock rise more anyway miss be mainly due weak japanese yen accord muken thermo fisher scientific tmo be process buy illumina competitor life technology life be schedule report early wednesday analyst be expect steady unspectacular growth new ibd member profit share sale rise
22,PKI,new analyst report cowen co offer upbeat assessment medical research equipment stock ahead first quarter earning thank improve end market
23,PKI,report life science diagnostic tool sector tuesday analyst doug schenkel write most company be poise meet beat expectation
24,PKI,expectation combine confidence build forward look commentary positive update end market help share price sector recover recent slump schenkel add
25,PKI,company reckon be best position beat estimate be fluidigm fldm illumina ilmn myriad genetic mygn orasure technology osur perkinelmer pki thermo fisher scientific tmo
26,PKI,fluidigm belong ibd medical system equipment group rank industry track illumina myriad perkinelmer thermo fisher be ibd medical research equipment service group rank orasure be medical product group rank
27,PKI,stock myriad have highest ibd composite rating be follow illumina perkinelmer thermo fisher orasure fluidigm
28,PKI,myriad have have best stock action late reach year high friday share be more begin year
29,PKI,company life science diagnostic tool benefit growth most end market schenkel say
30,PKI,coverage universe include major customer end market academic government industrial apply biopharma healthcare hospital
31,PKI,have be show improvement say
32,PKI,base check management commentary past few month continue believe academic government end market be stable improve schenkel note
33,PKI,industrial cyclical end market not be improve quickly hope say be encourage sign
34,PKI,remain enthused outlook improve end market favorable comparison drive continue relative outperformance schenkel write
35,PKI,related myriad tata motor rs leader correction new analyst report cowen co offer upbeat assessment medical research equipment stock ahead first quarter earning thank improve end market report life science diagnostic tool sector tuesday analyst doug schenkel write most company be poise meet beat expectation expectation combine confidence build forward look commentary positive update end market help share price sector recover recent slump schenkel add company reckon be best position beat estimate be fluidigm fldm illumina ilmn myriad genetic mygn orasure technology osur perkinelmer pki thermo fisher scientific tmo fluidigm belong ibd medical system equipment group rank industry track illumina myriad perkinelmer thermo fisher be ibd medical research equipment service group rank orasure be medical product group rank stock myriad have highest ibd composite rating be follow illumina perkinelmer thermo fisher orasure fluidigm myriad have have best stock action late reach year high friday share be more begin year company life science diagnostic tool benefit growth most end market schenkel say coverage universe include major customer end market academic government industrial apply biopharma healthcare hospital have be show improvement say base check management commentary past few month continue believe academic government end market be stable improve schenkel note industrial cyclical end market not be improve quickly hope say be encourage sign remain enthused outlook improve end market favorable comparison drive continue relative outperformance schenkel write related myriad tata motor rs leader correction
36,PKI,vision tenacity futuristic idea become reality firm drive ultramodern advance mainstream aim higher imagine live healthily past year age endgame ceo kevin hrusovsky see caliper life science calp have great purpose revolutionize medicine health care tell ibd caliper arm scientist
37,PKI,gene sequence instrument now spit so much datum researcher be turn cloud compute handle load lift outlook provider such service
38,PKI,perkinelmer pki maker scientific instrument be such company expand service business recently acquire geospiza provider lab software cloud base genomic datum service
39,PKI,perkinelmer aim provide more storage analysis service cloud faster less costly instrument let more lab sequence dna
40,PKI,have be lot datum generate say dan marshak perkin elmer chief scientific officer be early day
41,PKI,tip point high volume sequence come few year company such illumina ilmn life technology life release next generation sequence instrument
42,PKI,new technology sequence entire human genome now be do several day compare million dollar several month year
43,PKI,researcher also demand datum redundancy ensure don miss single gene so individual genome be typically sequence time further add datum pile
44,PKI,lower barrier entry afford new instrument have result amount genomic datum quintuple year
45,PKI,datum wave occur say paul knight analyst investment firm clsa cloud be essential
46,PKI,more advanced instrument
47,PKI,scientific instrument become more advanced instrument maker be grow pressure provide more datum analysis cloud access help customer cope volume datum generate knight say
48,PKI,emerge issue say
49,PKI,illumina few year begin offer server storage service package manage customer sequence datum reportedly be plan cloud service well
50,PKI,cloud have challenge be evident cloud service offer amazon com amzn have several day outage late april knock big website such foursquare commission period time incident lessen cloud appeal scientist already nervous hand precious datum
51,PKI,lack storage analysis service genomic datum isn only issue lab face similar datum problem research protein human cell
52,PKI,next generation instrument likely only worsen problem sequence technology advance faster compute technology
53,PKI,just store datum cloud isn enough order be used effectively datum be analyze present easy use way especially group person share access
54,PKI,vendor provide experience simple environment be go be able capture large share market doubt say michael schatz professor cold spring harbor lab clsa industry forum year
55,PKI,dna analysis often key
56,PKI,ease use grow importance more researcher delve dna sequence first time due part say perkinelmer drug development increasingly require dna protein analysis
57,PKI,part cloud base service perkinelmer do initial analysis work well walk researcher process sequence dna say dick begley company president emerge technology
58,PKI,interactively coach say
59,PKI,university florida center biotechnology research have used geospiza first software then cloud service start datum wave begin build
60,PKI,center provide sequence service researcher university elsewhere didn want devote own staff build more efficient user interface say william farmerie center associate director emerge science
61,PKI,need make access datum convenient possible say have row datum spreadsheet mind numbing
62,PKI,cloud base service also let researcher reorganize datum way want rather center have produce custom make product individual request say
63,PKI,still cloud compute not be cure research center datum issue farmerie say also consider add more server
64,PKI,look possible solution get hand say gene sequence instrument now spit so much datum researcher be turn cloud compute handle load lift outlook provider such service perkinelmer pki maker scientific instrument be such company expand service business recently acquire geospiza provider lab software cloud base genomic datum service perkinelmer aim provide more storage analysis service cloud faster less costly instrument let more lab sequence dna have be lot datum generate say dan marshak perkin elmer chief scientific officer be early day tip point high volume sequence come few year company such illumina ilmn life technology life release next generation sequence instrument new technology sequence entire human genome now be do several day compare million dollar several month year researcher also demand datum redundancy ensure don miss single gene so individual genome be typically sequence time further add datum pile lower barrier entry afford new instrument have result amount genomic datum quintuple year datum wave occur say paul knight analyst investment firm clsa cloud be essential more advanced instrumentsas scientific instrument become more advanced instrument maker be grow pressure provide more datum analysis cloud access help customer cope volume datum generate knight say emerge issue say illumina few year begin offer server storage service package manage customer sequence datum reportedly be plan cloud service well cloud have challenge be evident cloud service offer amazon com amzn have several day outage late april knock big website such foursquare commission period time incident lessen cloud appeal scientist already nervous hand precious datum lack storage analysis service genomic datum isn only issue lab face similar datum problem research protein human cell next generation instrument likely only worsen problem sequence technology advance faster compute technology just store datum cloud isn enough order be used effectively datum be analyze present easy use way especially group person share access vendor provide experience simple environment be go be able capture large share market doubt say michael schatz professor cold spring harbor lab clsa industry forum year dna analysis often keyease use grow importance more researcher delve dna sequence first time due part say perkinelmer drug development increasingly require dna protein analysis part cloud base service perkinelmer do initial analysis work well walk researcher process sequence dna say dick begley company president emerge technology interactively coach say university florida center biotechnology research have used geospiza first software then cloud service start datum wave begin build center provide sequence service researcher university elsewhere didn want devote own staff build more efficient user interface say william farmerie center associate director emerge science need make access datum convenient possible say have row datum spreadsheet mind numbing cloud base service also let researcher reorganize datum way want rather center have produce custom make product individual request say still cloud compute not be cure research center datum issue farmerie say also consider add more server look possible solution get hand say
65,PKI,consumer buy shiny new apple aapl ipad business buy state art manufacturing system don see be take be make scene work be perform company public have never hear case re talk company list thursday ibd electronic tech leader stock screen
66,PKI,federal antitrust regulator jan approve thermo fisher scientific tmo acquisition laboratory equipment maker dionex dnex thermo fisher last year sell more scientific test equipment service dionex specialize chromatography system allow lab separate measure component complex chemical mixture thermo fisher aim close
67,PKI,update loss be broad base financial pressed back class news regulator delay promise quick fix so call toxic asset hold many bank other institution
68,PKI,nyse composite end flat nasdaq composite edge ever so slightly lower week dow clip decline
69,PKI,citigroup lead dow downside juniper network jnpr fall hardest nasdaq juniper be also loss leader worsted only fifth third bancorp fitb
70,PKI,be tough day someone forget tell amazon com amzn gap gain late thursday online retailer say book earning sale well analyst view other component flowserve fls paccar pcar jump heavy trading
71,PKI,next week monday promise be busy day economic datum commerce release personal income spending construction spending datum december institute supply management put index general gauge outlook corporate buyer
72,PKI,monday earning calendar include be aerospace beav corn product international cpo sysco syy prior open independent oil gas heavyweight anadarko apc sandisk sndk athero communication athr check close
73,PKI,update higher volume loss threaten stock rally
74,PKI,juan carlos arancibia
75,PKI,market close session lows friday broad decline
76,PKI,tumble nasdaq nyse composite dow accord early number
77,PKI,volume rise give market distribution day come just day market follow selling put market rally serious doubt
78,PKI,financial slide report plan remove bad asset bank balance sheet be peril
79,PKI,steel other metal stock also weaken goldman sachs analyst give bearish outlook steel maker downgrade steel other
80,PKI,update dow head week
81,PKI,alan elliott
82,PKI,index be choppy remain session lows late trading
83,PKI,slump nyse composite nasdaq dow give respectively
84,PKI,dow slip loss week head final hour trading nyse nasdaq hold fractional gain vs last friday close
85,PKI,volume be tracking higher loss continue be broad decline issue lead advancer better nyse nearly nasdaq
86,PKI,commodity continue generally lower oil price remain just barrel hold morning gdp number implication further decline demand
87,PKI,teleflex international tfx pop provide guidance line analyst consensus diversify engineering service provider put full year ep vs estimate company plan report result feb
88,PKI,update index dive volume rise
89,PKI,patrick
90,PKI,market attempt get back break even end stock take sharp turn downward sink intraday lows
91,PKI,dow fall nyse composite nasdaq sank
92,PKI,volume be higher board indicate institutional selling
93,PKI,financial dove government bad bank rescue idea have hit snag asset valuation problem accord report cnbc
94,PKI,ruddick rdk supermarket operator gap fall company report earning late thursday show profit fall penny cent share stock pare much loss however
95,PKI,proctor gamble pg be lower full year outlook add sale quarter possibly rest year fall company be often thought recession resistant
96,PKI,perkinelmer pki maker genetic screening environmental analysis tool gap lose company say expect profit fall year range midsingle digit midteen stock hit year low
97,PKI,update index climb lows stick decline
98,PKI,alan elliotta mixed spate earning report stir choppy trading session
99,PKI,nyse composite nasdaq dow be lower dip index have trim loss
100,PKI,only banking financial biotech index nasdaq be sector post deepest loss exchange juniper network jnpr broadcom brcm continue rack heavy loss
101,PKI,midcaps fall further putt
102,PKI,volume remain shifty rise nasdaq edge lower nyse
103,PKI,industry group slide lower machinery farm computer datum storage group draw worst loss
104,PKI,airgas arg pull back strong trading jpmorgan downgrade distributor industrial medical gase neutral overweight thursday wednesday allentown pa firm report fiscal first quarter earning fall airgas cite severance charge link layoff well souring business condition operate result top consensus estimate
105,PKI,update loss grow session halftime
106,PKI,vincent mao
107,PKI,major stock index extend loss midday friday putt week gain jeopardy
108,PKI,nasdaq lose dow fall drag loss procter gamble pg mmm caterpillar cat drop also weigh dow mining construction equipment firm cut additional job meanwhile nyse composite lose
109,PKI,volume be tracking even nasdaq slightly higher nyse
110,PKI,leader board get hit
111,PKI,stanley sxe reversed early gain drop slice day day move average late thursday provider service top view jump fiscal earning guide sale range vs view
112,PKI,quality system qsii also reversed fall slice day line appear be find support day line software maker report earning view late wednesday
113,PKI,stock have be
114,PKI,netflix nflx slip downgrade stifel nicolaus cut online movie rental firm sell hold still remain past buy point cup handle pattern
115,PKI,upside brink cfl rise brisk trade security service firm climb fourth straight session recently find support day line
116,PKI,update index head lowland volume turn mixed
117,PKI,alan elliott
118,PKI,softer expect rise january consumer sentiment be apparently not market be look index groan lower weight downside economic datum
119,PKI,nyse composite fall hardest nasdaq composite dow ride close carry loss
120,PKI,amazon amzn kla tencor klac continue pack huge gain nasdaq monster worldwide mww juniper network jnpr clock biggest price loss
121,PKI,volume eke just shade higher nyse remain few click nasdaq
122,PKI,decliner lead advance issue nyse not quite nasdaq
123,PKI,university michigan consumer sentiment index crawl higher january december read consensus view news compound earlier news friday show gdp make sharpest downward jog
124,PKI,march crude future remain largely unchanged hover just barrel mark natural gas trade dime gold be spot ounce dollar rise euro fall vs yen
125,PKI,stock compass mineral cmp jump better powerful trading table road salt supplier be get boost foul winter weather harsh shortage road salt supply year share be month correction have be unable top resistance week move average
126,PKI,idexx laboratory idxx step heavy action earning clear consensus view veterinary animal health supply maker be struggle build upside month consolidation
127,PKI,downside irrigation system maker lindsay lnn crash massive trading issue downside guidance omaha base company say expect fiscal sale slip prior year result due steep slowdown international order
128,PKI,lindsay announcement spil valmont industry vmi topple also massive trading maker metal tower other large scale infrastructure component be deep month correction
129,PKI,overseas hong kong hang seng index edge japan tokyo nikkei tumble yen continue gain strength toshiba nintendo ntdoy rac big loss
130,PKI,stock post mild late session loss europe commodity drag bank financial attempt pull higher
131,PKI,update stock fade early gain
132,PKI,vincent mao
133,PKI,better expect gdp report give stock early lift friday gain quickly withered
134,PKI,nasdaq dow be mostly unchanged nyse composite fall shed
135,PKI,volume be tracking sharply lower board
136,PKI,exxon mobil xom rise top fourth quarter view oil giant post earning share year earlier cent estimate sale tumble still beat view exxon earn full year largest annual profit ever publicly trade company
137,PKI,group mate chevron cvx also gain post lower expect sale
138,PKI,downside juniper network jnpr gap tumble sale miss analyst estimate late thursday company match view rise profit sale grow only view morning piper jaffray cut stock neutral buy lower price target
139,PKI,genentech dna fall roche make lower hostile bid biotech roche drop buyout bid share take deal directly shareholder
140,PKI,update stock set mixed open gdp report
141,PKI,vincent mao
142,PKI,stock future point mixed open friday follow smaller expect drop gross domestic product
143,PKI,nasdaq future rise point vs fair value future rise fraction point dow future fall point
144,PKI,economic front gross domestic product fall final quarter biggest decline almost year better expectation dip future rebound news consumer spending account third gdp fall
145,PKI,datum chicago pmi consumer sentiment be shortly open
146,PKI,corporate news amazon com amzn rally pre market follow thursday night stellar quarterly report rough retail environment online retailer earning unexpectedly rise cent share cent view sale also beat view grow
147,PKI,procter gamble pg report fiscal second quarter profit share cent prior year line view latest result include gain cent stem sale folger coffee business smucker revenue fall view share lose pre market
148,PKI,honeywell hon slip pre open sale miss estimate thank cost cut maker aircraft equipment chemical control system deliver earning cent share year year line view sale fall view
149,PKI,caterpillar cat lose goldman sachs place construction mining equipment maker conviction sell list
150,PKI,citigroup jpmorgan chase jpm well fargo wfc be lower pre open cnbc report problem government lead initiative help bank rid bad asset update loss be broad base financial pressed back class news regulator delay promise quick fix so call toxic asset hold many bank other institution nyse composite end flat nasdaq composite edge ever so slightly lower week dow clip decline citigroup lead dow downside juniper network jnpr fall hardest nasdaq juniper be also loss leader worsted only fifth third bancorp fitb be tough day someone forget tell amazon com amzn gap gain late thursday online retailer say book earning sale well analyst view other component flowserve fls paccar pcar jump heavy trading next week monday promise be busy day economic datum commerce release personal income spending construction spending datum december institute supply management put index general gauge outlook corporate buyer monday earning calendar include be aerospace beav corn product international cpo sysco syy prior open independent oil gas heavyweight anadarko apc sandisk sndk athero communication athr check close update higher volume loss threaten stock rallyby juan carlos market close session lows friday broad decline tumble nasdaq nyse composite dow accord early number volume rise give market distribution day come just day market follow selling put market rally serious doubt financial slide report plan remove bad asset bank balance sheet be peril steel other metal stock also weaken goldman sachs analyst give bearish outlook steel maker downgrade steel other update dow head week alan elliottindex be choppy remain session lows late trading slump nyse composite nasdaq dow give respectively dow slip loss week head final hour trading nyse nasdaq hold fractional gain vs last friday close volume be tracking higher loss continue be broad decline issue lead advancer better nyse nearly nasdaq commodity continue generally lower oil price remain just barrel hold morning gdp number implication further decline demand teleflex international tfx pop provide guidance line analyst consensus diversify engineering service provider put full year ep vs estimate company plan report result feb update index dive volume rise patrick market attempt get back break even end stock take sharp turn downward sink intraday lows dow fall nyse composite nasdaq sank volume be higher board indicate institutional selling financial dove government bad bank rescue idea have hit snag asset valuation problem accord report cnbc ruddick rdk supermarket operator gap fall company report earning late thursday show profit fall penny cent share stock pare much loss however proctor gamble pg be lower full year outlook add sale quarter possibly rest year fall company be often thought recession resistant perkinelmer pki maker genetic screening environmental analysis tool gap lose company say expect profit fall year range midsingle digit midteen stock hit year low update index climb lows stick decline alan nyse composite nasdaq dow be lower dip index have trim loss only banking financial biotech index nasdaq be sector post deepest loss exchange juniper network jnpr broadcom brcm continue rack heavy loss midcaps fall further putt volume remain shifty rise nasdaq edge lower nyse industry group slide lower machinery farm computer datum storage group draw worst loss airgas arg pull back strong trading jpmorgan downgrade distributor industrial medical gase neutral overweight thursday wednesday allentown pa firm report fiscal first quarter earning fall airgas cite severance charge link layoff well souring business condition operate result top consensus estimate update loss grow session halftimeby vincent maomajor stock index extend loss midday friday putt week gain jeopardy nasdaq lose dow fall drag loss procter gamble pg mmm caterpillar cat drop also weigh dow mining construction equipment firm cut additional job meanwhile nyse composite lose volume be tracking even nasdaq slightly higher nyse leader board get hit stanley sxe reversed early gain drop slice day day move average late thursday provider service top view jump fiscal earning guide sale range vs view quality system qsii also reversed fall slice day line appear be find support day line software maker report earning view late wednesday stock have be netflix nflx slip downgrade stifel nicolaus cut online movie rental firm sell hold still remain past buy point cup handle pattern upside brink cfl rise brisk trade security service firm climb fourth straight session recently find support day line update index head lowland volume turn mixed alan elliotta softer expect rise january consumer sentiment be apparently not market be look index groan lower weight downside economic datum nyse composite fall hardest nasdaq composite dow ride close carry loss amazon amzn kla tencor klac continue pack huge gain nasdaq monster worldwide mww juniper network jnpr clock biggest price loss volume eke just shade higher nyse remain few click nasdaq decliner lead advance issue nyse not quite nasdaq university michigan consumer sentiment index crawl higher january december read consensus view news compound earlier news friday show gdp make sharpest downward jog march crude future remain largely unchanged hover just barrel mark natural gas trade dime gold be spot ounce dollar rise euro fall vs yen stock compass mineral cmp jump better powerful trading table road salt supplier be get boost foul winter weather harsh shortage road salt supply year share be month correction have be unable top resistance week move average idexx laboratory idxx step heavy action earning clear consensus view veterinary animal health supply maker be struggle build upside month consolidation downside irrigation system maker lindsay lnn crash massive trading issue downside guidance omaha base company say expect fiscal sale slip prior year result due steep slowdown international order lindsay announcement spil valmont industry vmi topple also massive trading maker metal tower other large scale infrastructure component be deep month correction overseas hong kong hang seng index edge japan tokyo nikkei tumble yen continue gain strength toshiba nintendo ntdoy rac big loss stock post mild late session loss europe commodity drag bank financial attempt pull higher update stock fade early gainsby vincent maoa better expect gdp report give stock early lift friday gain quickly withered nasdaq dow be mostly unchanged nyse composite fall shed volume be tracking sharply lower board exxon mobil xom rise top fourth quarter view oil giant post earning share year earlier cent estimate sale tumble still beat view exxon earn full year largest annual profit ever publicly trade company group mate chevron cvx also gain post lower expect sale downside juniper network jnpr gap tumble sale miss analyst estimate late thursday company match view rise profit sale grow only view morning piper jaffray cut stock neutral buy lower price target genentech dna fall roche make lower hostile bid biotech roche drop buyout bid share take deal directly shareholder update stock set mixed open gdp reportby vincent maostock future point mixed open friday follow smaller expect drop gross domestic product nasdaq future rise point vs fair value future rise fraction point dow future fall point economic front gross domestic product fall final quarter biggest decline almost year better expectation dip future rebound news consumer spending account third gdp fall datum chicago pmi consumer sentiment be shortly open corporate news amazon com amzn rally pre market follow thursday night stellar quarterly report rough retail environment online retailer earning unexpectedly rise cent share cent view sale also beat view grow procter gamble pg report fiscal second quarter profit share cent prior year line view latest result include gain cent stem sale folger coffee business smucker revenue fall view share lose pre market honeywell hon slip pre open sale miss estimate thank cost cut maker aircraft equipment chemical control system deliver earning cent share year year line view sale fall view caterpillar cat lose goldman sachs place construction mining equipment maker conviction sell list citigroup jpmorgan chase jpm well fargo wfc be lower pre open cnbc report problem government lead initiative help bank rid bad asset
151,PKI,bid strengthen cad cam base dental unit dentsply sirona inc xray free report recently announce definitive agreement acquire orametrix lead industry provider innovative technology solution company also offer advanced cad platform develop dental professional deliver consistently predictable orthodontic outcome transaction be expect be complete second quarter be cad cam dentsply cad cam be dental imaging platform major foundation global dental market cad cam be field dental supply prosthodontic used computer aid design computer aid manufacturing technology fact dental supply market look promising moment last year market have gain compare index rally dentsply sirona inc price consensus dentsply sirona inc price consensus dentsply sirona inc quote deal detailfinancial term deal have be keep wrapped dentsply post acquisition company be able provide end end digital dental professional address increase demand aesthetic acquisition orametrix be likely strengthen dentsply footprint global dental industry notably company announce plan broaden orametrix technology service post buyout dentsply be likely incur additional investment expense be dilutive overall earning share meanwhile orametrix post revenue approximately acquisition be likely bolster company technology equipment segment segment consist dental implant cad cam system imaging system treatment center orthodontic product fourth quarter sale improve segment cc fact acquisition introduce comprehensive orthodontic offer include full arch clear aligner solution dentsply have be underperform company medtech space lackluster margin trend decline earning foreign exchange headwind have be plague company however research report technavio global dental cad cam market witness cagr more believe dentsply be strive overcome problem such deal company price performance have be dull well dentsply share have lose compare industry decline year time interestingly uptick share price be witness post announcement orametrix buyout notably share dentsply have inched close follow press release further company agreement medtech bigwig patterson company canada be likely drive sale recently dentsply witness rebound sale asia particularly japan strong growth russia zack rank key picksdentsply have zack rank sell few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
152,PKI,mar issue update research report luminex corporation lmnx free report company have broad product portfolio comprise advanced xmap xtag multicode technology however company operate highly competitive life science industry luminex carry zack rank hold portfolio strength buoy optimismluminex large install instrument base consist luminex lx luminex lx flexmap system magpix technology company widen accelerate market acceptance xmap technology development marketing distribution partnership lead company life science market luminex molecular portfolio soon include next gen verigene system company continue target clinical trial commencement system expect gi panel end second quarter fiscal comprehensive format incorporating many additional clinical study verigene other molecular platform follow additionally management expect license technology group continue generate lt mid single digit annual revenue growth contribute profit further luminex be make noteworthy progress major product ary system represent major revenue opportunity company be focuse fortify market leadership infectious disease ary system be sample answer platform luminex corporation price consensus luminex corporation price consensus luminex corporation quotein fourth quarter increase volume verigene ary internal manufacturing process improvement lead significant improvemnet gross margin further net revenue platform be management expect grow high rate consequently make feasible achieve goal exit year rate headwindson flip side luminex face cutthroat competition niche space moment industry be characterize rapid continuous technological innovation add wo luminex prospect be likely be mar future change reimbursement landscape new molecular diagnostic code system establish center medicare medicaid service cms recently protect access medicare act pama require clinical laboratory report cms volume laboratory test price paid private payor have lead drop luminex customer base unfavorable price movement luminex have underperform industry past year notably stock have gain compare unfavorably industry growth further current level be significantly lower index rally decline consumable revenue stiff competition continue dampen stock performance key picksa few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
153,PKI,instituto mexicano del seguro social imss have select varian medical system inc var free report equip treatment center mexico modern radiotherapy treatment system include edge system image guide stereotactic radiosurgery varian eymsa provide edge system vitalbeam system varian provide full suite treatment plan oncology information manage cancer patient site notably eymsa be varian long standing distributor mexico company new edge radiosurgery system allow physician treat tumor noninvasively outside body carefully shape high energy ray vitalbeam system offer high quality high throughput radiation therapy low cost enable treatment center expand clinical capability serve more patient development oncologyvarian be strive boost oncology segment last quarter oncology revenue increase year year basis regard varian recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company company initiate first education workshop radiotherapy practitioner algerium recently company announce first cancer patient be treat used hyperarc high definition radiotherapy hdrt new type radiosurgery treatment sacro cuore don calabrium cancer care center negrar verona italy fourth quarter revenue inched cer segment late company have be focuse expansion brazil recently varian announce receipt anvisa registration halcyon system brazil company have announce plan open new facility jundiai brazil indicate long term commitment partnership brazilian ministry health facility have be fully equip provide varian trilogy linear accelerator hand training physician market prospectsaccord report market market global radiotherapy market be project reach worth cagr consider bountiful opportunity niche space believe company latest development be strategic fit such prospect varian latest development oncology segment buoy optimism be also line company effort establish premier cancer care provider share price estimate revision trendover past month varian share have outperformed industry term price stock have return compare favorably industry rally just current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate have rise share zack rank other key picksvarian carry zack rank buy few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
154,PKI,mar issue update research report idexx laboratory inc idxx free report company witness strong organic revenue growth international business additionally companion animal market fundamental remain solid tremendous global runway growth stock carry zack rank buy also lead molecular diagnostic company have be outperform industry past month stock have rally compare gain industry meanwhile idexx continue demonstrate solid growth globally strong international expansion fourth quarter company witness double digit organic revenue growth international business upside be owing continue consumable revenue gain support catalyst instrument base average testing utilization international market company witness considerable organic lab revenue gain support positive customer response sdma well significant growth rapid assay sale addition management experience steady growth reference lab lead consistent gain europe furthermore cag organic revenue growth low double digit strong vetlab consumable cag diagnostic recur organic revenue growth be impressive be also optimistic company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention move ahead expect company gain commercial launch catalyst sdma test north america january idexx too enter global agreement diagnostic company apply biocode same month moreover idexx have strong cash balance allow carry share repurchase nevertheless high dependence third party distributor intense competition continue threat other stock considersome other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
155,PKI,mar issue update research report davita inc dva free report stock carry zack rank hold operate division davita davita kidney care focus set global standard clinical social operational practice kidney care however company have be grapple labor union issue california ohio davita kidney care unit have be gain prominence worldwide major service provide center hemodialysis home hemodyalisis peritoneal dialysis kidney transplant urology diabetology vascular access surgery deserve mention fourth quarter net consolidated revenue kidney care unit be year year adjust operate income segment be year year further davita be steadily expand international market past few year company have strengthen position emerge develop market brazil china colombia germany india malaysia netherlands poland portugal saudi arabia strategic alliance well acquisition dialysis center be anticipate help davita deliver more efficient patient care currently davita be seek expand major european asian country acquisition partnership meanwhile california labor union propose ballot initiative be likely davita footprint state proceed initiative company have incur significant time cost support advocacy effort be likely dampen top line growth come quarters management situation be likely render large number center california financially unsustainable severely limit patient access outpatient dialysis care end fourth quarter company also announce union be pursue similar initiative ohio however have not include potential advocacy cost california ohio guidance range price performanceover last month davita have outperformed industry company return almost higher industry growth current level also compare favorably gain roughly davita inc price davita inc price davita inc quotekey picksa few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
156,PKI,varian medical system inc var free report recently announce st petersburg center nuclear medicine sergey berezin medical institute conclude first pediatric patient treatment company flagship probeam proton therapy system notably center be expect treat approximately patient year solid prospect zack rank buy stock be attractive pick moment be probeam proton therapy system varian medical probeam system be lead platform advanced cancer care technology be world first commercially available pencil beam scanning system be most precise form proton therapy available platform come company particle therapy business deliver intensity modulate proton therapy impt be consider be better other legacy proton therapy delivery method last quarter varian medical book new proton order university alabama birmingham sylvester comprehensive cancer center university miami management confirm order be probeam system varian medical system inc price varian medical system inc price varian medical system inc quotefavorable stock performanceover past year varian medical outperformed industry term price performance company return compare favorably sub industry gain also current return be higher growth varian medical solid performance oncology business probeam proton therapy improve margin launch halcyon radiotherapy treatment system be key highlight moment strong revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be also positive other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
157,PKI,mar issue update research report cvs health cvs free report increase demand pbm pharmacy benefit management specialty pharmacy be major growth driver stock dull retail performance last few quarters seem have disappoint investor company carry zack rank hold share company have outperformed industry past year stock have lose compare decrease broader industry notably cvs health exit fourth quarter solid note earning revenue remain ahead zack consensus estimate year year rise top line be owing strong pharmacy service segment have benefit upside specialty pharmacy company sturdy pbm selling season be growth booster positive note company be already make decent progress selling season good news be have be banking gross win approximately net new business client retention rate meanwhile be look forward company commencement momentous healthcare consolidation health insurance giant aetna successful completion deal cvs health expect earn term synergy low mid single digit accretion second year post transaction closure moreover omnicare target pharmacy buyout be gradually drive enterprise value cvs health further management expect drug price inflation product launch higher utilization new pbm client fuel growth additionally expect pharmacy service segment be stable growth platform flip side company highly competitive retail pharmacy business be big concern face stiff competition pharmacy segment be availability low cost pharmacy option other retail business continue add pharmacy department portfolio particularly discount retailer have make substantial inroad gain major market share apart cvs health have deliver sluggish number retail long term care business recent past company decision restrict participate tricare network many fully insure prime network be due negative impact pharmacy sale script comp key picksa few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
158,PKI,thermo fisher scientific inc tmo free report bid broaden human identification hide portfolio recently announce buyout integenx inc notably integenx be developer rapid dna platform use law enforcement forensic forensic application however financial detail deal have be keep wrapped company integenx rapidhit platform software analysis tool related consumable highly complement thermo fisher short tandem repeat str chemistry human identification qpcr capillary electrophoresis system encouragingly note integenx have widespread presence country provide assistance prosecutor law enforcement application generate forensic dna profile sample very short process time believe addition integenx tech platform aid thermo fisher boost top line contribution hide portfolio human identification portfolio glancethermo fisher robust hide portfolio encompass dna quantification kit pcr amplification kit human identification professional service next generation sequence ngs solution apply biosystem product such quantifile trio globalfiler yfiler kit apply biosystem genemapper id software copan nucleic card floqswab collection system cater kind demand niche market develop portfolio last september thermo fisher announce receipt approval unite state federal bureau investigation fbi authorize usage company apply biosystem yfiler pcr amplification kit generate genetic profile uploading combine dna index system market potentialper report global human identification market be anticipate value see cagr thus latest development have come opportune time company cash bountiful opportunity high potential niche market price performanceover past year thermo fisher share have outperformed industry belong stock have gain compare industry rise zack rank key picksthermo fisher carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank stock company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
159,PKI,fresenius medical care fms free report be currently top perform stock medtech sector further increase share price strong fundamental indicate bull run stock have zack rank buy wide range dialysis product deliberate initiative attain market traction solid international foothold well strategic acquisition divestment be major growth catalyst company fresenius project revenue growth constant currency cc net income attributable shareholder be likely increase therefore haven take advantage share price appreciation yet time add stock portfolio price performance estimate revision trend estimate fresenius medical moved upward past day reflect analyst optimism stock company have see zack consensus estimate current year earning be revise upward respectively share company have outperformed industry year time stock have moved compare industry rally let focus factor make fresenius medical attractive pick investor attractive pick growth strategy fresenius medical have set strong long term objective call growth strategy chalk few strategic initiative attain solid market traction postulate initiative company aim boost revenue corresponding average annual growth rate regard revenue increase year year basis reach improvement be attribute strong performance health care service further management forecast increase revenue tune organic growth acquisition same time company expect high single digit annual growth net income addition stock impressive performance core dialysis business fresenius medical intend achieve target expand care coordination dialysis segment well end fourth quarter company reconfirm mid term outlook growth strategy global efficiency program phase ii fresenius medical launch second phase global efficiency program gep ii program aim be identify realize efficiency potential enhance overall competitiveness company start gep ii intend achieve sustain cost improvement eur annum wide range dialysis product service company provide wide range dialysis product own dialysis clinic third party clinic include modular machine component dialyzer bloodline system hd hemodialysis solution concentrate water treatment system fresenius medical offer wide array hemodyalisis peritoneal dialysis acute dialysis product well earlier company sell more dialysis machine worldwide dialyzer date company account almost half global sale dialysis product patient worldwide regularly undergo dialysis treatment other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
160,PKI,mar issue update research report steris plc ste free report company have be actively try expand adjacent market strengthen core business acquisition dilution however company operate tough competitive landscape raise concern stock carry zack rank hold share company have outperformed industry past year stock have surge compare industry rally steris exit third quarter fiscal mixed note earning beating zack consensus estimate revenue miss same however be encourage favorable underlie market trend new product service offering company organic growth be strong specialty service life science apply sterilization segment be particularly upbeat steris series acquisition first month fiscal buyout company aim strengthen healthcare product healthcare specialty service apply sterilization technology business furthermore finance cash hand credit facility borrowing company have incur acquisition cost net cash acquire include contingent consideration think developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service pursue back back acquisition long run expand business customer base courtesy strong financial position be also impressed company recent organizational change serve customer better way additionally expect move enhance company cost structure further growth free cash flow reserve be indicative company strong cash balance meanwhile steris compete pharmaceutical research industrial customer several large company boast extensive product portfolio wide global reach well several small company limit product offering operation few country company expect confront intense competition new infection prevention sterile process contamination control surgical support product service enter market hamper steris growth considerably moreover many steris customer be undergo consolidation partly owing healthcare cost reduction measure initiate peer pressure well legislator regulator third party payor believe company fail check customer consolidation rate right now then affect business well financial standing key picksa few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
161,PKI,laboratory corporation america holding labcorp lh free report have recently enter national agreement interpace diagnostic group inc idxg free report field cytopathology hand alliance expand interpace nationwide network cytology provider support thyroid molecular business unit other be helpful strengthen labcorp core specialty diagnostic arm notably be not first time labcorp have partner interpace fact latest agreement build original deal inked earlier contract enabled electronic order result report labcorp interpace proprietary thygenx thyramir test report provide more specific diagnostic information presence thyroid cancer patient initial biopsy fail indicate thyroid nodule be malignant benign new agreement dianon pathology member labcorp specialty testing group perform thyroid biopsy analysis result be indeterminate then interpace perform molecular test apart doctor order automatic reflex interpace test dianon event indefinite biopsy assessment case dianon automatically refer sample interpace perform company proprietary assay thygenx thyramir be important note labcorp work hard new innovation academic institution part key strategic plan capture grow lab testing market advanced assay tool diagnostic company successfully continue provide foundation new collaboration health system large physician group manage care partner constantly increase scale competency level clinical laboratory medicine resort acquisition range routine capability highly esoteric testing company other recent tie up worth mention be major health system partnership namely mount sinai health system paml pacific northwest base market lead reference outreach laboratory labcorp anchor health system gradually become research hub improve access trial well covance site activation investigator patient recruitment capability labcorp have also create ample growth opportunity woman health medical drug monitoring genetic oncology testing well effect critical collaboration such walgreen andme also partnership mount sinai paml former owner providence catholic health continue expand additionally labcorp expect transaction benefit full year ownership growth generate approximately incremental profitable revenue share price performance past month share labcorp have outperformed industry stock have gain compare industry growth zack rank key pickslabcorp carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
162,PKI,bioscrip inc bio free report report adjust net loss continue operation cent share fourth quarter wider zack consensus estimate year loss cent report net loss continue operation period come cent share wider year earlier loss cent revenueswith completion core pbm business divestment bioscrip now have simplified business structure focuse core infusion service net revenue quarter review be decline year year huge downside result company shift strategy focus grow core revenue mix apart impact cure act contract modification complete sep be major deterrent however top line exceed zack consensus estimate bioscrip inc price consensus ep surprise bioscrip inc price consensus ep surprise bioscrip inc quote notably net revenue fourth quarter include core product mix improvement prior year period gross margin report time frame expand basis point bps year year significant upside be drive seasonal revenue strength leverage company infrastructure reduce product cost operate expense be reduction tally fourth quarter exit cash cash equivalent compare end guidance company have provide revenue view range zack consensus estimate metric lie company guide range additionally bioscrip expect incur restructure expense band primarily reflect cost related redesign optimize revenue cycle management process company also expect capital expenditure takebioscrip exit fourth quarter dismal note lower expect earning performance revenue be consensus mark huge year year decline be disappointment nonetheless be encourage company progress fourth quarter courtesy new multus faceted core plan improve financial position company also expect core revenue home solution continue core growth be accretive portfolio moreover be upbeat bioscrip completion contract transition projection core revenue rise management outlook sound promising zack rank key picksbioscrip have zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
163,PKI,share orthofix international ofix free report scale new week high mar close session bit lower share company have outperformed industry past month stock have gain compare gain industry rise stock have market cap companyha positive earning surprise trail quarters also have long term expect earning growth rate orthofix carriesa zack rank hold company have impressive growth style score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock impressive style score combine favorable zack rank strong buy buy offer best investment opportunity take stable stock performance consideration expect orthofix scale higher come quarters base several growth driver strong fourth quarter performance orthofix exit fourth quarter solid note earning sale beating zack consensus estimate top line be substantially drive strength biologic spine fixation business expect continue back improve performance sale partner expand distributorship network introduction product promising prospect year spelt success orthofix be company transform spine fixation strategic business unit deliver exceptional growth sale momentum addition robust stream new product period company have already launch product have even schedule be release ahead strong current year guidance be also indicative enhance prospect fda nod ce mark receipt physiostim market be upbeat orthofix recent ce mark fda approval next generation physiostim regulatory approval be likely boost company revenue moreover orthofix also plan unveil stim ontrack new application mobile device physiostim gadget acquisition spinal kinetic inc company have recently inked definitive agreement buy spinal kinetic inc buyout be line company aim strengthen foothold spine hardware market post completion deal orthofix expand spine fixation portfolio addition spinal kinetic ce marked artificial disc key picksbetter rank stock broader medical sector include bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
164,PKI,mar issue update research report bioscrip inc bio free report company struggle reimbursement challenge core business continue grow stock have zack rank sell bioscrip exit fourth quarter dismal note lower expect earning performance revenue be consensus mark huge year year decline be disappointment downside be due shift company strategy solely focus grow core revenue mix include contract change unite healthcare be complete september also external challenge reimbursement cut persist pertain st century cure act hampered growth full year result be thus discourage result catastrophic disruption hurricane irma harvey third quarter cure act reimbursement cut past month share bioscrip have underperform broader industry stock have gain compare rise broader industry healthcare industry also highly competitive scenario fact bioscrip rival include large well establish company equip higher financial marketing technological resource bioscrip inc price bioscrip inc price bioscrip inc quote positive note co base lead infusion service provider have continue progress new multus faceted core plan improve financial position scheme involve identify execute strategy accelerate core revenue growth build favorable product mix drive operational efficiency raise revenue collection well increase employee effectiveness additionally fourth quarter company make significant advancement implement single repeatable model enforce operate cost reduction back solid synergy draw supply chain rationalization growth nursing productivity enhance shipping utilization improve patient board time key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
165,PKI,keep line strategy fortify hold high potential geographical region gnc holding inc gnc free report recently announce plan expand presence india india company operate collaboration master franchise partner guardian healthcare service pvt ltd latest announcement guardian add gnc holding product store india regard new store be expect shelf gnc product compare approximately retail location present apart gnc holding have be target other channel retail commerce distribution expansion international business key growth drivergnc holding international business have be key growth driver company recent year revenue segment increase higher cross border commerce sale china last quarter late company have be experience solid growth china regard gnc holding recently announce plan enter strategic partnership joint venture agreement harbin pharmaceutical group hold co ltd meanwhile company have witness improvement trend mexico south korea hong kong market potentialper report associate chamber commerce industry india assocham india nutraceutical market be estimate value see cagr approximately forecast period thus view such datum believe gnc holding aggressive expansion plan india be strategic share price performancein past month gnc holding have be underperform industry stock have lose compare industry decline believe latest development help stock rebound zack rank key picksgnc holding carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
166,PKI,cooper company inc coo free report report adjust earning first quarter fiscal beating zack consensus estimate increase year year believe upside be drive robust revenue growth stock have zack rank hold revenue increase constant currency exchange rate cer year year basis figure also outpaced zack consensus estimate stellar top line performance be drive silicone hydrogel lense lead clariti myday daily space biofinity monthly space segmental company have business segment coopervision cvi coopersurgical csi cooper company inc price consensus ep surprise cooper company inc price consensus ep surprise cooper company inc quotecvirevenue coopervision segment increase constant currency cc year year basis segment continue gain company silicone hydrogel lense lead solid prospect myday clariti biofinity platform come major catalyst cvi segment robust performance toric cvi revenue multifocal single use sphere lense single use sphere lense propel solid growth multifocal revenue rise year year cc toric revenue increase single use sphere lense sale climb cc sale single use sphere lense rise geographically cvi revenue inched americas respective asia pacific emea cc csirevenue coopersurgical segment decline cc year year basis however company witness increase segment report basis back paragard acquisition fertility category csi revenue see drop sale cc also office surgical product category decline cc margin detailsa percentage revenue adjust gross margin csi segment be report quarter basis point bps year year margin be negatively impact inventory step associate paragard buyout percentage revenue adjust gross margin cvi segment be report quarter higher revenue year quarter reflect increase bps avorable currency product mix hence adjust gross margin whole cooper company be revenue bps year year adjust operate margin percentage revenue be net revenue fiscal first quarter bps year year basis fiscal total revenue be now expect band compare previous zack consensus estimate fiscal revenue be peg guide range revenue cvi segment be now estimate band higher meanwhile csi revenue range have be slash prior adjust earning share be now anticipate band versus earlier zack consensus estimate fiscal adjust earning stand guide range takecooper company end first quarter fiscal solid note company coopervision business have always be post impressive result company raise guidance fiscal be promising however intense competition contact lens space continue increase pricing pressure company notably cooper company have complete acquisition paragon vision science add lead ortho technology company lens portfolio consider outstanding performance stock expect cooper company scale higher come quarters regard positive long term growth hold promise key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report athenahealth inc athn free report petm athenahealth sport zack rank strong buy perkinelmer carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year athenahealth report adjust earning share fourth quarter year year revenue totale don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
167,PKI,share edward lifescience corporation ew free report scale new week high mar close session lower company have outperformed industry last month stock have gain compare gain industry stock have market cap company have positive earning surprise last quarters also have long term expect earning growth rate further company estimate revision trend current year be favorable past couple month analyst moved north movement opposite direction earning estimate rise share company year historical growth rate be also favorable compare industry edward lifescience carry zack rank buy company have impressive growth style score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity take stable stock performance consideration expect edward lifescience scale higher come quarters base several growth driver strong fourth quarter performance edward lifescience fourth quarter performance be quite promising revenue earning beating zack consensus estimate be also encourage strong performance company product line company also perform well respect gross adjust operate margin company be focuse product innovation research development solid guidance edward lifescience have raise sale expectation high end previously project range zack consensus estimate full year revenue be well guide range adjust earning share expectation have also be raise previous zack consensus estimate full year adjust earning stand low end company guide range ce mark centera valve market be upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf segment acquisition harpoon medical edward lifescience recently acquire harpoon medical inc privately hold medical technology company focuse beating heart repair degenerative mitral regurgitation agreement harpoon medical flagship beating heart repair procedure mitral valve patient harpoon system be add edward lifescience surgical heart valve therapy portfolio treat structural heart disease other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
168,PKI,genomic health inc ghdx free report report fourth quarter adjust earning share ep cent reflect improvement year quarter cent adjust ep however miss zack consensus estimate cent report ep come cent improve year figure penny full year adjust ep come penny compare favorably zack consensus estimate loss cent year number loss cent revenue detailtotal revenue quarter rise year year miss zack consensus estimate growth unite state international market drive top line moreover quarter genomic health witness solid invasive breast cancer growth net revenue totale miss zack consensus estimate figure however improve year number genomic health inc price consensus ep surprise genomic health inc price consensus ep surprise genomic health inc fourth quarter product revenue unite state rise product revenue growth be fuel rise prostate test revenue hike invasive breast cancer revenue international product revenue totale report quarter quarter company deliver more oncotype dx test result year year margin trendin quarter review genomic health gross margin expand basis point bps year year company also witness rise operate expense owing rise research development expense uptick general administrative expense increase selling marketing expense report quarter genomic health report operate income show year year improvement year accordingly operate margin expand bps financial updategenomic health exit cash cash equivalent short term marketable security include corporate equity investment reflect improvement record end company issue guidance genomic health expect full year revenue range reflect growth zack consensus estimate be guide range company expect adjust basic ep band cent zack consensus estimate be peg cent takegenomic health exit fourth quarter disappointing note nevertheless be encourage year year rise revenue drive solid performance unite state internationally prostate cancer oncotype dx genomic prostate score test witness expand private coverage be also upbeat company signing exclusive licensing agreement cleveland diagnostic research collaboration agreement janssen pharmaceutical also launch oncotype dx ar nucleus detect buoy optimism company also witness positive development oncotype dx breast recurrence score test genomic health sole reliance breast oncotype dx test be concern moreover company rise operate expense challenge zack rank key picksgenomic health carry zack rank strong sell few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report athenahealth inc athn free report petm athenahealth sport zack rank strong buy perkinelmer carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer post fourth quarter adjust ep cent adjust revenue be approximately year adjust ep fourth quarter year year basis revenue totale don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
169,PKI,major breakthrough field physiostim orthofix international ofix free report have secure approval fda well european ce mark next generation physiostim company physiostim bone growth stimulator provide surgical treatment option particularly patient nonunion fracture repair fact such extremely critical condition show visible sign heal aforementioned class iii medical device be build orthofix proprietary pulse electromagnetic field pemf technology platform accord company pemf signal create low level electrical field fracture site stimulating bone heal orthofix sound highly positive physiostim claim device have occupied lead position prescribe bone growth stimulator unite state combine spinal fusion stimulator company also state physiostim device be accompany stim ontrack new application mobile device app used first market feature enable physician remotely track view patient adherence prescription huge market prospectwe be certainly look forward path breaking achievement musculoskeletal heal device company bone growth stimulation space show indication grow leap bound go grand view research report bone growth stimulator market size be value more american suffering arthritis arthritic problem rapidly rise due age obesity factor patient population be likely increasingly reach needless add endemic arthritis be drive demand bone growth stimulation product take global datum consideration market market report state global bone growth stimulator market be estimate witness cagr major growth propeller be grow patient preference invasive minimally invasive surgical treatment increase target patient population procedural benefit offer bone stimulation device bone fracture treatment view expect orthofix achieve huge customer adoption rate physiostim post product launch unite state europe price performance past month share orthofix have outperformed industry belong stock have gain compare industry rise zack rank key picksorthofix carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
170,PKI,bid make genomic research cost effective pacific bioscience california inc pacb free report recently announce new version sequel software new polymerase pacific bioscience flagship platform sequel system have be fortify company footprint worldwide latest development sequel system now achieve gb single molecule real time smrt cell genomic library double throughput used ultra long insert kb genome assembly enhancement increase throughput overall performance smrt sequence key application notably pacific bioscience have increase throughput smrt cell fold smrt sequence technology be first commercialize throughput increase cost effectiveness sequence project human plant animal market enable researcher increase size scope project sequel system glancesequel system be nucleic acid sequence platform base smrt technology be develop partnership roche pacific bioscience agreement roche be terminate sequel system be still significant contributor pacific bioscience top line believe sequel system higher throughput scalability lower upfront capital investment well smaller size weight attract cost sensitive customer fourth quarter consumable revenue growth be drive higher sequel instrument utilization average annualize pull revenue sequel instrument be more be near recent developmentsin january pacific bioscience announce agreement bgi genomic purchase additional sequel system significantly expand capacity smrt sequence bgi global sequence service business currently operate sequel system pacbio rs ii sequence system october pacific bioscience california form alliance genomic datum drive medicine company bluebee develop advanced assembly pipeline integrate company technology company be alsocontinu work new version zmw smrt cell company have also expressed plan complete developmental chip end year notably company have receive order sequel system bgi china be expect further strengthen foothold country also end pacific bioscience confirm be track perform beta testing new enzyme software sequel system industry prospectsper market market global genomic market be expect grow cagr reach worth consequently prospect long read sequence market niche space genomic industry be also grow leap bound believe pacific bioscience slew latest development be well time industry further recent report decisive bio insight next generation sequence manufacturer market size reach grow annum rate touch primarily drive adoption worldwide clinical customer price performance past month stock have gain outperform industry gain roughly zack rank key pickspacific bioscience have zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
171,PKI,amedisys inc am free report have be gain investor confidence consistently positive result past month company have outperformed industry stock have gain compare industry also company have outperformed gain renown home health hospice service provider have market cap company year project growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate increase share style score amedisys sport growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential additionally company exhibit vgm score here stand value growth momentum research vgm score be simply weight combination parameter be comprehensive tool allow investor filter standard score system pick winning stock regard amedisys have favorable annualize project earning growth rate compare industry company sale asset ratio versus industry signify be solid growth pick let find recent positive trend be sustainable look amedisys solid fourth quarter result term earning revenue be encourage company long term strategy evolve traditional home health hospice care company be focuse bring home continuum care be amedisys intend better serve patient diversify source payment so become less reliant medicare regard company witness encourage growth medicare medicare revenue home health hospice division fourth quarter be upbeat amedisys strategic acquisition past year regard latest buyout have be intercity home care personal care provider headquarter malden renown home health hospice service provider have wider presence massachusett also note home health industry be poise grow significantly term drive positive demographic trend unite state meanwhile amedisys continue benefit age demographic population home health cheaper care modality addition continue pressure healthcare system believe operator such amedisys continue benefit increase volume shift higher cost institutional setting lower cost environment such home health be also optimistic recently pass bipartisan budget act congress reduce company reimbursement impact furthermore company strong cash balance position bolster investor confidence stock flip side escalate operate expense continue threat also intensely competitive landscape regulatory concern be major bottleneck home health hospice industry other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
172,PKI,mar issue update research report quest diagnostic inc dgx free report huge reimbursement concern company focus potentially strong area stock carry zack rank hold share quest diagnostic have outperformed industry past year stock have gain broader industry decline be encourage note recent time quest diagnostic have witness significant growth infectious disease testing prescription drug monitoring wellness business company lend attention core diagnostic information service business well discipline capital deployment several new collaboration hospital integrate delivery network continue act major growth driver be look forward company recently close buyout mobile medical examination service national provider home base health risk assessment related service apart guidance issue promise bullish trend continue later quest diagnostic provide upgrade long term growth outlook base new extend point strategy generate shareholder value accelerate growth drive operational excellence major commercial laboratory service provider expect revenue growth period however bottom line rise be expect better top line faster rate mid high single digit range company increase partnership strength other health care leader be create ample opportunity earning revenue boost simultaneously improve patient experience well reduce overall cost care endure several quarters dull volume company have finally noticed improvement term volume pricing however sustainability progress be still doubt further reimbursement wo remain also quest diagnostic be highly disappoint recent cms center medicare medicaid service proposal related protect access medicare act december company key member american clinical laboratory association support lawsuit slap act secretary department health human service complaint file cms operate hhs purview charge failure follow congressional directive implement market base laboratory payment system stock considersome better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
173,PKI,cryolife inc cry free report report adjust earning share ep cent fourth quarter year year adjust ep however manage surpass zack consensus estimate cent full year adjust earning come cent reflect decline year figure figure surpass zack consensus estimate cent revenue detailrevenue quarter increase year year moreover figure beat zack consensus estimate revenue be primarily drive double digit revenue growth bioglue tissue process moreover revenue include contribution recently complete acquisition jotec full year revenue come year period beating zack consensus estimate millioncryolife inc price consensus ep surprise cryolife inc price consensus ep surprise cryolife inc quoteon segmental basis product revenue increase year year fourth quarter segment revenue come bioglue biofoam follow preservation service revenue increase quarter review year quarter segment company witness solid growth cardiac vascular tissue revenue geographical basis company revenue unite state rise international revenue increase operational updatecryolife gross profit report quarter climb year year however gross margin contract basis point bps general administrative marketing expense fourth quarter rise year year research development expense shot year year operate expense totale fourth quarter year year adjust operate loss quarter be compare unfavorably operate profit year quarter financial updatecryolife exit cash cash equivalent restrict security compare end cryolife expect revenue band zack consensus estimate full year revenue stand guide range company also expect adjust earning share range cent zack consensus estimate full year earning be peg cent company guide range takecryolife exit fourth quarter promising note be encourage note company have be witness growth product line strong performance geography moreover company have be gain directly selling product end user be also optimistic company focus product innovation completion jotec buyout however escalate operate expense seem be discourage also tough competitive landscape act dampener zack rank key pickscryolife have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report athenahealth inc athn free report petm athenahealth sport zack rank strong buy perkinelmer carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter athenahealth report adjust ep fourth quarter year year basis revenue totale year year basis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
174,PKI,mar issue update research report nuvasive inc nuva free report strong spine market spell huge scope zack rank hold stock pricing payer pressure come major headwind notably nuvasive exit fourth quarter dismal note top line miss zack consensus estimate business also deliver dull performance softness spinal hardware surgical support business positive note company solid international business register more growth fifth consecutive quarter buoy optimism stock investor management international region hold tremendous growth opportunity nuvasive also nuvasive surgical support business have perform robustly recent time segment flourish be attribute biotronic acquire july integration still track pertain large scale buyout company anticipate benefit build scale service business management believe addition biotronic nuvasive profile have enhance company service offering be deliver greater consolidation procedurally integrate portfolio currency volatility reimbursement issue competitive landscape have be continuously pose challenge stock also pricing pressure persist big concern nuvasive company face decline product price due stiff competition spine market past month nuvasive have underperform industry belong stock have decline industry gain key pickssome better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate zack rank buy breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
175,PKI,mar issue update research report amedisys inc am free report company have be expand customer base strategic buyout moreover personal care segment have be grow strong stable latest integrate tuck acquisition stock carry zack rank buy renown home health hospice service provider have be outperform industry past month stock have rally compare industry gain be upbeat amedisys strategic acquisition past year regard latest buyout have be intercity home care personal care provider headquarter malden notably intercity home care entire asset base have be take amedisys subsidiary associate home care renown home health hospice service provider have wider presence massachusett intercity home care have presence greater boston north shore merrimack valley community management believe company have enough cash execute more such acquisition day ahead be also encourage stabilization company personal care business have also be gain recently integrate tuck acquisition amedisys be look forward cash huge prospect segment moreover company be work expand geographical presence personal care business be also optimistic recently pass bipartisan budget act congress reduce company reimbursement impact furthermore company have long term strategy evolve traditional home health hospice care company be focuse bring home continuum care be amedisys intend better serve patient diversify source payment so become less reliant medicare regard company witness encourage growth medicare medicare revenue home health hospice division last report quarter meanwhile escalate operate expense decline gross margin continue raise concern other key picksother top rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
176,PKI,abbott free report have be limelight receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm notably abbott breakthrough pediatric mechanical heart valve help treat newborn infant congenital heart defect chd need valve replacement procedure moreover approval company have expand master series portfolio structural heart business interestingly master series line now offer valf diameter size vary mm furthermore approval be majorly attribute positive result clinical trial patient damage diseased malfunctioning heart valve age year apart widening portfolio approval allow abbott timely cater unmet need niche market glimpse structural heart businessabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business sale growth segment be drive double digit growth heart failure structural heart neuromodulation diabetes care last report quarter notably structural heart business account total revenue medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mitral regurgitation last november company announce receipt japan ministry health labour welfare mhlw approval same believe latest development help company boost top line contribution business market prospectsper report research market publish cardiovascular business global pediatric interventional cardiology market be expect see cagr company child be born chd unite state year thus addition master hp mm help abbott cash abundant opportunity pediatric interventional cardiology market share price movementover past month abbott have be outperform industry stock have gain compare industry zack rank key picksabbott carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
177,PKI,chimerix inc cmrx free report report net loss continue operation cent share fourth quarter wider net loss cent year however same be narrower zack consensus estimate loss cent full year net loss come share narrower year revenuesin fourth quarter chimerix report contract revenue year year top line however exceed zack consensus estimate year year decline result fall reimbursable expense related company barda developmental contract full year contract revenue come drop year period level research development expense totale year year report quarter downside be primarily due ongoing advance trial initiation adapt trial general administrative expense amount surge year year primarily increase market education launch readiness chimerix inc price consensus ep surprise chimerix inc price consensus ep surprise chimerix inc quote consequently loss operation come wider prior year quarter operate loss be attribute significantly lower revenue year year escalate cost expense exit cash cash equivalent short term investment compare record end takechimerix exit fourth quarter positive note narrower estimate loss revenue surpass zack consensus estimate however year year decrease top line be concern nonetheless be encourage company progress fourth quarter courtesy advancement lead product candidate brincidofovir company witness impressive enrollment multiple ascend dose study iv bcv quarter review company commence adapt study unite state eu study be design provide comparative datum brincidofovir patient life threaten adenovirus infection company be also progress well ongoing first time human study cmx zack rank key pickschimerix have zack rank hold few better rank stock have already report solid earning result be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency basis wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
178,PKI,henry schein inc hsic free report latest deal grifol grfs free report add stimulus distribution business company have sign distribution agreement enable former market distribute latter ml normal saline solution sodium chloride injection usp market notably grifol be lead producer plasma derive medicine forerunner research development therapeutic alternative company manufacture ml normal saline solution industrial complex murcia spain receive fda approval market product unite state only last year grow demand saline product market believe partnership be strategically beneficial henry schein company solution grifol have capacity quickly meet customer need shortage iv solution company gain impetus global supply infrastructure well henry schein widespread network regard note henry schein distribution business boast broad global footprint distribution center locate apart north america europe company have presence australia new well emerge market china brazil israel czech republic poland be latest target hub grifol apart company significant distribution partner be terason dentsply sirona henry schein exclusively distribute terason usmart nexgen canadian dental subsidiary distribute entire dentsply sirona product line share price movement past month share henry schein have underperform industry belong stock have lose contrast industry gain expect latest development help boost investor confidence stock zack rank key pickshenry schein carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
179,PKI,orthofix international ofix free report recently inked definitive agreement buy spinal kinetic inc buyout be line company aim strengthen foothold spine hardware market spinal kinetic be privately hold developer manufacturer artificial cervical lumbar disc post completion deal orthofix expand spine fixation portfolio addition spinal kinetic ce marked artificial disc notably artificial disc be capable mirror natural motion spine be therefore prefer many surgeon however artificial disc be yet receive fda approval notably spinal kinetic have already file pre market approval pma fda treat single level cervical degenerative disc disease ddd used cervical disc financial detailson fulfillment certain customary condition deal be expect be close second quarter term agreement orthofix be liable pay cash close consideration certain contingent milestone payment regard company pay spinal kinetic achieve target fda approval cervical disc reach trail month sale target moreover buyout be likely contribute top line company project organic revenue growth rate rise courtesy deal further month pma approval receipt unite state orthofix expect acquisition be accretive adjust earning share ebitda spine fixation sbu glanceorthofix spine fixation strategic business unit sbu manufacture distribute wide range implant product used surgical procedure company continue witness impressive top line contribution unit last quarter segment see constant exchange rate growth year quarter uptick be attribute new product launch adopt strategic initiative february orthofix announce clearance receipt limit launch forza xp expandable spacer system unite state continue development company be satisfied progress ide clinical trial focuse used pulse electromagnetic field technology treat osteoarthritis knee lower repair failure rotator cuff surgery market potentialper report market research global artificial disc market revenue be estimate reach rise instance ddd improve technology higher awareness treatment procedure follow increase healthcare spending age population be expect stimulate demand market furthermore orthofix expect double digit growth global artificial disc market upcoming thus latest development have come opportune time company cash bountiful opportunity high potential niche market price performanceover past month orthofix share have outperformed industry belong stock have gain compare industry rise zack rank key picksorthofix carry zack rank hold few other better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
180,PKI,corporation abc free report have be healthy growth trajectory late past month company have outperformed industry stock have gain compare industry rally also company have outperformed index gain lead pharmaceutical service company focus provide drug distribution related service reduce health care cost improve patient outcome have market cap companyha positive earning surprise last quarters also have long term expect earning growth rate backed such prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction resultantly earning estimate improve share style score sport value score indicate company strong prospect research show stock value style score combine zack rank strong buy offer best upside potential regard have favorable price earning growth peg ratio compare broader industry moreover surpass industry cash flow share signify be favorable value pick let find recent positive trend be sustainable be upbeat active pursuit acquisition strengthen core area recently company announce buyout largest independent wholesaler unite state cash mwi veterinary acquisition have diversify company exist pharmaceutical distribution service business attractive animal health market hold huge potential moment meanwhile acquisition pharmedium enhance company ability provide market lead service solution health system customer segment be play increasingly important role healthcare market unite state believe benefit generic growth long run first quarter fiscal marked company consecutive quarter greater revenue growth part business end first quarter management confirm company strategic focuse effort be drive generic product volume growth offset historic deflation rate notably company be well position ensure product reach market patient access traditional complex new therapy site care strong organic growth rate pharmaceutical market improve patient access care improve economic condition population demographic introduction new innovative drug hepatitis drug well consistent brand pricing environment drive growth also company world courier business have be fare well notably end first quarter fiscal world courier company own office be spread more country investigational drug depot locate emerge market worldwide other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
181,PKI,varian medical system inc var free report have be healthy growth trajectory late positive tiding regulatory front have lend company competitive edge medtech space solid prospect zack rank buy stock be attractive pick moment varian medical have outperformed industry last month stock have gain higher industry stock have market cap company have positive earning surprise last quarters also have long term expect earning growth rate company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity company estimate revision trend current year have be encourage well past couple month estimate moved north movement opposite direction earning share estimate rise let find recent positive trend be sustainable factor drive varian medicalpositive regulatory tiding varian medical recently announce receipt regulatory clearance antitrust authority german federal cartel office fco acquisition sirtex medical limit transaction be expect strengthen varian medical footprint australia close varian medical equip mexico center instituto mexicano del seguro social imss have select varian medical equip treatment center mexico modern radiotherapy treatment system include edge system image guide stereotactic radiosurgery evinance innovation acquisition varian medical recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company deal be initiate last september varian medical have state utilize evinance patented technology offer better service client other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
182,PKI,qiagen qgen free report announce international panel physician association ippa have endorse quantiferon tb gold qft immigrant medical screening management innumerable migrant suffer latent active tuberculosis tb year consequently prudent usage qiagen qft aid curb challenge public health come quarters do ippa endorse qft notably ippa be not profit physician education group work country receive immigrant refugee press release ippa call modern class tb test know interferon gamma release assay igra essential safety efficacy screening program design early detection tb infection post center disease control cdc division global migration quarantine announcement expand tb testing requirement ippa endorse use qft immigration medical screening cdc announcement expand tb testing requirement be effective oct prior announcement guideline tb testing be limit child age previously immigrant have option use tst igra however new guideline require igra testing immigrant adult child apply legal status unite state tst method longer be accept immigration screening panel physician practice abroad appoint receive country government take care mandatory pre departure medical examination migrant now be require use igra tb screening notably be more half migrant year receive permanent lawful residence unite state qft unit glancebuilt quantiferon tb gold qft platform qft provide enhance analysis tb infection advanced kit make tb testing innovative antigen possible measure cell mediate immune response cd cd cell believe approval help qiagen expand customer base drive uptake qft test consequently boost top line qft be register more country europe middle east africa asia latin america qft be also endorse world health organization igra campaign eradicate tb quantiferon tb diagnostic test kit fall qiagen molecular diagnostic segment be highest revenue grosser last report quarter notably segment contribute total revenue last report quarter substantial growth quantiferon latent tb test qiasymphony automation system consumable portfolio solid performance companion diagnostic pharma collaboration development qftin regard post receipt fda approval june qiagen have announce complete launch fourth generation blood test tb infection qft unite state furthermore continue slew development qiagen announce signing collaboration agreement diasorin january post collaboration qiagen quantiferon tb diagnostic test be available diasorin liaison portfolio fully automate analyzer qiagen recently announce receipt japan ministry health labor welfare approval qft diagnostic detect tb infection market prospectsaccord research market datum publish business wire global tb diagnostic market be expect see cagr consider bullish market sentiment believe latest development have arrived opportune moment share price have be gain investor confidence consistently encourage result past month company share price have outperformed industry stock have gain contrast industry decline zack rank key picksqiagen carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
183,PKI,boston scientific bsx free report recently broaden endoscopy portfolio buyout privately hold company emcision limit presence canada financial term deal have be keep wrapped company expect deal prove accretive earning post post acquisition boston scientific endoscopy portfolio include emcision fda approve ce marked habib endohpb probe notably habib endohpb probe be innovative endoscopic bipolar radiofrequency device coagulate tissue gi tract moreover habib endohpb probe aids treatment palliative care patient diagnosed cancer glimpse endoscopy businessboston scientific endoscopy division develop manufacture device treat variety digestive disease include affect oesophagus stomach liver pancreas duodenum colon revenue division rise year year last report quarter upside be drive strength biliary hemostasis endochoice ambulatory surgery center portfolio company also witness organic revenue growth segment last november boston scientific complete integration endochoice endoscopy business acquire endochoice holding focus development pathology service infection control product single use device treat variety condition thus believe latest buyout help boston scientific boost top line contribution endoscopy business market prospectsper market datum forecast report global pancreatic cancer therapeutic market be project reach value cagr period upbeat prospect market be primarily base rise consumption tobacco unhealthy lifestyle practice smoking age population obesity company death annually be attribute cancer globally thus addition habib endohpb probe help boston scientific cash abundant opportunity pancreatic cancer therapeutic market share price movementover past month boston scientific have be outperform industry stock have gain compare industry gain zack rank key picksboston scientific carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
184,PKI,abiom inc abmd free report scale new week high feb eventually close bit lower company share have gain last month compare broader industry gain headquarter danver abiom be engage develop manufacturing marketing medical product design assist replace pump function case heart failure be currently top perform stock medtech space improvement price performance strong fundamental indicate stock bullish run therefore haven take advantage price appreciation yet time add stock portfolio long term expect earning growth rate also hold promise solid stock have market cap abiom year historical growth rate be also favorable compare broader industry company have zack rank hold indicate robust fundamental expectation line performance term company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity factor drive stocklet take look major factor have be boost abiom late strong earning resultsabiom recently exit third quarter fiscal better expect revenue margin quarter company witness breakthrough term record revenue earning growth also expansion margin buoy optimism guidance raisedbase strong third quarter performance company raise fiscal revenue guidance again earlier fourth quarter revenue be estimate year year basis guidance operate margin fiscal have also be raise earlier expectation regulatory approval impella product lineabiom recently announce expand fda pre market approval pma flagship impella impella cp impella impella ld heart pump expand pma heart pump now be used treat heart failure associate cardiomyopathy lead cardiogenic shock include peripartum postpartum cardiomyopathy also abiom recently announce flagship impella impella cp heart pump have receive pma fda expand use product now be used elective urgent high risk percutaneous coronary intervention procedure bcc research global market cardiac medical device be project reach cagr consider prospect niche space expect abiom gain solid market traction year come northward estimate revisionfive estimate current quarter moved north past day southward revision indicate analyst optimism zack consensus estimate adjust earning increase current quarter much cent also year year growth be expect positive trend signify analyst bullish sentiment key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson have zack rank company have long term expect earning growth rate breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
185,PKI,edward lifescience corporation ew free report announce receipt ce mark self expand centera valve valve be used severe symptomatic aortic stenosis patient high risk open heart surgery however centera valve be not approve commercial sale unite state company edward centera valve be repositionable retrievable be deliver low profile french motorize delivery system ce mark be base centera eu trial result be present europcr study enrolled high risk patient center europe australia new outcome trial demonstrated high survival rate low rate disable stroke new permanent pacemaker day regulatory approval be likely boost company transcatheter heart valf thv segment precisely thv focusthv segment include technology design treat heart valve disease used catheter base approach opposed open surgical technique fourth quarter company report thv sale growth prior year quarter double digit procedure growth europe latest development be likely further enhance company prospect europe outside unite state underlie growth rate be contribution region late edward lifescience have witness multiple development thv segment edward lifescience announce receipt fda approval aortic mitral valve valve procedure used sapien transcatheter heart valve june management release positive patient outcome sapien valve include high survival rate low rate stroke paravalvular leak market potentialtaking consideration huge growth potential thv market recent ce mark centera valveis strategic persistence market research report global heart valve repair replacement market be project reach worth cagr share price estimate revision trendedward lifescience have be gain investor confidence consistently positive result last year company share price have outperformed industry stock have gain compare industry current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank other key picksedward lifescience carry zack rank buy few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
186,PKI,perkinelmer inc pki free report be top perform stock medtech space improve price performance strong fundamental reflect stock bullish run thus haven take advantage share price appreciation yet time add stock portfolio company have perform impressively fourth quarter be likely sustain momentum upcoming period attractive pick share price appreciationa glimpse company price trend reveal stock have have impressive run bourse last month perkinelmer share have return compare favorably index rally current return be also higher industry gain northward estimate revisionnine estimate current year earning moved north last day versus downward revision indicate analyst optimism period zack consensus estimate rise share company hold zack rank buy indicate robust fundamental expectation outperformance term perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote promising company have issue adjust earning share guidance furthermore revenue be expect be range organic growth project be zack consensus estimate earning cent current quarter reflect year year growth moreover earning be expect register growth zack consensus estimate revenue be current year reflect year year growth moreover revenue be expect grow improve operate operate margin continue improve back productivity initiative volume leverage broad spectrum product new product integration be expect improve product mix also drive gross margin also stringent cost control be expect drive operate margin further exit fourth quarter solid note discovery analytical solution segment register organic growth upside be attribute product introduction healthy growth major region company have also be benefitting latest acquisition euroimmun laboratory diagnostic ag majorly drive diagnostic segment sale report quarter euroimmun alliance have add autoimmune allergy testing company portfolio well additional infectious disease testing capability addition euroimmun tulip diagnostic increase company headcount diagnostic more employee significantly bolster research development sale clinical capability other key picksa few other top rank stock broader medical space be amphastar pharmaceutical inc amph free report hca healthcare inc hca free report athenahealth inc athn free report stock sport zack rank strong buy see complete list today zack rank stock here amphastar have impressive expect long term growth rate last month stock have rally hca healthcare have project long term growth rate last month stock have gain athenahealth have long term growth rate last month stock have gain hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
187,PKI,medtronic plc mdt free report have present positive datum home pediatric study patient age year notably datum be base minime system be demonstrated advanced technology treatment diabetes international conference vienna austria study result multus center study have enrolled participant year age group trial consist week run phase study phase month participant choose continue used system part continue access program moreover study result demonstrated datum pivotal trial minime system patient age year used study result company have apply expand fda approval include patient range year eligible used minime system same time company be work expand usage product child age year hope be harbore effectiveness system get greater customer adoptability time minime glancepost receipt fda approval medtronic have commercially launch minime system june be hybrid close loop insulin delivery system type diabetic patient age year older minime system feature medtronic latest guardian sensor glucose sensor increase accuracy enhance performance be only fda approve sensor control hybrid close loop system include diagnostic technology continuously check sensor health system also carry medtronic most advanced algorithm know smartguard hcl technology development diabetes witness sluggish growth diabetes business last quarter however company gain strong uptake new sensor augment insulin pump system unite state well international market growth be temporarily offset limit supply continuous glucose monitor cgm sensor moreover strong customer enrollment priority access program briefly affected revenue management diabetes business witness revenue growth third quarter fiscal company have finished shipping pump priority access program also company be move steadily sensor capacity expansion plan schedule be complete fourth quarter fiscal additionally medtronic gear international launch minime launch cgm system guardian connect sugar iq late new professional cgm ipro regard company also announce favorable result support use cgm person type diabetes october apart be upbeat corporation johnson johnson diabetes care company exit insulin pump business medtronic partner support transition patient caregiver healthcare provider notably patient used insulin pump be offer choice switch medtronic pump market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth diabetes market report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe latest positive study result have come opportune moment share price have be gain investor confidence consistently positive result past month company share price have outperformed broader industry stock have gain comparison broader industry increase zack rank key picksmedtronic carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company be zack rank player company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
188,PKI,genomic health inc ghdx free report announce use oncotype dxgenomic prostate score gps test lead considerably higher use active surveillance month compare testing same time period publish reviews urology result large independently conduct study bring collective publish clinical utility evidence study nearly man show impact gps test treatment plan study assessed nearly identify record examine active surveillance use patient test oncotype dx gps test result demonstrated man receive gps test active surveillance use be more higher man do not receive genomic test press release publication also solidify evidence gps testing initial management early prostate cancer ability appropriately direct active surveillance use low risk patient development prostate cancergenomic health recently announce multus year research collaboration agreement janssen pharmaceutical partnership company evaluate responsiveness genomic health oncotype dx gps test janssen prostate cancer drug pipeline november genomic health announce exclusive licensing agreement biotechnology company cleveland diagnostic inc deal genomic health be authorize develop market early late stage new prostate cancer diagnostic test base cleveland diagnostic proprietary isopsa reagent sia technology also october new study result be publish validate oncotype dx genomic prostate score test ability predict prostate cancer death development metastase year study oncotype dx gps test be now uniquely validate predict long term endpoint well risk adverse pathology again august genomic health expand medicare coverage oncotype dx gps test post issuance positive final local coverage determination lcd palmetto gba medicare administrative contractor mac management successful implementation final lcd october total number medicare patient eligible gps test increase market prospectsper report grand view research global prostate cancer therapeutic market be expect see cagr consider huge potential market believe latest agreement be strategic fit genomic health gain more share space stock performance solidover past year genomic health have be trading broader industry stock have gain industry rally zack rank key picksgenomic health carry zack rank sell better rank stock broader medical sector be bio rad laboratory bio free report resm inc rmd free report perkinelmer pki free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate resm have zack rank company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
189,PKI,feb issue update research report idexx laboratory inc idxx free report stock carry zack rank buy lead molecular diagnostic company have be trading broader industry stock have gain past month compare broader industry idexx exit fourth quarter solid note moreover strong year year growth organic revenue raise guidance earning share be encourage stellar performance be drive strong sale cag business fourth quarter cag organic revenue rise low double digit strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth be upbeat company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover strong top line growth quarter be drive considerable contribution rest business segment be also upbeat company witness double digit organic revenue growth international business reflect continue consumable revenue gain support catalyst instrument base average testing utilization additionally company have strong cash balance allow carry share repurchase meanwhile majority idexx consolidated revenue have be derive sale product international market thus strengthen rate exchange dollar relative other currency have negative impact revenue derive currency other dollar profit product manufacture unite state sell internationally also company high dependence third party distributor be concern other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report resm rmd free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock have zack rank resm have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
190,PKI,omnicell inc omcl free report report adjust earning exclude time tax benefit tax reform share cent fourth quarter beating zack consensus estimate couple cent figure be high end guide range cent earning improve year figure cent well revenue timing headwind fourth quarter strong gross margin improvement solid control operate expense result upside adjust ep full year adjust earning come compare year figure figure surpass zack consensus estimate omnicell inc price consensus ep surprise omnicell inc price consensus ep surprise omnicell inc quote revenue detailadjust revenue fourth quarter increase year year miss zack consensus estimate also figure be earlier provide guidance owing timing specific large install account delay full year adjust revenue come year period figure miss zack consensus estimate segmental basis omnicell automation analytic revenue increase year year fourth quarter however revenue medication adherence segment rise year year operational updateomnicell gross profit report quarter increase gross margin expand basis point bps accord company adjust gross margin provide company fourth quarter be reflect expansion bps year year sg expense fourth quarter increase year year research development expense rise year year operate expense be fourth quarter year year adjust operate expense quarter totale year quarter financial updateomnicell exit cash cash equivalent compare end first quarter omnicell expect adjust revenue band include impact selling cost reduction revenue company expect first quarter adjust earning range cent share zack consensus estimate first quarter revenue be peg earning share cent omnicell expect product booking range also company expect adjust revenue band include impact selling cost reduction revenue company also expect adjust earning be band share zack consensus estimate full year earning share be peg company guide range zack consensus estimate full year revenue stand company guide range takeomnicell fourth quarter performance be impressive year year increase earning revenue further company segment witness year year growth be encourage note company be work product innovation also omnicell be expect gain recent launch strategic partnership last december company announce xr automate central pharmacy system same month company announce ivx operate ivx cloud create significant technological advancement sterile compound process enable pharmacy safely efficiently compound prepare iv dose improvement margin be also encourage however tough competitive landscape act dampener zack rank key picksomnicell have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
191,PKI,quest diagnostic inc dgx free report fourth quarter adjust earning share ep beat zack consensus estimate cent year number adjust ep report quarter exclude certain tax benefit record result tax cut job act tcja report ep come surge year quarter figure full year adjust ep come share increase year adjust number cent ahead zack consensus estimate report revenue fourth quarter inched year year marginally line zack consensus estimate accord company year year improvement come back successful execution point strategy accelerate growth drive operational excellence quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate quotevolume measure number requisition increase year year fourth quarter also revenue requisition increase diagnostic information service revenue quarter rise year year basis cost service report quarter be year year gross margin come reflect basis point bps expansion year year operate expense selling general administrative expense increase report quarter accordingly adjust operate margin show contraction bps quest diagnostic exit year cash cash equivalent compare year quarter full year net cash provide operate activity be compare year period fourth quarter company repurchase share dec quest diagnostic be left authorization previous share repurchase plan outlookquest diagnostic have provide guidance exclude impact special item amortization expense etb excess tax benefit associate stock base compensation adjust ep full year be project range zack consensus estimate fall guide range revenue be expect range annualize growth current zack consensus estimate revenue be peg ahead company project range operate cash flow be expect current estimate capital expenditure be peg takequest diagnostic fourth quarter earning exceed zack consensus estimate revenue remain line same positive note company be currently refocusing core diagnostic information service business work discipline capital deployment be also highly optimistic company focus point strategy company several new collaboration hospital integrate delivery network continue act major growth driver flip side last couple year quest diagnostic face several reimbursement issue hurt revenue company be concern cms center medicare medicaid service proposal related protect access medicare act notably december company key member american clinical laboratory association acla have come forward support lawsuit file acla act secretary department health human service hhs lawsuit charge cms operate purview hhs have fail follow congressional directive implement market base laboratory payment system company have not positively take latest center medicare medicaid service cms publication propose medicare reimbursement rate clinical laboratory test clinical lab fee schedule clf be currently request cms delay implementation pama protect access medicare act zack rank key pickscurrently quest diagnostic carry zack rank hold few better rank stock report solid earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent bottom line soar year year revenue report quarter rise year year basis perkinelmer release fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal narrower year figure cent top line improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
192,PKI,varian medical system inc var free report recently announce have receive regulatory clearance antitrust authority german federal cartel office fco acquisition sirtex medical limit bid become global leader multus disciplinary integrate cancer care solution varian medical sign agreement acquire australia base global life science company onjan favorable price performanceover past year varian medical outperformed industry term price performance company share have return compare favorably industry rally also current return be higher index gain strong revenue various oncology imaging component product focus inorganic growth strong overseas presence emerge country be positive deal transaction be expect strengthen varian medical footprint australia close acquisition be accretive earning share first fiscal close transaction acquisition be likely provide customer wider range cancer care solution deal be expect expand varian medical addressable market interventional oncology management varian leverage capability treatment plan delivery image guidance process oncology practice management software radiation safety unit sirtex interventional oncology platform sirtex be global leader focus interventional oncology therapy company have distribution operation unite state europe asia regulatory approvalvarian medical get early termination wait period hart scott rodino antitrust improvement act deal act company be not permit complete schedule merger acquisition transfer security asset have make detailed filing federal trade commission department justice further company ensure transaction not affect commerce current antitrust law german fco also approve propose acquisition confirm do not violate act restraint competition oncology segment get boostvarian medical oncology segment apac be likely get boost post deal closure oncology system be varian medical largest operate business segment last quarter net oncology revenue totale year year basis gross order be year quarter apac gross order increase year year strong order growth greater china japan operate earning segment rise market potentialper research market global oncology market be estimate witness cagr international emerge market be equip address grow incidence cancer company strong overseas presence enable cash opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly australia be grow faster rate domestic market however company face stiff competition accuray incorporate aray free report oncology technology space zack rank other stock considervarian medical have zack rank buy other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
193,PKI,medtronic plc mdt free report announce receipt fda approval guardian connect continuous glucose monitoring cgm system diabetes patient age year notably system be available first quarter medtronic fiscal year july guardian connect cgm guardian connect be first only standalone cgm system help diabetes patient be aware potential high low glucose event minute advance notably guardian connect enable patient use multiple daily injection mdi manage disease proactively patient relative stay inform track glucose real time even receive text alert system system user have exclusive access sugar iq smart diabetes assistant help deal regular complication related diabetes sugar iq assistant consistently study response individual glucose level food intake insulin dosage daily routine other factor sugar iq assistant combine guardian connect transform difficult determine pattern personalize well actionable insight enable patient keep glucose level target range press release latest sensor withintelligent algorithms allow user predict understand glucose excursion particularly hypoglycemia be likely make diabetes more comprehensible person inject insulin used cgm help diabetes patient achieve more glycemic time range reduce risk hypoglycemia diabetes business consistently try enhance diabetes business medtronic witness rise constant exchange rate diabetes business revenue third quarter fiscal company benefit positive uptake new sensor augment insulin pump system unite state international market enhance production capacity same recently company announce fda have approve new arm indication guardian sensor continuous glucose monitor cgm be used minime insulin pump notably medtronic expect double digit growth segment fourth quarter fiscal courtesy consistent performance minime system unite state enhance sensor supply capacity additionally medtronic have be gear international introduction minime launch new professional cgm ipro market potentialan agee population unhealthy lifestyle rise awareness higher expenditure healthcare be likely drive growth highly competitive diabetes market report mordor intelligence global market diabetes care device be project reach value cagr consider bullish market sentiment believe latest development have arrived opportune moment stock performance estimate revisionover past month share medtronic have underperform industry stock have return compare industry rally index gain also estimate revision trend current year be unfavorable estimate move south last month compare opposite direction earning estimate fall share zack rank key picksmedtronic carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
194,PKI,mckesson mck free report report third quarter fiscal earning share beating zack consensus estimate earning surpass year quarter figure notably third quarter gaap earning share include net tax benefit drive tax cut job act mckesson post sale beating zack consensus estimate prior year quarter mckesson corporation price consensus ep surprise mckesson corporation price consensus ep surprise mckesson corporation quotequarter detailmckesson operate segment distribution solution technology solution growth rate give be year year basis distribution solution revenue be quarter report basis constant currency cc basis revenue north america pharmaceutical distribution service be quarter report basis cc international pharmaceutical distribution service revenue be report basis cc upside be drive acquisition market growth medical surgical distribution service revenue be third quarter technology solution adjust operate profit be third quarter management segment witness lower profit thank divestment enterprise information solution business negative impact reduce reimbursement company retail pharmacy business marginsas percentage revenue gross margin contract basis point quarter third quarter adjust operate profit be cc year year basis adjust operate margin distribution solution segment be net revenue cc financial conditiona dec mckesson have cash cash equivalent first month year mckesson repay long term debt paid acquisition notably mckesson repurchase common stock invest internally paid dividend fiscal outlookmckesson expect gaap earning share range fiscal result lower tax rate adjust earning same be expect range previous range company announce declare regular dividend cent share common stock dividend be payable april stockholder record march zack rank price carry zack rank hold last month mckesson have be trading broader industry company share have gain compare broader industry rally current level be lower index return just pricing pressure independent retail pharmacy channel be headwind further intense competition currency headwind reimbursement issue be challenge add wo revenue technology solution be expect deteriorate year year company report impressive resultsa few better rank stock report favorable result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
195,PKI,baxter international inc bax free report report fourth quarter adjust earning share cent beat zack consensus estimate cent improve year quarter figure cent baxter have zack rank hold figure also come company guidance cent last quarters company deliver positive earning surprise average be baxter post sale marginally beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quotesegmental detailshospital productssale hospital product segment rise cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand injectable pharmaceutical hospital pharmacy compound service sale segment benefit solid demand company advanced surgery product cytotoxic contract manufacturing service renal productssale segment increase cc renal product sale be support improve performance major product line therapy globally notably solid performance chronic acute renal therapy drive sale segment consistent effort increase productionper management company puerto rico facility affected hurricane be ramp production additionally baxter have be work closely fda support supply certain product domestic market be caution importation baxter facility ireland australia canada mexico england italy brazil fourth quarter baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa oxiris leverage company flagship prismaflex system be expect lend company competitive edge global market recently company upgrade sigma spectrum infusion system launch devicevue advanced asset tracking system baxter be first only smart infusion pump manufacturer offer tagless end end acid tracking application design consultation potential customer drive operational efficiency maximize clinical value pump investment baxter estimate sale growth approximately cc adjust earning full year be expect band share baxter expect first quarter range cent however baxter expect sale first quarter be affected approximately due disruption puerto rico facility glancein baxter register revenue cc year year basis sale hospital product totale net sale baxter renal sale totale more year net sale baxter increase annual dividend rate repurchase worth share also pursue internal external initiative augment growthour takebaxter end fourth quarter encourage note beating zack consensus estimate count company impressive performance hospital product renal segment hold promise recently baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa further recent launch devicevue comprehensive asset tracking solution available exclusively hospital boost company product portfolio flip side foreign currency headwind intense competition lackluster sale growth have be dampening baxter performance long generic competition be headwind further recent hurricane be expect dent company result term company report solid earning resultsa few better rank stock report decent result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
196,PKI,idexx laboratory inc idxx free report report fourth quarter adjust earning share ep cent exclude negative impact cent share due tax reform adjust ep figure surpass zack consensus estimate cent report ep come cent full year report ep come share moreover report earning figure be comparable constant currency basis revenue detailrevenue rise year year organic basis surpass zack consensus estimate worldwide sale year come year year report basis figure also surpass zack consensus estimate year year upside be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quote segmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other fourth quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue grow organically revenue other segment rise organically marginsgross profit increase report quarter however gross margin contract basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense rise operate margin quarter improve bps financial positionidexx exit fiscal cash cash equivalent end net cash provide operate activity be compare year period guidanceidexx raise revenue outlook previous reflect organic revenue growth expectation compare state previously zack consensus estimate revenue be peg guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis compare state previously zack consensus estimate ep be peg guide range takeidexx exit fourth quarter solid note moreover solid year year growth organic revenue raise ep guidance be encourage stellar performance be drive strong sale cag business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment zack rank other key picksidexx have zack rank buy few other top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent improve prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
197,PKI,illumina inc ilmn free report report adjust earning share ep fourth quarter beat zack consensus estimate adjust earning surpass year number include time item company report ep cent compare cent year include provisional estimate time transition tax impact tax reform full year adjust ep come beating zack consensus estimate moreover figure beat year number revenuesin quarter review illumina revenue grow year year top line beat zack consensus estimate net revenue totale outpace zack consensus estimate figure also improve year number management top line growth fourth quarter be attribute strong uptake sequence consumable instrument well microarray portfolio moreover novaseq platform continue drive growth close novaseq system currently customer hand launch january product revenue total revenue increase year year service other revenue be year year illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc updateadjusted gross margin come reflect expansion basis point bps year year owing favorable product mix sequence consumable exclude amortization acquire intangible asset include stock base compensation expense adjust gross margin be highlight expansion bps year research development expense be year year selling general administrative expense rise however adjust operate margin reflect rise bps year quarter financial updateillumina exit cash cash equivalent short term investment net cash provide operate activity be compare year project full year revenue growth range meanwhile zack consensus estimate revenue be peg adjust certain net specify item full year adjust earning share continue operation be expect band zack consensus estimate earning stand low end project range takeillumina exit fourth quarter solid note be encourage year year increase front management be hopeful product novaseq recently launch iseq broad clinical portfolio comprise veriseq nipt solution nextseqdx miseqdx drive top line moreover improve margin buoy optimism meanwhile company be operate tough competitive landscape be concern zack rank key picksillumina have zack rank hold few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning prior year quarter revenue increase year year constant exchange rate cer perkinelmer report fourth quarter adjust earning cent company report adjust revenue approximately surpass year quarter accuray report loss cent second quarter fiscal cent narrower year figure total revenue increase year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
198,PKI,align technology inc algn free report fourth quarter adjust earning share ep come exclude net expense share impact tax reform report ep come cent adjust ep figure be year year earning be also higher company guide range cent figure beat zack consensus estimate cent full year adjust ep come beating zack consensus estimate moreover figure beat year number revenuesrevenue grow year year quarter surpass zack consensus estimate revenue be well ahead company guide range net revenue totale outpace zack consensus estimate figure also improve year number align technology inc price consensus ep surprise align technology inc price consensus ep surprise align technology inc quote management top line be drive year year increase invisalign case shipment fourth quarter upside be drive growth north america international region expand customer base increase utilization moreover increase revenue itero scanner contribute top line segment detailrevenue clear aligner segment total revenue soar year year report quarter primarily drive continue strong invisalign case volume growth customer channel geographical region fourth quarter invisalign case shipment amount year year aid growth region well expansion customer base quarter align technology invisalign case be ship doctor worldwide be north america international region revenue scanner service improve significant marginsgross margin quarter review be basis point bps year year spite rise cost net revenue quarter align technology witness year year increase selling general administrative expense rise research development expense operate margin expand bps financial detailsalign technology exit cash cash equivalent short term marketable security marked rise report quarter align technology repurchase share stock april stock repurchase program company currently have approximately left buy back program first quarter company project ep cent revenue company project invisalign case shipment band year meanwhile current zack consensus estimate first quarter ep be cent revenue estimate be fall project range takealign technology end fourth quarter solid note be upbeat continue strength invisalign volume gp dentist see higher demand north america follow summer holiday season orthodontist witness increase adult patient footfall busy season precede quarter internationally be encourage strength emea asia pacific market scanner service company witness strong uptake itero scanner gp dentist record contract come gp summit last september moreover increase uptake due recent deal patterson dental align itero element intraoral scanning system also contribute top line company witness solid demand itero scanner emea asia pacific well align technology have strong cash balance enable carry share repurchase turn provide solid return investor flip side company be expose foreign exchange fluctuation seasonal demand fluctuation higher operate expense pertain increase head count higher investment target expansion geographical presence portfolio zack rank other key picksalign technology carry zack rank buy other top rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank see complete list today zack strong buy rank stock here resm post second quarter fiscal adjust earning prior year quarter revenue report quarter increase year year constant exchange rate cer perkinelmer report fourth quarter adjust earning cent company report adjust revenue approximately surpass year quarter accuray report loss cent second quarter fiscal cent narrower year figure total revenue increase year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
199,PKI,zimmer biomet holding inc zbh free report report fourth quarter adjust earning share year year line zack consensus estimate reportedly net earning come compare year quarter cent notably report net earning include time tax benefit approximately recently enact tax reform legislation full year adjust earning share come line zack consensus estimate however figure beat year number revenue detailsfourth quarter net sale come mark increase constant exchange rate cer year year net sale also surpass zack consensus estimate net sale totale surpass zack consensus estimate figure also beat year number full year sale increase prior year cer exclude approximately basis point contribution ldr hold corporation acquisition quarter sale generate americas be year year cer same emea europe middle east africa gross asia pacific however register growth cer segmentssale knee be year year cer hip record increase cer prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record marginal improvement cer dental be quarter other revenue increase marginsgross margin come reflect expansion bps fourth quarter selling general administrative expense be however research development expense decline adjust operate margin expand bps quarter cash positionzimmer biomet exit year cash cash equivalent compare end third quarter total long term debt be compare end precede quarter full year operate cash flow be compare year period company also paid dividend fourth quarter company have issue first quarter guidance sale be project range represent change negative positive negative negative constant currency basis compare prior year quarter be inclusive negative impact related approximately less bill day compare year earlier quarter current zack consensus estimate lie guide range adjust ep quarter be expect remain band zack consensus estimate remain guide range takezimmer biomet end quarter positive note be also encourage company consistent effort product renovation research development be optimistic synergy ldr hold acquisition broaden complement company musculoskeletal range be also impressed strong strategic financial goal combine entity expect reach however be disappoint company decline sale knee segment cer zack rank key pickszimmer biomet have zack rank sell few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately surpass year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter increase year year don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now be reissue article correct mistake original version publish earliertoday longerbe rely
200,PKI,perkinelmer inc pki free report be currently top perform stock medtech space improve price performance strong fundamental instill confidence investor therefore haven take advantage stock price appreciation yet time add portfolio company have perform impressively first quarter be likely sustain momentum upcoming period past year share perkinelmer have rally significantly outperform industry growth just past day zack consensus estimate earning share rise cent company have zack rank buy indicate possibility outperformance term let find recent positive trend sustain stock impressive performance long run make attractive pick solid exit first quarter solid note earning cent share surpass zack consensus estimate revenue inched core discovery analytical solution da segment revenue totale quarter year year organic revenue increase year year revenue diagnostic segment gross reflect year year increase also show improvement organically raise perkinelmer expect adjust earning share be significantly higher previously issue guidance company project revenue earlier issue range unfavorable foreign exchange environment act deterrent quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion broad spectrum deliver comprehensive suite scientific informatic software solution aggregate datum actionable insight automate scalable way company product consist industry lead chemdraw software electronic lab notebook include cloud base element saas offer enterprise notebook solution tibco spotfire platform scientific datum analytic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
201,PKI,maintain streak positive earning surprise perkinelmer inc pki free report report first quarter adjust earning cent share beating zack consensus estimate base waltham lead medtech company report adjust revenue approximately beat zack consensus estimate revenue also surpass year quarter figure stock carry zack rank buy perkinelmer have outperformed industry year time stock have return higher industry return almost segment analytical solution da robust growth end market revenue da totale first quarter year year organic revenue increase year year perkinelmer have be focuse finalize organizational change associate life science business da unit come profit da segment company report first quarter adjust operate income year quarter perkinelmer register high single digit organic revenue growth asia mid single digit organic revenue growth americas europe bric region perkinelmer report solid organic revenue growth drive continue strength brazil india end first quarter management perkinelmer confirm company be now offer product line china da segment perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote further company be also expect close acquisition china expand elemental analysis product da business solid growth life science apply market boost company business china diagnostic segmentrevenue be compare year reflect year year increase reflect improvement organically diagnostic business perkinelmer infectious disease business exclusively serve emerge market continue show strong growth increase mid digit year year basis reproductive health business diagnostic also grow mid single digit year year however apply genomic business be year year basis due lesser expect micro fluidic sale adjust operate income segment come compare first quarter margin analysisadjust gross profit quarter come year year adjust gross margin percentage revenue be quarter basis point bps year year company expect significant gross margin expansion next year adjust operate income perkinelmer come year year adjust operate margin percentage revenue be quarter basis point bps year year guidance full year perkinelmer expect adjust earning share be significantly higher previously issue guidance notably zack consensus estimate be currently peg share significantly company estimate company expect revenue previously issue range zack consensus estimate be currently peg lower company estimate unfavorable foreign exchange environment put solid pressure quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion exit first quarter solid note strong performance da segment growth da be bolster strength lifescience end market informatic profile onesource offer company experience healthy growth major geography asia americas europe bric nation solid prospect elemental analysis product line hold promise furthermore positive guidance solid long term outlook boost investor confidence stock flipside have diversify portfolio unfavorable foreign exchange be primary concern softness industrial end market due unfavorable timing instrument order have be major dampener perkinelmer further company continue acquire large number company increase integration risk also high debt level hinder company expansion plan earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
202,PKI,investor be always look stock be poise beat earning season perkinelmer inc pki free report be such company firm have earning come pretty soon event be shape quite nicely report be perkinelmer be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface pki report analyst have very recently bump estimate pki give stock zack earning esp head earning season perkinelmer inc price ep surprise perkinelmer inc price ep surprise perkinelmer inc quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give pki have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead perkinelmer beat be card upcoming report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
203,PKI,perkinelmer inc pki free report first quarter result expect release apr market close be likely show steady growth core diagnostic business prove be major driver decline revenue other segment mar overall result fourth quarter fiscal company report adjust earning cent share beating zack consensus estimate cent meanwhile revenue be approximately beat zack consensus estimate revenue also surpass year quarter notably first quarter zack consensus estimate earning be peg cent reflect year year growth same revenue be pin indicate growth perkinelmer deliver average positive earning surprise trail quarters perkinelmer inc price ep surprise perkinelmer inc price ep surprise perkinelmer inc quotelet dig deeper diagnostic revenue focusdiagnostic revenue account total revenue last quarter revenue segment rise year also reflect improvement organically segment have be fortify company market position term exclusiveness service respective market diagnostic market company offer product be used detect genetic disorder perkinelmer also provide digital ray flat panel detector infectious disease testing solution diagnostic portfolio first quarter result be likely indicate strong growth diagnostic revenue last report quarter operate profit margin segment percentage revenue be basis point bps year year be also encourage note zack consensus estimate diagnostic segment be sequentially other factor playeuroimmun buyout divestment medical imaging business acquisition euroimmun medical laboratory diagnostic ag have be major driver segment perkinelmer announce completion euroimmun buyout approximately cash december euroimmun be autoimmune testing company emerge player infectious disease allergy testing space management euroimmun buyout have expand perkinelmer capability help gain considerable traction have lead increase diagnostic employee more strengthen company platform company be optimistic increase spending be likely account product revenue fourth quarter euroimmun contribute revenue approximately represent growth be also likely add bps perkinelmer organic growth discovery analytical solution da revenue da totale fourth quarter year quarter perkinelmer have be focuse finalize organizational change associate life science business da lately company have collaborate helix develop commercialize sequence base test help consumer take proactive health management decision however zack consensus estimate revenue be sequentially guidance company issue adjust earning guidance adjust earning be expect share further expect report revenue range include approximately foreign exchange tailwind euroimmun perkinelmer project organic revenue growth thus perkinelmer be confident improve growth trajectory first quarter quantitative model show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp perkinelmer be uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
204,PKI,water corporation free report be schedule report fourth quarter result open bell jan last quarter company adjust earning beat zack consensus estimate overall water corp outpaced estimate trail quarters average positive surprise let see thing be shape announcement factor considerwater corp key strength include lead position pharmaceutical market broad global customer base impressive lineup product particularly global pharmaceutical business be company largest single market have be major profit churner water division past few quarters believe stable demand pharmaceutical business modest recovery industrial market well growth recur revenue benefit fourth quarter result moreover company remain bullish industrial business backed increase regulation food safety quality strict condition food testing environmental fine chemical application additionally increase demand research intensive product especially company mass spectrometry solution be positive business be likely bolster fourth quarter sale last report quarter company benefit largely lc lc ms platform company liquid chromatography benefit acquity arc system mass spectrometry grow impressively drive acquity qda xevo family tandem quadrupole believe robust traction acquity cortec line product strength end market be likely prove conductive upcoming result however fact remain rise expense high interest expense remain burden consequently erode profitability upcoming result significant portion company revenue be generate market make vulnerable fluctuation exchange rate believe currency fluctuation put pressure top line growth margin quarter review further company grapple stiff competition several international instrument manufacturer well other company domestic foreign market company key technology hplc uplc ms lc ms thermal analysis rheometry calorimetry product line be part highly competitive industry be subject rapid change technology earning whispersour proven model do not conclusively show earning beat water corp time be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp water corp have earning esp uncover best stock buy sell re report earning esp filter water corporation price ep surprise water corporation price ep surprise water corporation quotezack rank company carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model show have right combination element post earning beat quarter analog device inc adi free report have earning esp zack rank see complete list today zack rank stock here amtek inc ame free report have earning esp zack rank perkinelmer inc pki free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
205,PKI,perkinelmer inc pki free report be expect release fourth quarter result jan market close last quarter company register adjust earning cent share beat zack consensus estimate cent further adjust revenue approximately also beat zack consensus estimate solid performance discovery analytical solution unit well diagnostic segment drive perkinelmer top line fourth quarter fact zack consensus estimate discovery analytical solution revenue be currently peg reflect improvement third quarter further zack consensus estimate diagnostic segment revenue be peg last quarter perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quotenotably perkinelmer have also outperformed industry last year stock have gain surpass industry rally let take look thing be shape prior fourth quarter earning announcement factor considerview upbeat zack consensus estimate perkinelmer fourth quarter earning be cent share reflect year year growth revenue consensus estimate be peg year year earlier management confirm company have be progress favorably original guidance cite begin fiscal expect better expect financial result fourth quarter company revise guidance adjust earning share full year regard perkinelmer now expect full year adjust earning share band compare previous range further post first quarter earning company raise revenue guidance well favorable market trend perkinelmer continue witness favorable market condition first time more year company experience positive organic growth region world end market operate last quarter expect company maintain momentum quarter be report look specifically end market pharma biotech diagnostic be expect see strong sale fourth quarter acquisition drive growth acquisition strategic partnership have prove be key growth catalyst perkinelmer recently company complete previously announce acquisition euroimmun medical laboratory diagnostic ag acquisition euroimmun expand perkinelmer reach autoimmune allergy diagnostic market also fortify company foothold cure new infectious disease management be optimistic acquisition drive growth fiscal solid product portfolio perkinelmer deliver comprehensive suite scientific informatic software solution aggregate datum actionable insight automate scalable way company launch new mass spectrometry platform qsight triple quad lc ms ms clinical market last quarter qsight have already receive very positive response niche space be expect provide perkinelmer competitive edge medtech space fourth quarter company product include industry lead chemdraw software electronic lab notebook include cloud base element saas offer enterprise notebook solution tibco spotfire platform scientific datum analytic perkinelmer expand portfolio be help company market share worldwide thus perkinelmer be confident improve growth trajectory fourth quarter quantitative model conclusively show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp perkinelmer be most accurate estimate be be line zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp company positive esp make surprise prediction feasible stock worth lookhere be few similar medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank see complete list today zack rank stock here bioverativ inc have earning esp zack rank baxter international inc bax free report have earning esp zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
206,PKI,patterson company inc pdco free report report adjust earning cent share third quarter fiscal miss zack consensus estimate cent earning fall year year net sale dip year quarter beat zack consensus estimate adjust effect foreign currency exchange sale decline year year basis decrease sale gross margin compression mar company result report quarter patterson company inc price consensus patterson company inc price consensus patterson company inc quote patterson company have zack rank buy segmental company currently distribute product mainly subsidiary patterson dental patterson animal health dental segment provide virtually complete range consumable dental product equipment software turnkey digital solution value add service dentist dental laboratory north america third quarter dental sale total sale decline cc year year approximately change sale force disruption enterprise resource plan implementation expansion company digital equipment portfolio mar revenue segmentdental consumablesale segment be year year dental equipment softwaresale segment decline year year basis other service segment be primarily compose technical service part labor software support service office supply decrease year year basis animal health segment be lead distributor product service technology production companion animal health market north america come third quarter performance platform total sale sale increase almost cc year year basis global companion animal sale inched production animal sale increase reflect strong performance swine beef cattle segment margin profit report quarter be year year percentage revenue gross margin contract basis point bps quarter operate income third quarter be year year percentage revenue operate margin expand bps quarter share repurchase updatepatterson company repurchase approximately share outstanding common stock report quarter company also paid cash dividend shareholder guidance company expect adjust earning share fiscal range share much lower previously issue range patterson company expect deal amortization expense cent share company estimate integration business restructure expense cent share takelackluster sale earning performance dampen patterson company fourth quarter result however be upbeat company animal health segment have be perform well lately company provide wide range consumable supply equipment software value add service company broad spectrum product cushion economic downturn medtech space believe diversify product portfolio strong veterinary business prospect accretive acquisition strategic partnership be key growth catalyst flip side downbeat guidance indicate loom concern ahead decrease revenue dental segment be headwind recent decline segment be drive decrease sale cerec digital technology product management expect headwind technology base equipment business persist fiscal key picksother top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
207,PKI,masimo corp masi free report report earning cent share fourth quarter outperform zack consensus estimate cent bottom line improve year quarter figure cent revenue improve year quarter beat zack consensus estimate segmental analysisproduct revenue product revenue deliver strong quarter double digit growth fourth quarter masimo acquire significant renewal renown hospital hospital system revenue growth segment be double digit product revenue also witness impressive growth overseas market new product include nomoline capnography sedline brain function monitoring organ oximetry contribute result revenue segment be year year company worldwide direct product revenue increase year year basis direct product revenue be total product revenue oem sale increase year year basis fourth quarter account total product revenue revenue sale masimo rainbow product surge fourth quarter compare year quarter royalty other revenuesrevenue segment be quarter year quarter management royalty revenue medtronic mdt free report decline margin analysistotal gross profit fourth quarter be year year gross margin be net revenue basis point bps year year product gross margin fourth quarter be net revenue compare year quarter balance sheetat end fourth quarter total cash cash equivalent be compare year quarter masimo repurchase approximately share common stock total cost revenue be estimate total product revenue be estimate royalty other revenue be estimate adjust earning share ar expect reflect increase approximately year year other company solid earning resultsother medtech company report impressive result earning season be petm express pet free report perkinelmer pki free report petm report third quarter fiscal result jan adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent jan adjust revenue be approximately year quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
208,PKI,dexcom inc dxcm free report report earning share ep cent fourth quarter beating zack consensus estimate also figure improve loss cent year quarter full year loss cent be narrower loss cent year quarter figure be also better zack consensus estimate loss cent total revenue grow year quarter revenue surpass zack consensus estimate full year revenue come beating zack consensus estimate figure also improve year number segmental detailssensor revenue other revenue total revenue grow year year basis transmitter revenue increase prior year quarter receiver revenue grow year year operational detailsdexcom generate gross margin percentage revenue expansion basis point bps year year international business display continue growth quarter generate revenue year year basis notably international business represent total revenue fourth quarter research development expense totale quarter year year selling general administrative expense totale report quarter increase year year financial updatefull year dexcom have cash cash equivalent short term marketable security versus end guidancedexcom reaffirm full year guidance company expect full year revenue range gross profit margin be project band report operate expense exclude investment intensive program be expect increase takedexcom exit fourth quarter solid note year year growth revenue earning be encourage expansion gross margin buoy optimism company be also focuse product innovation peer performancesome medical stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
209,PKI,luminex corporation lmnx free report report adjust earning cent share fourth quarter surpass zack consensus estimate cent adjust earning also increase year year gaap basis company report fourth quarter loss cent share consider necessary adjustment expect company tax obligation defer tax asset liability related passage tax cut job act revenue quarter increase almost year year outpace zack consensus estimate luminex corporation price consensus ep surprise luminex corporation price consensus ep surprise luminex corporation quote glancefull year earning share come cent share increase year number ahead zack consensus estimate cent full year revenue come increase year adjust number ahead zack consensus estimate system sale segment report total revenue assay revenue account total sale royalty revenue contribute total revenue year consumable sale contribute year other revenue segment also contribute service revenue contribute total revenue year segment analysissystem sale revenue increase year year basis notably company ship multiplexing analyzer quarter here note system include magpix lx flexmap also company place sample answer molecular system contract reach total number active customer more assay revenue assay revenue grow year year royalty revenue sale segment increase year year basis consumable sale revenue segment decline exit full year cash cash equivalent compare end marginsgross profit increase year quarter primarily drive higher revenue gross margin expand basis point bps increase volume verigene ary internal manufacturing process improvement result strong gross margin expansion adjust operate expense totale reflect decline year quarter selling general administrative expense increase research development expense contract year year meanwhile adjust operate margin expand massive bps revenue growth most segment gross profit expansion consistent effort control operate expense boost company operate margin quarter guidanceluminex provide annual revenue guidance range indicate growth midpoint year year company expect first quarter revenue band bottom lineluminex exit fourth quarter solid note company see strong top line solid cash flow well profit company also witness favorable tiding regulatory front regard company win fda nod ary group strep assay management be sixth assay fda have clear use ary system last year also be look forward company recently provide long term outlook be quite promising company expect achieve total revenue band increase cagr further expansion operate margin buoy optimism flip side low consumable revenue raise concern furthermore year year drop expense be discourage cutthroat competition niche space be headwind zack rank key picksluminex carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
210,PKI,mar issue update research report cooper company coo free report company carry zack rank hold cooper company maintain lead position specialty lens market support exclusive product biofinity clariti however intense competition contact lens space continue build pressure pricing company flagship silicone hydrogel lense be expect see strong sale come quarters first quarter fiscal revenue increase back silicone hydrogel lense lead clariti myday daily space biofinity monthly space company be also focuse expand geographically launch myday toric daily disposable contact lense unite state be line management believe toric market grow faster overall market company cash opportunity strong portfolio recent addition myday toric moreover cooper company coopervision segment be key driver segment gain silicone hydrogel lense lead solid prospect myday clariti biofinity platform outlook contact lens industry be favorable be encourage note cooper company be progress well respect inorganic expansion bid boost inorganic growth cooper company announce coopervision have complete buyout paragon vision science fourth quarter share cooper company have gain past year outperform industry gain flip side cooper company operate highly competitive market company business segment face considerable competition continue exert pressure pricing also company extensive international presence make highly vulnerable fluctuation exchange rate key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
211,PKI,medtronic plc mdt free report recently present encourage outcome pivotal extreme risk study real world notion trial nordic aortic valve intervention trial corevalve tavr system datum be present american college cardiology acc annual scientific session development remain part company consistent effort strengthen position high potential transcatheter aortic valve replacement tavr market be project reach datum cision study result notion trial enrolled patient age least year be subject surgical aortic valve replacement savr tavr corevalve system notably study evaluate patient year post implant corevalve tavr system result demonstrated patient experience enhance quality lifealong strong hemodynamic performance year believe result boost uptake corevalve tavr system development corevalve tavr corevalve evolut platform comprise corevalve corevalve evolut corevalve evolut pro system notably july medtronic receive fda approval extend use self expand corevalve evolut tavr system approval patient symptomatic severe aortic stenosis intermediate risk open heart surgery become eligible treatment used technology again march corevalve evolut pro system receive fda approval be used symptomatic patient be high extreme risk open heart surgery continue slew development last september medtronic announce initiate post market forward pro clinical study measure performance corevalve evolut pro transcatheter aortic valve implantation tavi system regular clinical treatment thus believe clinical study datum display efficiency product help company gain traction coronary structural heart csh space interestingly medtronic csh third quarter fiscal revenue be constant exchange rate back low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk market prospectsper report medgadget global heart valve repair replacement market be expect grow cagr believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr thus release positive study datum help medtronic cash abundant opportunity pancreatic cancer therapeutic market share price movementover past month company share price have underperform broader industry stock have gain comparison broader industry gain believe latest development help stock rebound zack rank key picksmedtronic carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
212,PKI,cogentix medical inc recently announce have enter definitive merger agreement laborie medical technology deal laborie medical technology buy outstanding share cogentix medical net worth company be lead player urology gynecology colorectal fieldscogentix medical expect transaction close first half second quarter once complete cogentix medical become wholly own subsidiary laborie medical technology price medical share have return past year compare index rally stock have also outperformed industry gain cogentix medical have market cap cogentix medical have zack rank hold agreement detailper term agreement laborie medical technology initiate tender offer outstanding share cogentix medical common stock share cash company execute deal wholly own subsidiary lm parent inc camden merger sub inc follow successful completion tender offer be second step merger outstanding share cogentix medical common stock be not tender be converted right receive share common stock cash transaction be subject other customary close condition notably cogentix medical be lead player global urology market company recent initiative sign licensing agreement allow launch endo urology product line unite state be noteworthy product be focuse minimally invasive treatment kidney stone initial response physician product have be positive management latest transaction be also great financial opportunity deliver strong margin expansion long haul market potentialper market market urology device market be estimate reach worth cagr consider prospect niche space expect cogentix medical gain solid prominence day come however company face stiff competition medtech giant medtronic plc mdt free report key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
213,PKI,mar issue update research report illumina inc ilmn free report zack rank hold stock share company have outperformed broader industry last month stock have gain higher broader industry rise illumina exit fourth quarter solid note earning revenue beating zack consensus estimate additionally metric improve year year basis apart progress margin scenario instilled investor confidence stock be also optimistic illumina expansion strategy enhancement portfolio sequence product development strategic partnership therapeutic diagnostic service provider regard illumina sign commercial agreement earlier january distribute thermo fisher scientific ion ampliseq technology researcher conduct study next generation sequence platform san diego base illumina be tool integrate system provider analysis genetic variation function company focus product innovation research development evident recent launch iseq sequence system post promising fourth quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio meanwhile company face stiff competition sequence snp single nucleotide polymorphism genotyp gene expression molecular diagnostic market several bigwig already enjoy significant market share intellectual property portfolio well regulatory expertise also national institutes health funding issue raise concern key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
214,PKI,accuray incorporate aray free report gain strong demand radixact platform solid growth european apac region also hold promise lately contribution order performance emea japan region have also be solid stock have zack rank buy radixact be company latest device contribute revenue second quarter fiscal result radixact system comprise tomotherapy order more radixact unit have be recognize product launch further system be be accept true workhorse product market courtesy significantly improve product performance functional efficacy broad case mix versatility grow adoption surgical treatment option successful execution restructure plan accretive acquisition be other positive recently accuray announce launch precision treatment plan system system leverage company flagship radixact cyberknife system platform company plan build technology precision upgrade fiscal significantly improve treatment speed overall throughput exist cyberknife system accuray also announce clearance new ibms datum management system tomotherapy be centralize database share make datum accessible multiple accurate system add flexibility improve efficiency radiation therapy department study have prove cyberknife provide long last pain relief procedure trigeminal neuralgia patient further heidelberg university hospital heidelberg germany oscar lambret cancer center lille france be first world connect system dull price performancein past year accuray have underperform industry term price performance company share have return industry rally almost moreover current level compare unfavorably index growth believe cutthroat competition dull international sale be reason downside accuray incorporate price accuray incorporate price accuray incorporate quoteother key picksa few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
215,PKI,quest diagnostic incorporate dgx free report have rally last year outperform industry decline stock have market cap company year historical growth rate be also favorable compare index solid prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable company have positive earning surprise last quarters also have long term expect earning growth rate current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share market be upbeat company recently report fourth quarter result year year increase adjust earning revenue be encourage companyis also refocusing core diagnostic information service business work discipline capital deployment also investor be look forward quest diagnostic recently announce definitive agreement buy lead national provider home base health risk assessment related service mobile medical examination service deal be slate close first quarter moreover last december quest diagnostic complete buyout shiel medical laboratory fresenius medical care fms free report healthcare company work renal other chronic condition shiel lab specifically serve new york new jersey area latest development be expect drive quest diagnostic operational excellence takeover be expect expand company patient service center network area other key picksa couple top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
216,PKI,feb issue update research report becton dickinson company bdx free report popularly know bd stock carry zack rank buy bd focus expand overseas emerge market product launch acquisition drive strategy be significant growth catalyst meanwhile company end first quarter fiscal impressive note beating zack consensus estimate count strong guidance fiscal instill confidence investor bd have be banking solid segmental growth late first quarter fiscal bd medical segment generate revenue constant currency cc year year basis bd life science segment generate revenue cc year quarter result company report net revenue prior year quarter cc strategic acquisition have also be key catalyst bd recently company acquire bard management bd be way become biggest medical technology device company world approximately annualize revenue include accretion bard acquisition bd expect fiscal revenue increase range report basis however revenue be expect grow range cc notably revenue be likely be affected change dispense business model becton dickinson company price becton dickinson company price becton dickinson company quote company expect adjust earning share range previous range current range indicate growth approximately report basis approximately cc bd collaborative move fresenius medical care fms free report provide sodium chloride saline customer be also noteworthy bd enjoy strong presence instrument market buyout boost competitive position sequence market company be expect continue pursue strategic acquisition boost long term growth prospect bd announce agreement italy base euroclone development global distribution molecular assay molecular assay be exclusively formulate detect sexually transmit pathogen bd euroclone plan launch molecular assay outside unite state favorable price performancein last year bd have outperformed broader industry term price company share have return compare favorably broader industry rally other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
217,PKI,feb issue update research report amedisys inc am free report stock carry zack rank hold renown home health hospice service provider have be trading broader industry past month stock have rally broader industry decline late company have make number strategic acquisition recent be tenet healthcare home health hospice operation arizona deal value amedisys claim buyout be strategic fit be likely help company provide high quality post acute service key market consolidation allow amedisys improve delivery care patient management care continuum market amedisys personal care segment have be grow strong stable latest integrate tuck acquisition moreover company be upbeat bountiful prospect segment october amedisys announce subsidiary associate home care complete buyout intercity home care personal care provider headquarter malden also favorable home health final rule buoy optimism report healthcarefirst rule be finalize implement home health grouping model schedule rollout meanwhile amedisys be poise benefit age demographic population need higher acuity patient home nursing environment moreover company strong cash balance position bolster investor confidence stock flip side escalate operate expense decline gross margin continue raise concern also intensely competitive landscape regulatory concern weigh home health hospice industry key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company be zack rank player company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
218,PKI,mar issue update research report abiom inc abmd free report lead medical product developer stock carry zack rank hold company robust demand impella product line have be key growth catalyst however stiff competition add wo impella abiom flagship product line have continue be growth driver impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart platform reflect stellar performance third quarter market be upbeat abiom flagship impella impella cp heart pump receive pre market approval pma fda expand use note impella support have already be integrate hospital germany japan also abiom recently announce expand fda pre market approval pma flagship impella impella cp impella impella ld heart pump past year abiom have return outperform gain same time frame current level be also better industry growth competition treatment provider heart related disease be intense be subject rapid technological change evolve industry requirement standard abiom product compete temporary cardiac assist device throat be acquire st jude company also face stiff competition organization develop permanent heart assist product other major headwind abiom be likely face increase pricing pressure due grow competitionin key market also stretched valuation currency fluctuation add wo key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
219,PKI,mar issue update research report athenahealth inc athn free report company strong product portfolio solid network expansion strategy unique business model be tailwind consequently athenahealth be top perform stock medtech sector stock sport zack rank strong buy further improvement share price strong fundamental indicate analyst bullish sentiment price performance estimate revision trend estimate athenahealth have moved upward past day reflect analyst optimism stock zack consensus estimate earning have be revise upward respectively share company have outperformed industry year time stock have return compare industry rally athenahealth inc price consensus athenahealth inc price consensus athenahealth inc quote let focus factor make athenahealth attractive pick investor favorable portfolio comprise wide array product include electronic health record revenue cycle management medical bill patient engagement care coordination population health management epocrate end fourth quarter athenahealth launch first machine learn model automate faxe company also pilot service authorization management be likely expand client base athenainsight online news hub report healthcare activity trend healthcare provider identify patient have be fortify company footprint athenahealth expand patient record sharing capability commonwell carequality full year company expect adjust operate margin range company have not provide guidance adjust earning athenahealth estimate total revenue range other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report perkinelmer pki free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy perkinelmer have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
220,PKI,feb issue update research report haemonetic corporation hae free report stock carry zack rank buy lead provider hematology product solution have be trading industry last month stock have rally compare industry gain stock have also outperformed gain haemonetic exit third quarter fiscal promising note earning revenue beating zack consensus estimate continue momentum new business generation geographical expansion have help company deliver strong result quarter expansion gross operate margin buoy optimism be upbeat haemonetic growth plasma franchise strong end market demand plasma derive continue drive growth haemonetic be also confident maintain growth commercial plasma collection business further raise fiscal adjust earning guidance be encourage company strong cash position also boost investor confidence flip side haemonetic operate very competitive environment manual automate system include like mak system moreover company have be witness sluggish revenue growth blood center franchise significantly affect result past few quarters management also doesn expect early recovery blood center outcome add concern other key pickssome other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
221,PKI,healthcare diagnostic major arch rival quest diagnostic incorporate dgx free report laboratory corporation america holding lh free report labcorp be same page regard much contentious topic protect access medicare act pama clinical lab fee schedule recently company member american clinical laboratory association acla have come forward support lawsuit file acla act secretary department health human service hhs lawsuit charge center medicare medicaid service cms operate purview hhs have fail follow congressional directive implement market base laboratory payment system lawsuit claim cms ignore congress directive state pama instituted highly flaw datum report process set market rate advance prohibit overwhelming majority laboratory report private payer datum used determine medicare rate lab test move have instead result new medicare lab rate be not market specific hence entire process clearly demonstrate cms failure protect access laboratory service medicare beneficiary press release labcorp new rate be allow come effect affect medicare beneficiary well disrupt healthcare system quest diagnostic flaw process cause serious financial harm potentially thousand hospital independent physician office laboratory make harder medicare beneficiary get access medical testing particularly remote rural area nursing home depend laboratory testing service earlier third quarter earning release labcorp quest diagnostic have issue certain objection response sep publication cms propose medicare reimbursement rate clinical laboratory test clinical lab fee schedule clf mandate pama company only laboratory submit datum hospital physician office laboratory be prevent report rate mentioned laboratory majorly denote independent lab convey severity situation clear term quest diagnostic state base datum submit cms company alone represent nearly market datum cms collect other possibly badly hit clinical laboratory thank latest cms mandate clinical lab fee schedule name emerge davita inc dva free report perkinelmer inc pki free report quest diagnostic labcorp perkinelmer carry zack rank hold davita have zack rank strong sell zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
222,PKI,perkinelmer inc pki free report report third quarter adjust earning cent share beating zack consensus estimate cent company base waltham report adjust revenue approximately beat zack consensus estimate revenue also surpass year figure segment detailsrevenue discovery analytical solution da totale third quarter year quarter meanwhile operate profit margin percentage revenue be compare prior year quarter level diagnostic segment revenue be compare year quarter reflect increase organically meanwhile operate profit margin segment percentage revenue be compare year quarter perkinelmer inc price consensus ep surprise perkinelmer inc price consensus ep surprise perkinelmer inc quote margin detailsadjust gross margin percentage revenue be quarter basis point bps year year deterioration be result acquisition divestiture execute adjust selling general administrative sg expense percentage revenue be bps year quarter research development expense percentage revenue rise bps third quarter result company overall adjust operate margin continue operation be net revenue bps year year basis financial detailsin first month perkinelmer operate cash flow continue operation be company conclude quarter approximately debt cash guidance company revise adjust earning guidance full year perkinelmer now expect adjust earning share band compare previous range zack rank key have zack rank hold few better rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report second quarter fiscal earning cent cent year quarter gross margin expand bps year year luminex report third quarter adjust earning cent year year company revenue quarter increase almost year year intuitive surgical post third quarter adjust earning year year basis revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
223,PKI,perkinelmer inc pki free report be expect release third quarter result nov close bell last quarter company register adjust earning cent share line zack consensus estimate furthermore adjust revenue approximately lag zack consensus estimate perkinelmer decision restructure discovery analytical solution da diagnostic segment hold promise third quarter furthermore company divestiture medical imaging segment last quarter be expect impact earning season let take look thing be shape prior third quarter earning announcement perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quotefactor considerview upbeat zack consensus estimate perkinelmer third quarter earning stand cent share signify year year growth revenue consensus estimate stand year year third quarter perkinelmer project revenue range represent organic revenue growth approximately third quarter adjust earning share be expect range cent cent solid global foothold perkinelmer have be develop biochemical molecular testing menu meet need pharmaceutical company serve market china india last quarter company win newborn screening tender russia mexico add strong demand china laboratory business launch last year be expect yield solid result quarter be report perkinelmer also acquire goa india base tulip diagnostic private ltd undisclosed amount tulip be acquire early january be bullish buyout help perkinelmer tap opportunity emerge market diagnostic takeover be also likely strengthen perkinelmer foothold infectious disease testing space foreign exchange volatility increase exposure international market increase risk foreign exchange volatility foreign exchange pose headwind approximately top line last quarter fluctuation currency exchange rate adversely impact company international sale due sluggish european economy revenue earning be likely be affected adversely season quantitative model do not conclusively show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp perkinelmer be uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp company negative esp make surprise prediction difficult here be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp zack rank see complete list today zack rank stock here penumbra inc pen free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
224,PKI,water corporation free report have brilliant earning beat streak span quarters positive earning surprise company break line earning quarters last year second quarter water corp continue impressive streak company adjust earning share trump zack consensus estimate bottom line figure fared even better year year comparison reflect striking growth prior year quarter tally remarkable broad base top line expansion spectacular growth asia aid earning beat solid operational execution backed company efficient business model also lend strength result further decline interest expense aid quarterly profit headlinesin report quarter water corp net sale grow year year also come ahead zack consensus estimate upside top line come back robust performance industrial end market constant currency basis bio pharmaceutical end market constant currency basis momentum be further aid growth constant currency basis government academic market also impressive contribution sale key product major geography supplement quarterly sale growth addition water corp recur revenue instrument system sale grow respectively drive top line growth term geography water corp witness strong sale asia europe post growth respectively constant currency however sale americas continue reflect weakness decline year year total selling administrative expense quarter come incur second quarter research development outlay quarter be compare incur year rise expense operate income quarter climb year year water corporation price consensus ep surprise water corporation price consensus ep surprise water corporation corp cash cash equivalent investment quarter end amount just higher record dec company total liability quarter end increase dec takewater corp lead position high performance liquid chromatography mass spectrometry market be key strength have act strong revenue driver past few quarters company bright pharmaceutical business start healthy note look set continue momentum go ahead be also see encourage trend industrial business governmental academic market have also turn performance look poise maintain growth trend come quarters water corp exposure pharma biotech industry be primarily regulate commercial lab environment demand be discretionary not prone cyclicality help company mitigate uncertain client spending stem macroeconomic volatility additionally give fact liquid chromatography be used huge variety application water corp be well poise benefit significantly business move ahead zack rank other stock considerwater corp currently hold zack rank buy other similarly rank stock same space include bruker corporation brkr free report mettler toledo international inc mtd free report perkinelmer inc pki free report see complete list today zack rank strong buy stock here bruker corporation generate huge beat trail quarters average positive surprise mettler toledo have striking earning surprise history last quarters have beaten estimate average beat perkinelmer also have decent earning surprise history average beat trail quarters beating estimate thrice more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
225,PKI,amedisys inc am free report report adjust earning share ep continue operation cent fourth quarter year year however earning miss zack consensus estimate cent full year adjust ep come miss zack consensus estimate however figure improve year number fourth quarter net service revenue gross year year top line also beat zack consensus estimate net revenue totale line zack consensus estimate figure improve year number quarter company home health division net service revenue totale fourth quarter reflect improvement year year medicare revenue rise year year medicare revenue improve year year hospice division net service revenue gross year year include medicare revenue medicare revenue recently company integrate additional operate segment business personal care corporate personal care net service revenue totale reflect increase year number meanwhile corporate segment do not register revenue end fourth quarter company gross margin contract basis point bps fourth quarter increase gross profit expense salary benefit rise other expense drop adjust operate income report quarter reflect increase year adjust operate margin expand bps year figure amedisys exit cash cash equivalent compare end company long term obligation exclude current portion be net cash provide operate activity be compare year period takeamedisys end fourth quarter mixed note home health hospice division company witness encourage growth medicare medicare revenue amedisys be currently explore opportunity segment be also upbeat company solid performance recently launch personal care segment favorable demographic trend strategic acquisition bode well company however escalate operate expense decline gross margin continue raise concern also intense competitive landscape regulatory concern continue challenge home health hospice industry peer performancesome medical stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
226,PKI,mar issue update research report abaxis inc abax free report company have be witness strength veterinary business base encourage consumable segment growth however rise expense bleak gross operate margin scenario have be raise concern stock carry zack rank hold manufacturer portable medical human veterinary animal blood analysis system provide clinician rapid blood constituent measurement medical veterinarian market globally have outperformed industry past month stock have gain compare industry be upbeat abaxis double digit consumable growth veterinary business consumable product line total rotor revenue grow double digit apart other veterinary consumable include hematology reagent rapid assay stat cartridge coagulation cartridge urine analysis strip drive veterinary consumable revenue moreover abaxis have be emphasize product innovation research development regard january company receive approval usda center veterinary biologic vetscan flex rapid test solid global sale piccolo instrument be encourage management healthcare delivery consolidate unite state group network healthcare conglomerate abaxis piccolo be position capture lion share diagnostic test market meanwhile escalate operate expense have be exert pressure bottom line moreover abaxis face intense competition medical veterinary market regard company compete firm have substantially greater resource front financial research development operation marketing key picksa few better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate boast zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
227,PKI,mar issue update research report integra lifescience holding corporation iart free report stock carry zack rank hold integra lifescience exit fourth quarter solid note strong year year increase revenue back company recently acquire business johnson johnson codman neurosurgery business derma science buoy optimism however tough competitive landscape add company wo past year integra lifescience have outperformed industry stock have gain compare decline industry come quarterly result integra lifescience see organic growth codman specialty surgical css segment fourth quarter report revenue quarter grow back revenue codman neurosurgery be attribute sequential double digit growth register tissue ablation business owing strong capital sale newly launch cusa clarity apart dural repair business perform well year year organic growth strength duragen duraseal product line be also encourage note segment see year year revenue growth period nonetheless believe company be try execute growth plan efficient management team moreover rise year year investment research development be encourage also company promising guidance instill investor confidence stock however integra lifescience face intense competition surgical implant medical instrument market company need be innovative product front fend competition moreover consolidation industry lead intense pricing pressure also significant margin contraction cause escalate cost expense raise concern further company generate significant revenue international business increase vulnerability adverse currency movement key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank athenahealth be zack rank player company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
228,PKI,teleflex incorporate tfx free report share lose close announce earning result mar company report adjust earning share fourth quarter beating zack consensus estimate earning improve year figure revenue detailadjust revenue fourth quarter increase year year constant exchange rate cer miss zack consensus estimate owing temporary softness segmental basis vascular north america revenue increase cer year year fourth quarter teleflex incorporate price consensus ep surprise teleflex incorporate price consensus ep surprise teleflex incorporate quote interventional north america revenue increase fourth quarter year quarter cer anesthesia north america revenue be year quarter cer surgical north america revenue fourth quarter be year quarter cer emea revenue increase year quarter fall cer asia revenue rise quarter year quarter cer oem revenue climb year quarter decline cer other revenue increase cer quarter review operational updateteleflex gross profit report quarter increase year year gross margin expand basis point bps sg expense fourth quarter rise year year research development expense rise year year operate expense totale fourth quarter year year adjust operate margin quarter be bps year quarter financial updateteleflex exit cash cash equivalent compare end glancefull year adjust earning come compare year figure reflect increase full year adjust revenue come year period teleflex expect adjust revenue growth cer band company also expect adjust earning share band zack consensus estimate full year earning share be peg company guide range zack consensus estimate full year revenue stand taketeleflex exitedfourth quarter mixed note be encourage note company be work product innovation however contraction operate margin be discourage also tough competitive landscape act dampener zack rank key picksteleflex have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
229,PKI,bio rad laboratory inc bio free report report fourth quarter earning share year loss cent thus make huge improvement zack consensus estimate be peg earning share notably net income quarter be favorably impact substantial benefit tax cut job act net sale come year year constant exchange rate cer top line closely beat zack consensus estimate year year rise sale be largely drive strong sale life science product include continue sturdy sale droplet digital pcr instrument consumable cell biology product quarter detailon segmental basis life science net sale come year year cer also sale droplet digital pcr ddpcr cell biology product line process medium rise back strong performance cer geographically north america europe asia pacific demonstrated sturdy flourish bio rad laboratory inc price consensus ep surprise bio rad laboratory inc price consensus ep surprise bio rad laboratory inc quote clinical diagnostic company register sale year year cer upside result increase blood typing immunology diabetes quality control product line gross margin report quarter contract basis point bps year year climb gross profit adjust operate margin however expand basis point surge adjust operate profit company exit year cash cash equivalent short term investment compare end full year net cash provide operate activity be compare year guidance bio rad expect currency neutral revenue growth approximately outlook anticipate continue strong sale life science segment increase growth diagnostic zack consensus estimate be peg operate margin constant exchange rate be target revenue bottom linebio rad post strong quarterly performance earning sale show sharp year year improvement sale growth be majorly drive company many life science product line diagnostic instrument placement be solid promising guidance further instill confidence stock however contraction gross margin quarter review be due toescalate warranty service cost largely associate higher instrument placement zack rank key picksbio rad have zack rank hold few better rank medical stock be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm perkinelmer sport zack rank strong buy becton dickinson company carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent soar prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year earlier quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency basis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
230,PKI,express script hold company esrx free report post fourth quarter adjust earning share beat zack consensus estimate further adjust earning improve share year quarter revenue also beat zack consensus estimate increase year quarter patient claim volume script fourth quarter result benefit rise patient claim strong customer retention adjust network claim be year year adjust home delivery specialty claim be fourth quarter year year result net adjust claim fourth quarter be flat year year basis notably adjust ebitda earning interest tax depreciation amortization adjust patient claim fourth quarter be higher report year quarter express script hold company price consensus express script hold company price consensus express script hold company quote margin detailsadjust gross profit fourth quarter be year year percentage revenue adjust gross margin expand basis point bps net revenue adjust selling general administrative expense be prior year quarter upside margin be drive operational cost improvement backed focus technology digital tool home delivery specialty service balance sheetnet cash flow provide operate activity be year year company exit quarter cash cash equivalent year quarter total debt end quarter be end fact company be strive reduce debt level guidance adjust claim first quarter be expect range adjust earning share first quarter be estimate range represent growth year year basis full year adjust earning be estimate band reflect growth year year revenue be expect band adjust ebitda be expect come guidance express script core business total adjust claim be expect range first quarter total adjust claim core business be expect net revenue be estimate range long term viewbuoyed strong result quarter express script enterprise value initiative be estimate cost notably management expect cumulative saving nearly further company target compound annual adjust ebitda growth rate core business be positive zack rank other key picksexpress script have zack rank buy few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company be zack rank player company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
231,PKI,penumbra inc pen free report report fourth quarter earning share cent compare favorably loss cent year quarter figure be also better zack consensus estimate loss penny company report full year adjust loss penny narrower zack consensus estimate loss cent figure also compare favorably year loss cent revenue report quarter rise year year constant exchange rate cer exceed zack consensus estimate net revenue totale outpace zack consensus estimate figure also improve cer year level geographic basis fourth quarter revenue unite state represent total sale gross year quarter same cer meanwhile international sale total sale advanced year year cer penumbra inc price consensus ep surprise penumbra inc price consensus ep surprise penumbra inc quote go product category revenue neuro product grow cer quarter review revenue peripheral vascular product business rise fourth quarter reflect increase cer year year operational updatepenumbra fourth quarter gross margin be reflect basis point bps expansion year year gross profit rise research development expense totale sale general administrative expense amount year year operate profit report quarter come compare favorably operate loss prior year quarter financial updatepenumbra exit cash cash equivalent compare end outlookpenumbra have provide guidance revenue company expect total revenue range zack consensus estimate lag guide range takepenumbra exit fourth quarter better expect result year year comparison earning be favorable moreover company witness strong growth geography product line company be focuse product innovation research development penumbra be active player fast grow interventional therapy space fact company product primarily cater unmet clinical need major market neuro peripheral vascular zack rank key pickspenumbra have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
232,PKI,abbott free report announce availability freestyle librelink app europe use smartphone iphone android notably diabetes patient used freestylelibre system europe longer need carry freestyle libre get glucose result diabetes patient now be able check glucose result directly smartphone company freestyle librelink app allow user hold smartphone freestyle libre sensor capture view real time glucose level also show hour glucose history glucose level be change freestyle librelink app customer have access several update new feature compare freestyle libre reader company also say app replace reader also be used combination other freestyle librelink customer have option share information physician libreview librelinkup be other digital health tool be part freestyle libre platform freestyle librelink app be free cost iphone android user initially be available european country also abbott be plan mobile app solution freestyle libre user outside europe base country regulatory approval development freestyle librefreestyle libre system be flagship sensor base continuous glucose monitoring cgm system company have be witness solid growth global diabetes care business notably diabetes care sale rise comparable operational basis last report fourth quarter buoy double digit international sale growth lead continue consumer uptake freestyle libre accordingly be leave stone unturned cash grow popularity system eliminate need daily finger stick follow fda approval september freestyle libre flash glucose monitoring system abbott recently achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage meanwhile abbott have be steadily progress development diabetes care segment last september company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company announce receipt health canada license freestyle libre flash glucose monitoring system june drive diabetes care segment see revenue growth third quarter continue acceptance freestyle libre internationally market potentialaccord report mordor intelligence global market diabetes care device be expect reach value cagr consider huge potential market believe latest development help abbott gain traction space share price estimate revision trendabbott have be gain investor confidence consistently positive result last month stock have outperformed broader industry have gain comparison broader industry current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank key picksabbott carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
233,PKI,qiagen qgen free report recently announce receipt japan ministry health labor welfare approval quantiferon tb gold qft diagnostic detect tuberculosis tb infection notably build quantiferon tb gold qft platform qft provide enhance analysis tb infection advanced kit make tb testing innovative antigen possible measure cell mediate immune response cd cd cell believe approval help qiagen expand customer base drive uptake qft test thereby boost top line quantiferon tb diagnostic test quantiferon tb diagnostic test kit fall qiagen molecular diagnostic segment be highest revenue grosser last report quarter notably segment contribute total revenue substantial growth quantiferon latent tb test qiasymphony automation system consumable portfolio solid performance companion diagnostic pharma collaboration regard post receipt fda approval june qiagen have announce complete launch fourth generation blood test tb infection quantiferon tb gold qft unite state furthermore continue slew development qiagen announce signing collaboration agreement diasorin january post collaboration qiagen quantiferon tb diagnostic test be available diasorin liaison portfolio fully automate analyzer be not first time qiagen be partner renown diagnostic ivd player june company have partner develop test base review selection process involve qiagen assay technology test diasorin liaison family analyzer latest announcement qft stand be first assay qiagen quantiferon portfolio be available use liaison family system moreover agreement company be work develop completely automate version quantiferon test read component use quantiferon tb test future quantiferon base test be adopt use liaison regard company plan launch ce marked quantiferon read component use liaison xl third quarter moreover launch unite state launch china be plan same market prospectsqiagen have be witness substantial demand thequantiferon tb diagnostic test kit notably company announce milestone conduct quantiferon tb test globally initial launch end accord research market datum publish business wire global tb diagnostic market be expect see cagr share price have be gain investor confidence consistently encourage result past month company share price have outperformed broader industry stock have gain contrast broader industry decline zack rank key picksqiagen carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
234,PKI,feb issue update research report cardiovascular system inc csii free report stock carry zack rank hold medical device manufacturer developer marketer innovative solution treat patient peripheral coronary arterial disease include arterial calcium see solid second quarter fiscal company witness year year rise revenue coronary arterial disease cad coronary arterial disease pad business also expansion gross margin be impressive cardiovascular system have be expand product portfolio enhance market reach currently cardiovascular system be pursue product improvement evaluate new technology strengthen broaden portfolio powerful micro invasive tool earlier company have receive fda approval diamondback coronary oas micro crown system facilitate stent delivery patient cad company also win approval japan ministry health labor welfare mhlw diamondback coronary oas micro crown launch commercially february also company receive fda approval radial access diamondback peripheral orbital atherectomy device treat pad be upbeat cardiovascular system new partnership have broaden portfolio company be now distributor orbusneich balloon product orbusneich pci balloon include sapphire ii pro be schedule get fda approval year mm coronary balloon moreover company have sign original equipment manufacturer oem agreement integer holding corporation csi brand zilient guidewire be also optimistic favorable trend pad well cad space american heart association many american suffer pad moreover age population couple rise incidence diabetes obesity be likely increase occurrence pad offer huge scope unique pad orbital atherectomy system oas cardiovascular system past month cardiovascular system have be underperform industry stock have decline industry rise furthermore company face cutthroat competition niche space oas product compete variety other product device treatment vascular disease include stent balloon angioplasty catheter atherectomy catheter well product used vascular surgery larger competitor stent balloon angioplasty market segment include bigwig abbott laboratory free report moreover profitability front cardiovascular system have long history net loss inception immediate recovery sight key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
235,PKI,allscript healthcare solution inc mdrx free report report fourth quarter adjust earning cent share be line zack consensus estimate adjust earning increase year year adjust revenue grow year year basis beat zack consensus estimate solid growth record core solution service fuel sunrise electronic health record platform allscript revenue cycle management service buoy optimism fourth quarter however booking fourth quarter be year year basis allscript healthcare solution inc price consensus allscript healthcare solution inc price consensus allscript healthcare solution inc quote segmental delivery support maintenance revenuesthis segment comprise software hardware subscription other transaction support maintenance revenue revenue segment increase year year client service revenuesthis segment take care recur manage service other project base client service client service revenue be year year basis recur recur baserecur revenuesrecur revenue cover subscription recur transaction support maintenance recur manage service adjust recur revenue increase year year basis notably company total recur revenue mix come net revenue fourth quarter recur revenuesthis segment comprise system sale other project base client service adjust recur revenue segment increase year year basis margin detailsa percentage revenue allscript register adjust gross margin fourth quarter compare year quarter margin contract basis point bps however management allscript estimate gross margin improve back synergy recent enterprise information solution acquisition software gross margin percentage revenue decrease bps year year basis client service margin fourth quarter come net revenue compare same period last year adjust operate expense quarter totale year year thank acquisition enterprise information solution business mckesson corporation mck free report selling general administrative expense increase research development expense rise year year basis allscript expect adjust revenue range year year basis zack consensus estimate revenue currently stand adjust ebitda be expect band year year adjust earning share be expect be cent cent increase year year zack consensus estimate adjust earning be currently pin cent share bottom lineallscript solid outlook instill investor optimism further recently complete acquisition practice fusion cloud base electronic health record aim primarily small independent physician practice be likely drive company inorganic growth transaction give allscript largest market share outpatient setting further company have enter agreement divest content business hyland software company solid growth core solution service hold promise moment allscript sunrise electronic health record platform revenue cycle management service be likely drive company top line quarters come however company continue reliance merger acquisition activity pose substantial integration risk intensify competition be major dampener company product have long sale cycle involve intensive decision make different managerial level allscript also expect modest increase operate expense support business growth long haul zack rank key picksallscript have zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
236,PKI,cheme corporation che free report fourth quarter adjust earning share ep be compare year figure figure also surpass zack consensus estimate full year adjust ep come beating zack consensus estimate moreover figure improve year number quarter detailsrevenue quarter increase year year beating zack consensus estimate net revenue totale outpace zack consensus estimate figure also improve year number cheme currently operate wholly own subsidiary namely vita healthcare corporation major provider end life care roto rooter lead commercial residential plumbing drain clean service provider fourth quarter net revenue vita healthcare totale reflect increase year year revenue be drive increase average net medicare reimbursement rate rise average daily census however be partially offset acuity mix shift impact revenue adverse impact revenue due medicare cap cheme corp price consensus ep surprise cheme corp price consensus ep surprise cheme corp quote roto rooter report sale fourth quarter year year accord company revenue water restoration increase year year gross margin expand basis point bps year year adjust operate margin contract nominal bps quarter rise selling general administrative expense cheme exit total cash cash equivalent end company have total debt end compare year dec company have approximately undrawn borrow capacity exist year credit agreement fourth quarter company do not repurchase share dec company have remain share repurchase authorization company project vita healthcare revenue growth range prior medicare cap also admission average daily census be expect increase medicare cap bill limitation be expect roto rooter business be likely grow full year guidance be backed increase job pricing water restoration service growth full year adjust ep be expect grow band compare report takecheme exit fourth quarter solid note also company witness year year growth front moreover be encourage note company subsidiary see year year revenue growth quarter expansion gross margin strong bottom line projection also buoy optimism further reimbursement related issue seasonality business competitive landscape dependence government mandate continue challenge key picksa few top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
237,PKI,bid enhance breast health portfolio hologic inc holx free report recently announce worldwide collaboration deal royal philips phg free report lead health technology company global partnership agreement provide integrate imaging solution woman health notably financial detail multus year exclusive global partnership agreement have not be disclose agreement have be sign offer integrate solution care professional solution include diagnostic imaging modality advanced informatic service screening diagnosis treatment woman world deal couple hologic innovative mammography technology philips lead portfolio ultrasound mri ct ray system advanced informatic broad range service be anticipate boost breast skeletal health solution segment former partnership hologic philips work project previously not be undertake company press release part multus modality deal hospital health system philips now be able offer select product hologic breast health portfolio include latter new dimension mammography system breast health unit focussolid growthwe be upbeat hologic consistent effort gain traction breast health business have contribute company overall top line growth first quarter fiscal segment have record growth constant currency quarter company unique direct consumer initiative segment have provide competitive edge niche space recent development segmentin november company announce development distribution agreement clarius mobile health portable ultrasound scanner system company also announce receipt clearance fda quantra breast density assessment software later month notably software be used hologic mammography system segment company have redesign strategy continue innovation leadership position mammography also november company announce plan make mammography system available dutch breast cancer screening program collaboration tromp medical hologic distributor netherlands line start hologic latest dimension mammography system be install mobile stationary screening facility netherlands september hologic announce commercial launch dimension mammography system europe notably conjunction enhance image quality radiologist system provide improve technologist moreover aim provide more comfortable mammography experience low dose option company be optimistic recent addition suite breast cancer screening diagnostic interventional solution breast health business market trend buoy optimismper report dpi research medium breast cancer screening market unite state be expect reach value roughly also report gbi research global breast cancer treatment market reach value cagr thus company clearly have solid prospect market share price performanceover past month hologic have decline underperform industry gain however company estimate revision trend current year have be encourage past couple month analyst moved north versus movement south earning estimate have be raise share same time frame zack rank key pickshologic carry zack rank buy couple top rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
238,PKI,opko health inc opk free report report loss cent share fourth quarter compare loss cent year zack consensus estimate quarter be peg loss cent company report full year loss cent compare unfavorably year loss cent revenuesin fourth quarter opko health generate total revenue year year report figure also miss zack consensus estimate net revenue totale year number gross profit fourth quarter be year year gross margin contract massive basis point bps year quarter opko health inc price consensus ep surprise opko health inc price consensus ep surprise opko health inc quoteresearch development expense totale year year selling general administrative expense amount consequently loss operation come highlight significant decline operate loss prior year quarter decline be attribute rise operate expense owing company significant investment associate commercial launch rayaldee consistent investment pharmaceutical pipeline financialsopko health exit cash cash equivalent marketable security compare record end takeopko health exit fourth quarter disappointing note nonetheless be encourage ongoing development company business include diagnostic business bio reference laboratory pharmaceutical business be also upbeat opko health grow revenue genedx bio reference genetic testing unit kscore test quarter however rise operate expense continue mar company financial zack rank key picksopko health have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
239,PKI,medtronic plc mdt free report announce fda have approve new arm indication guardian sensor continuous glucose monitor cgm used minime insulin pump notably guardian sensor be company latest most accurate cgm medtronic be only sensor have receive fda nod control automate insulin delivery hybrid close loop system minime be important note medtronic commercially launch minime system june system be hybrid close loop insulin delivery system type diabetic patient age year older minime system feature medtronic guardian sensor glucose sensor increase accuracy enhance performance new arm indication guardian sensor now offer more convenience flexibility patient be available unite state use minime system progress minime have be forge ahead initiative boost performance minime portfolio recently company expand product portfolio unveil minime advance infusion set recent offer diabetes business be commercially available canada hong kong certain country europe fourth quarter fiscal however company plan extensive launch same also company report positive datum home pediatric study patient age year outcome be base minime system be demonstrated advanced technology treatment diabetes international conference vienna austria development diabetes witness rise constant exchange rate diabetes business revenue third quarter fiscal company benefit positive uptake new sensor augment insulin pump system unite state well international market enhance production capacity same notably medtronic expect double digit growth segment fourth quarter fiscal courtesy consistent performance minime system unite state enhance sensor supply capacity additionally medtronic have be gear international introduction minime launch cgm system guardian connect sugar iq late new professional cgm ipro regard company have earlier announce favorable result support use cgm patient type diabetes october market potentialan agee population unhealthy lifestyle rise awareness well expenditure healthcare be likely drive growth diabetes market report mordor intelligence global market diabetes care device be project reach value cagr consider bullish market sentiment believe latest development have arrived opportune moment stock performance estimate revisionover last month share medtronic have underperform industry stock hasdipped industry growth index gain also estimate revision trend current year remain unfavorable estimate move south last month compare couple opposite direction earning estimate inched share same time frame zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate becton dickinson company be zack rank player company have long term expect earning growth rate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
240,PKI,dentsply sirona inc xray free report announce preliminary fourth quarter result company report adjust earning share ep cent beating zack consensus estimate penny however preliminary result metric decrease year year preliminary net sale increase year also figure surpass zack consensus estimate rise constant currency cc exchange rate top line be favorably impact approximately result inventory build distribution channel stock carry zack rank sell dentsply sirona inc price ep surprise dentsply sirona inc price ep surprise dentsply sirona inc quotenet sale exclude precious metal impact net sale company precious metal dental alloy product be used third party construct crown bridge material be subject risk fluctuation precious metal price avoid impact fluctuate price dentsply report net sale precious metal content show actual performance independent precious metal price volatility preliminary net sale segment be year year segmental business be organized report segment dental healthcare consumable technology dental healthcare segment comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product preliminary result sale improve segment cc technology equipment consist dental implant cad cam system imaging system treatment center orthodontic product metric increase segment cc geographic detailsin quarter sale unite state grow year year country cc net sale europe increase cc net sale rest world climb cc margin profit report quarter be year year percentage revenue gross margin expand basis point bps company report preliminary net sale year year consumable segment increase net sale net sale technology equipment segment jump however sale combine business technology equipment slip cc year year company register adjust earning share expect adjust ep range reflect cent adverse impact tax expense related tax reform revenue be project rise cc key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year becton dickinson report first quarter adjust earning share constant currency revenue totale cc don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
241,PKI,conm corporation cnmd free report be currently top perform stock medtech space improvement price performance strong fundamental reflect stock bullish run therefore haven take advantage price appreciation yet time add stock portfolio headquarter utica ny conm be major medical product manufacturer specialize surgical instrument device minimally invasive procedure monitoring company perform impressively have potential sustain momentum upcoming period long term expect earning growth rate be positive attractive pick solid resultsconm deliver stellar performance fourth quarter beating earning revenue estimate performance company business segment have be commendable orthopedic surgery rebound quarters decline solid focus innovation continue drive sale gain leverage international market raise guidance shrink debt instill optimism notably company long term debt decline year year basis share price appreciationa glimpse company price trend reveal stock have have impressive run bourse year date conm share have return versus index fall current return be also greater industry gain just northward estimate revisionsfour estimate current year moved north past day versus southward revision indicate analyst optimism company zack consensus estimate adjust earning rise current year positive trend signify analyst bullish sentiment company hold zack rank buy indicate robust fundamental expectation outperformance term zack consensus estimate revenue be peg year year company expect sale growth range constant currency cc adjust earning share be project range fiscal conm corporation price consensus conm corporation price consensus conm corporation quote general surgery consistent surgery consist complete line endo mechanical instrumentation minimally invasive laparoscopic procedure line cardiac monitoring product well electrosurgical generator related instrument constant currency basis general surgery grow fourth quarter post eighth straight quarter positive gain additionally domestic general surgery grow ride solid growth advanced surgical endoscopic technology deliver decent performance fourth quarter well full year base strong performance segment organization be position drive mid single digit revenue growth double digit earning growth organically sustainable basis solid market trendsconm be benefit increase trend used minimally invasive technique large percentage company product be design procedure use minimally invasive surgery lower cost reduce patient trauma recovery time length hospitalization research report market market suggest global minimally invasive surgical instrument market be estimate reach worth multiply cagr such solid market trend be likely fortify conm foothold niche space other key picksa few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
242,PKI,gnc holding inc gnc free report have be dominate headline announcement plan strike couple deal china lead pharmaceutical company harbin pharmaceutical group hold co ltd hayao notably company intend enter strategic partnership china joint venture agreement hayao term equity investment agreement hayao invest cash kind gnc holding follow close transaction hayao own gnc holding converted basis investment be anticipate strengthen gnc holding capital position however subject certain customary close condition unite state china transaction be expect close second half same time gnc holding enter joint venture agreement hayao notably leverage latter expertise operational manufacturing area well broad pharmaceutical distribution network china gnc holding plan strengthen presence china boom supplement market however closure hayao transaction be dependent successful completion gnc holding plan amend extend term loan facility interestingly gnc holding aim extend maturity date term loan facility year march issue abl term loan part plan maturity extension international business key growth drivernotably gnc holding international business have be key growth driver company recent year late company have be see solid growth china furthermore recent past company have witness improvement trend mexico south korea hong kong believe successful completion execution agreement significantly drive top line contribution china market potentialper report grand view research global market dietary supplement be expect see cagr report further state usage supplement treat cardiovascular disease malnutrition continue boost demand thus view such datum believe gnc holding joint venture plan hayao be strategic share price performancegnc holding have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain industry decline zack rank key picksgnc holding carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
243,PKI,gnc holding inc gnc free report report fourth quarter adjust earning share ep cent reflect massive year year increase adjust ep also surpass zack consensus estimate penny full year adjust ep compare adjust ep also surpass zack consensus estimate revenuesrevenue now exclude lucky vitamin period report quarter drop year year figure also miss zack consensus estimate gnc holding inc price consensus ep surprise gnc holding inc price consensus ep surprise gnc holding inc quote company report full year revenue compare year figure miss zack consensus estimateof same store sale increase domestic company own store include gnc com sale quarter review domestic franchise location same store sale decline segment detailsgnc holding report operation segment canada include company own store unite state puerto rico canada franchise store unite state commerce international include franchise location approximately country health store china operation manufacturing wholesale comprise manufacture product sell other segment third party contract manufacturing sale wholesale partner report quarter gnc holding revenue canada segment inched primarily drive increase same store sale company own store include gnc com partially offset decrease due discontinuation gold card program unite state introduction loyalty program domestic franchise location well revenue decline due lower wholesale sale include impact retail sale comp negative revenue international segment increase drive higher cross border commerce sale china revenue manufacturing wholesale segment exclude intersegment revenue decline segment third party contract manufacturing sale fall sale wholesale partner decrease year year quarter however intersegment sale increase year company increase focus proprietary product asset sale lucky vitamin sep lucky vitamin be now include other segment applicable prior period ensure comparability result drop fourth quarter revenue prior year quarter margingross profit increase report quarter result gross margin expand basis point bps selling general administrative expense contract accordingly adjust operate margin expand bps financial positiongnc holding exit cash cash equivalent end long term debt be end compare end net cash flow operate activity totale compare year further company generate free cash flow compare previous year new gnc plan updateearlier management have announce plan revamp exist business model dub new gnc company have be see change fourth quarter well transaction growth be fourth quarter more consumer have joined company loyalty program include approximately customer enrolled pro access membership takegnc holding exit fourth quarter mixed note however year year increase adjust earning be encourage also expansion gross adjust operate margin be encourage fourth quarter management witness positive response new gnc plan company have also be witness improvement transaction commerce business buoy optimism zack rank key picksgnc holding have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
244,PKI,davita inc dva free report report fourth quarter adjust operate earning cent share beating zack consensus estimate cent however earning decline year year basis total revenue increase year year miss zack consensus estimate davita carry zack rank hold davita healthcare partner inc price consensus davita healthcare partner inc price consensus davita healthcare partner inc quote segmental analysisas operate division davita davita kidney care focus set worldwide standard clinical social operational practice kidney care davita see impressive result kidney care business net consolidated revenue segment be year year adjust operate income segment be year year revenue dialysis lab business rise year year company patient care cost be approximately cent treatment compare last quarter third quarter davita patient care cost be favorably impact hurricane total dialysis treatment fourth quarter be treatment day indicate day increase year year basis fourth quarter davita acquire dialysis center open new center close unite state davita also acquire dialysis center open center close center outside unite state investor notice company major segment davita medical group dmg have be track divestment optum subsidiary unitedhealth group inc transaction be subject regulatory approval other customary close condition result dmg business operation have be report discontinue quarter financial updateon dec free cash flow continue operation be month end dec davita have operate cash flow be continue operation share repurchase updatedure quarter end dec davita repurchase total share common stock approximately average price share davita buy back almost share common stock average price share company project kidney care consolidated operate income range operate cash flow continue operation be estimate range effective tax rate be expect range key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
245,PKI,myriad genetic inc mygn free report have be dominate headline favorable result large study myrisk hereditary cancer test notably result be featured poster presentation genitourinary cancer symposium san francisco result patient study confirm more man prostate cancer have inherited hereditary mutation cancer cause gene management go result study be important expand use genetic testing man diagnosed prostate cancer consistent exist professional medical guideline management further add study result prove percentage woman breast cancer carry hereditary cancer cause mutation be same percentage man prostate cancer carry mutation company prostate cancer be most commonly diagnosed second lead cause cancer death american man go cancer fact figure report american cancer society man be diagnosed prostate cancer report also state roughly american man be presently suffering prostate cancer myriad genetic also state global market myrisk hereditary cancer other type hereditary cancer test be worth roughly annually view such datum believe favorable result boost company customer base top line great extent furthermore company have be leave stone unturned strengthen hold same regard last december myriad genetic present favorable riskscore test datum san antonio breast cancer symposium sabcs texas september company introduce riskscore myrisk hereditary cancer testing portfolio also present encourage riskscore test datum also announce favorable study result myrisk hereditary cancer suite moreover recently report second quarter fiscal marked fourth consecutive quarter year year hereditary cancer volume growth lead encourage response latest riskscore test myrisk hereditary cancer testing portfolio thus believe encourage datum study drive uptake myrisk hereditary cancer test price genetic have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain industry decline zack rank key picksmyriad genetic carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
246,PKI,feb issue update research report cardinal health inc cah free report stock carry zack rank buy company exit second quarter solid note courtesy encourage performance medical segment pharmaceutical segment also witness strong growth specialty business gain large number pharmaceutical distribution customer strong fiscal outlook buoy optimism cardinal health share price movement last year have fail impress stock have lose almost compare unfavorably industry gain cardinal health face risk lose considerable business case loss major customer turn severely impair revenue however company share price have be rise second quarter earning release stock have gain yesterday close cardinal health medical pharmaceutical offering lend company competitive edge niche space company offer industry expertise expand portfolio safe product also cardinal health follow acquisition drive strategy continue focus investment key growth business gain market traction boost profit cardinal health recently announce acquisition medtronic mdt free report patient care deep vein thrombosis nutritional insufficiency business buyout particularly boost company medical segment further cardinal health be pursue growth joint venture long term supply agreement company enter long term strategic agreement henry schein latter purchase cardinal health medical supply physician practice collaboration be expect drive core sale prove accretive cardinal health earning long term growth business profit company pharmaceutical segment be hurt generic pharmaceutical pricing huge investment pharmaceutical platform lackluster generic performance be likely mar cardinal health operational efficiency upcoming quarter intense competition customer concentration be other bottleneck other key picksa couple other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report bio rad laboratory have zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
247,PKI,laboratory corporation america holding lh free report labcorp have gain last year industry gain stock have market cap company year historical growth rate be also favorable compare index consider stable performance stock expect labcorp scale higher come quarters also company long term expect earning growth rate look promising company deliver positive earning surprise last quarters solid growth prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable company have impressive growth style score growth style score highlight vital metric company financial obtain clear picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity stock have vgm score northward revision current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year rise share company project annualize earning growth rate be strong earning market be upbeat company fourth quarter result year year increase adjust earning revenue be encourage labcorp diagnostic business be solid back increase acquisition organic volume expansion favorable foreign exchange scenario several quarters dull performance covance drug development have be deliver sturdy growth past couple term uptrend be attribute chiltern takeover robust organic growth positive foreign currency translation also guidance look promising believe integration newer acquisition labcorp be perfectly position drive long term profitable growth combination world class diagnostic drug development expertise knowledge service solid guidance full year revenue growth be estimate band include likely improvement basis point bps foreign currency translation zack consensus estimate current year revenue be peg adjust earning share ep guidance be project range consensus mark metric fall guidance free cash flow have be project growth be expect band year other key picksa few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
248,PKI,medtronic plc mdt free report expand product portfolio introduction minime advance infusion set recent offer diabetes business be commercially available canada hong kong certain country europe fourth quarter fiscal however company plan extensive launch same notably minime advance infusion set witness limit launch country initial product introduction period third quarter fiscal customer be satisfied experience minime advance infusion set limit launch period company be optimistic effectiveness system be expect witness greater customer adoptability time drive top line progress minime have be forge ahead initiative boost performance minime portfolio recently company report positive datum home pediatric study patient age year datum be base minime system be demonstrated advanced technology treatment diabetes international conference vienna austria notably medtronic commercially launch minime system june be hybrid close loop insulin delivery system type diabetic patient age year older minime system feature medtronic latest guardian sensor glucose sensor increase accuracy enhance performance development diabetes witness rise constant exchange rate revenue diabetes business third quarter fiscal company benefit positive uptake new sensor augment insulin pump system unite state well international market enhance production capacity same notably medtronic expect double digit growth segment fourth quarter fiscal courtesy consistent performance minime system unite state enhance sensor supply capacity additionally medtronic have be gear international launch minime launch cgm system guardian connect sugar iq late new professional cgm ipro regard company also announce favorable result support use cgm patient type diabetes october market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth diabetes market report mordor intelligence global market diabetes care device be project reach value cagr consider bullish market sentiment believe latest development have arrived opportune moment price have be underperform broader industry past month stock have decline versus industry rally however believe introduction minime advance infusion set help company regain investor optimism zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy becton dickinson be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
249,PKI,integra lifescience holding corporation iart free report report adjust earning share ep cent fourth quarter year figure adjust ep surpass zack consensus estimate cent full year adjust earning come reflect increase year quarter full year adjust ep also surpass zack consensus estimate integra lifescience holding corporation price consensus ep surprise integra lifescience holding corporation price consensus ep surprise integra lifescience holding corporation quote revenue discussiontotal revenue report quarter increase year year surpass zack consensus estimate exclude revenue acquisition discontinue product effect currency exchange rate organic revenue rise year year full year revenue come reflect increase figure also surpass zack consensus estimate solid revenue growth be primarily drive high organic revenue better expect performance recently acquire business johnson johnson codman neurosurgery business derma science come product category revenue company codman specialty surgical segment increase orthopedic tissue technology revenue come fourth quarter year year margin trendadjust gross margin contract basis point bps report quarter selling general administrative expense increase report quarter research development expense rise accordingly adjust operate margin see bps contraction fourth quarter financial positionintegra lifescience exit cash cash equivalent record end full year cash flow operate activity be year period company now expect full year revenue guidance high end range back more favorable foreign currency rate zack consensus estimate full year revenue be high end guide range company expect adjust earning diluted share be high end previously provide range zack consensus estimate adjust earning be peg company guide range full year company reiterate adjust gross margin band first quarter company expect adjust ep range cent represent growth year year zack consensus estimate first quarter adjust ep be peg cent company guide range first quarter company expect total revenue range include organic growth zack consensus estimate be guide range takeintegra lifescience exit fourth quarter solid note strong year year increase revenue back recent acquire business buoy optimism be also encourage note company segment see year year revenue growth quarter nonetheless believe company be try execute growth plan efficient management team moreover increase year year investment research development be encourage company promising guidance also instill confidence stock however significant margin contraction cause escalate cost expense be concern zack rank key picksintegra lifescience have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
250,PKI,medtronic plc mdt free report announce fda nod launch resolute onyx mm drug eluting stent de new stent be smallest size market presently resolute onyx de be available use size unite state europe country recognize ce mark stent have be exclusively design help interventional cardiologist treat patient coronary artery disease cad patient have small vessel be often untreatable larger stent technology percutaneous coronary intervention pci management believe introduction resolute onyx mm de enable doctor broaden treatment option patient smaller vessel notably resolute onyx de platform be only de feature core wire technology evolution continuous sinusoid technology be also be note resolute onyx mm clinical study support resolute onyx mm de study be present europcr annual meeting simultaneously publish journal american college cardiology jacc cardiovascular intervention coronary structural heart be consistently try enhance coronary structural heart csh segment be part cardiac vascular group cvg segment csh revenue third quarter fiscal be cer report low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk moreover continue uptake resolute onyx drug eluting stent unite state japan revive business market strategy gain traction csh sub segment seem be align datum provide transparency market research report global coronary stent market be expect see cagr more specifically de market coronary stent market be expand fast be estimate witness cagr period market be likely expand unite state asia pacific europe well rest world stock performance estimate revisionover last month medtronic have underperform industry decline compare industry gain last month also underperform gain market same time frame also estimate revision trend current year remain unfavorable estimate move south last month compare movement opposite direction earning estimate rise share same time frame zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
251,PKI,nuvasive inc nuva free report report fourth quarter adjust earning share ep cent reflect rise year quarter figure be par zack consensus estimate solid contribution international business lead year year improvement earning include time item company report fourth quarter net income share cent cent year full year adjust ep come line zack consensus estimate moreover figure improve year number revenue report quarter come marginally flat constant exchange rate cer year figure figure however miss zack consensus estimate net revenue totale line zack consensus estimate figure also improve year number nuvasive inc price consensus ep surprise nuvasive inc price consensus ep surprise nuvasive inc quote notably company announce preliminary result jan quarter company witness robust performance international market however upside be mar decline revenue notably pressure biologic business softness procedural volume spine market follow difficult comparison year figure lead disappointing performance unite state however management be satisfied key volume growth core hardware business notably company face headwind international business hurricane hit puerto rico report quarter company spinal hardware business decline however revenue business be flat adjust year figure magec sale notably rise pricing pressure product mix have offset case volume growth revenue surgical support business decline fourth quarter primarily due weakness biologic portfolio persistent sluggishness service business case volume growth however international business record growth cer report basis fifth consecutive time solid contribution key geography report quarter be increase cost good sell exclude amortization intangible asset expense accordingly gross profit decline moreover company report basis point bps year year contraction gross margin fourth quarter sale marketing administrative expense go research development expense contract nuvasive post adjust operate income report quarter reflect rise year figure adjust operate margin expand bps quarter company exit cash cash equivalent short term investment end outlooknuvasive provide guidance full year well guidance have be adjust recent buyout safepassage full year benefit tax reform suspension medical device tax company expect revenue range reflect organic growth moreover report basis company expect revenue growth range zack consensus estimate lag guide range foreign exchange rate be expect prove favorable nuvasive fact company expect foreign exchange rate have positive impact almost year nuvasive expect full year adjust ep current zack consensus estimate lag guide range additionally adjust operate margin year be expect bps year year basis exit fourth quarter unfavorable note miss zack consensus estimate revenue moreover company see softness business however solid performance international business more growth fifth consecutive quarter buoy optimism company expectation higher adjust operate profit margin least bps show focus operational efficiency house manufacturing facility moreover be upbeat recently complete buyout safepassage nuvasive acquisition strengthen company intraoperative neuromonitoring business line consolidated giant be expect deliver service more customer surgeon zack rank key picksnuvasive have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
252,PKI,feb issue update research report petm express inc pet free report stock carry zack rank strong buy company be strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product line several quarters drag new order sale be impressed petm improve performance last fiscal current year have demonstrated bullish momentum so far petm be also work improve effectiveness campaign have be quite successful drive sale internet petm offer wide range product dog cat horse believe improvement economic condition petm wide range product help drive growth come quarters however aim increase recognition brand name petm market product national advertising campaign procedure company have be incur huge expense related advertising campaign recent time hence escalate advertising expense exert pressure bottom line also tough competitive landscape be major concern stock performance estimate revisionover last year petm have outperformed industry company have gain compare industry also estimate revision trend current year be favorable estimate move north last month compare movement opposite direction earning estimate moved other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
253,PKI,integer holding corporation itgr free report report adjust earning cent share fourth quarter compare cent year quarter further earning beat zack consensus estimate cent revenue rise year year report basis exceed zack consensus estimate notably revenue improve organic basis sale grow report organic basis courtesy solid performance company cardio vascular business stock have zack rank sell integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quote segmental analysisinteger holding operate segment medical sale medical sale medical salessale segment be year year revenue increase organic basis total medical sale have subsegment advanced surgical orthopedic portable medical cardio vascular cardiac neuromodulation advanced surgical orthopedic portable medicalrevenue amount prior year quarter report basis comparable organic constant currency basis advanced surgical orthopedic portable medical revenue rise year year be primarily drive stable performance portable medical space new launch orthopedic arthroscopic platform cardio vascularrevenue segment totale prior year quarter come back strong demand exist oem product line contract component comparable organic constant currency basis revenue improve prior year figure be primarily drive higher customer demand vascular access product cardiac segment totale rise prior year quarter comparable organic constant currency basis cardiac neuromodulation revenue increase relentless focus customer relationship numerous value add service opportunity economic efficiency be expect drive sale segment fact company be well position optimize total cost ownership supply chain control segment medical sale sale segment totale year year report organic basis margin analysisinteger holding generate gross profit fourth quarter year year percentage revenue gross margin fourth quarter expand basis point bps total operate income fourth quarter be year year percentage revenue operate margin fourth quarter expand bps glancein integer holding register revenue improve report basis organic basis year year total medical sale quarter be net revenue medical sale be almost net revenue guidanceinteger holding expect revenue range adjust comparable basis reflect year year growth zack consensus estimate revenue be currently peg adjust earning be project range share reflect year year growth zack consensus estimate adjust earning be currently peg bottom lineinteger holding end fourth quarter solid note strong performance medical medical unit however cardiac neuromodulation remain flat year year integer holding cardiac rhythm management unit have be sluggish also revenue headwind be concern thank private insurance rate reduction higher provision rental revenue adjustment lower net patient addition owing continue reimbursement decline company expect rental revenue patient fall upcoming quarters major positive company provide positive guidance full year company steadfast focus customer relationship focus cost reduction burgeon financial performance be key catalyst integer holding derive significant portion revenue medicare service reimbursement program key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy becton dickinson have zack rank company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
254,PKI,becton dickinson company bdx free report popularly know bd be currently top perform stock medtech space improvement price performance strong fundamental indicate stock bullish run therefore haven take advantage share price appreciation yet time add stock portfolio stock have zack rank buy long term expect earning growth rate be positive bd arguably earning growth be utmost importance determine stock potential surge profit level indicate solid prospect long haul here take look other factor be likely provide bd competitive edge medtech quarters come factor worth price appreciation glimpse company price trend reveal share have return compare favorably index rally current return be also greater industry gain price surge be attribute strong investor optimism stock consider bd scale size commercial platform industry lead brand solid acquisition strategy be likely drive growth becton dickinson company price becton dickinson company price becton dickinson company quote recently company establish third business segment bd interventional notably recently acquire bard be integrate vertical regard management confirm bd be track become biggest medical technology device company world follow buyout acquisition be expect generate benefit complementary business geographical expansion also boost company share price upcoming day launch recently bd announce commercial availability ce ivd marked paxgene blood circulate cell free dna ccfdna tube european economic area switzerland western europe plastic tube used blood collection be develop preanalytix gmbh joint venture bd netherlands base provider sample insight solution qiagen qgen free report preanalytix be jointly form bd qiagen develop manufacture sell integrate standardized system sample collection stabilization purification rna dna human blood bone marrow study market market global molecular diagnostic market be project reach cagr northward estimate revision company zack consensus estimate earning fiscal reflect year year growth moreover earning be expect register growth fiscal fiscal zack consensus estimate revenue be peg reflect year year improvement moreover revenue be expect witness growth fiscal becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quote guidance strong include accretion bard acquisition bd expect fiscal revenue increase range report basis however revenue be expect grow range notably revenue be likely be affected change dispense business model company expect adjust earning share range current range indicate growth approximately report basis approximately cc geographical expansion bd continue focus geographical expansion overseas market particular emerge market first quarter fiscal international revenue grow year year basis growth be drive kiestra installation strength core microbiology diagnostic system well strong sale clinical instrument bioscience unit strength pre filled flush device mps strong growth pharmaceutical system also contribute international growth develop market revenue grow first quarter include anticipate headwind dispense change basis point bps growth be drive strong performance europe pharmaceutical system diagnostic system combination bd bard augment company growth profile develop market fiscal bd estimate develop market growth report basis adjust basis market be expect grow year year exclude estimate bps impact dispense change hurricane puerto rico other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
255,PKI,haemonetic corporation hae free report report adjust earning share ep cent third quarter fiscal surge year year bottom line also beat zack consensus estimate cent metric be favourably attribute cent lower tax rate cent currency translation partly offset couple cent dilution increase share count report basis haemonetic post net loss cent share compare earning cent prior year quarter metric include net transition tax earning certain foreign subsidiary previously tax defer however same be partly offset benefit revaluation defer tax item used lower corporate tax rate effective jan total revenuesrevenue be year year constant exchange rate cer report quarter top line also exceed zack consensus estimate year year growth be consistently backed strong result north america improve international result key market haemonetic corporation price consensus ep surprise haemonetic corporation price consensus ep surprise haemonetic corporation quote revenue product report operate result business franchise plasma haemostasis management cell process blood center plasma report revenue total revenue be year year cer revenue bloodcenter total revenue decline cer hemostasis management franchise revenue total revenue rise cer revenue cell process be cer total revenue third quarter adjust gross margin be basis point bps year year drive favorable mix productivity currency adjust operate income be quarter rally year year adjust operate margin expand bps year year quarter review favourable foreign currency translation contribute basis point year year operate margin improvement financial exit third quarter fiscal cash cash equivalent compare end precede year company generate operate cash flow year date adjust free cash flow transformation restructure cost be quarter increase year period fiscal revise fiscal revenue guidance company expect full year revenue be line fiscal revenue exclude currency impact bps view plasma revenue growth have be raise range project earlier outlook hospital revenue rise have be update earlier expectation blood center revenue be likely decline range previous guidance be decrease zack consensus estimate revenue be peg company raise adjust ep guidance previous band zack consensus estimate remain guide range takehaemonetic exit third quarter fiscal promising note earning revenue beating zack consensus estimate continue momentum new business generation geographical expansion have help company deliver strong result late however be disappoint company sluggish blood center business moderate overall growth report cycle encourage progress noticed plasma hospital company strong cash position boost investor confidence increase fiscal adjust earning guidance be also impressive zack rank key pickshaemonetic have zack rank hold few better rank stock have report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue increase year year constant exchange rate cer breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
256,PKI,myriad genetic inc mygn free report report adjust earning share ep cent second quarter fiscal year year moreover adjust ep beat zack consensus estimate solid margin exceed company guide range cent report earning come cent share quarter compare net cent year quarter revenuestotal revenue be year year quarter review figure however outpaced zack consensus estimate be company guidance year year decline be however cause fall hereditary cancer testing revenue owing price reduction long term contract myriad genetic inc price consensus ep surprise myriad genetic inc price consensus ep surprise myriad genetic inc quote however decline be partially offset grow new product volume expand reimbursement new product increase international rna kit revenue moreover be fourth consecutive quarter company witness year year hereditary cancer volume growth lead encourage response newly launch riskscore test myrisk hereditary cancer testing portfolio quarter detailssegment wise molecular diagnostic test total revenue record total revenue year year account decline hereditary cancer testing revenuesto endopredict testing revenue grow year year report quarter moreover vectra da testing revenue come year year other testing revenue decline prolaris testing space volume maintain double digit growth fiscal first quarter well increase average selling price benefit medicare favorable intermediate lcd be put effect sep prolaris test rake revenue quarter also hereditary cancer testing revenue decline due price reduction long term contract however volume growth exceed company growth target year year basis pharmaceutical clinical service revenue accounting rest quarter totale reflect year year increase margin trendsgross margin quarter review contract basis point bps accord management gross margin performance be affected hereditary cancer test pricing issue partially offset improve efficiency hereditary cancer production process result elevate initiative increase new product reimbursement operate expense decrease rise selling general administrative sg expense be offset slash research development expense report quarter financial positionmyriad genetic exit fiscal second quarter cash cash equivalent marketable security compare end precede quarter year date cash flow operation totale compare year period year date company register free cash flow compare year period guidancemyriad genetic have raise guidance fiscal revenue provide earlier zack consensus estimate lie guide range bottom line front company lift adjust ep range previous current zack consensus estimate be company guide range management have provide guidance third quarter fiscal company estimate adjust earning share cent total revenue zack consensus estimate adjust ep be cent revenue be viewmyriad genetic register better expect performance second quarter fiscal however year year decline revenue be disappointing positive note company observed strong growth genesight endopredict testing revenue recent fda approval encourage test result buoy optimism flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation zack rank key picksmyriad genetic have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
257,PKI,laboratory corporation america holding lh free report labcorp report fourth quarter adjust earning share ep year quarter bottom line also exceed zack consensus estimate time benefit related tax cut job act report quarter affected adjust ep cent approximately report basis labcorp net earning come share compare year period full year adjust ep be miss zack consensus estimate however metric register growth year adjust number net revenue fourth quarter increase year year however top line lag zack consensus estimate close margin year year rise net revenue be owing growth acquisition organic growth net revenue growth revenue acquisition first month close acquisition benefit approximately basis point foreign currency translation laboratory corporation america holding price consensus ep surprise laboratory corporation america holding price consensus ep surprise laboratory corporation america holding quote net revenue year be precede year number metric be also ahead zack consensus estimate quarter reviewlabcorp report operate segment labcorp diagnostic covance drug development report quarter labcorp diagnostic report net revenue year year fuel tuck acquisition organic volume measure requisition exclude requisition acquisition first month completion acquisition gain foreign currency translation roughly basis point company report rise total volume measure requisition increase revenue requisition concern quarter several quarters drag sale covance drug development report rise net revenue fourth quarter upside be primarily back chiltern buyout organic growth foreign currency translation benefit nearly basis point gross margin deteriorate bps report quarter adjust operate income decline year year adjust operate margin contract bps year quarter rise selling general administrative expense labcorp exit year cash cash equivalent compare end full year operate cash flow be year period free cash flow come year quarter quarter discussion company return shareholder share repurchase have share worth remain exist authorize share repurchase plan outlooklabcorp have provide guidance revenue growth be expect remain band include likely improvement bps foreign currency translation zack consensus estimate current year revenue be peg adjust ep guidance have be project range consensus mark metric fall guide range free cash flow have be anticipate growth band prior year takelabcorp post mixed fourth quarter performance adjust earning top zack consensus estimate net revenue fall short mark positive note strong year year growth earning revenue be encourage labcorp diagnostic business be solid back increase acquisition organic volume expansion favorable foreign exchange scenario also several quarters dull performance covance drug development have be report sturdy growth past couple term uptrend be primarily owing chiltern takeover robust organic growth positive foreign currency translation guidance also look promising believe integration newer acquisition labcorp be perfectly position drive long term profitable growth combination world class diagnostic drug development expertise knowledge service zack rank key pickslabcorp have zack rank hold few better rank stock have report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue increase year year constant exchange rate cer more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
258,PKI,corporation abc free report post adjust earning share first quarter fiscal beating zack consensus estimate improve year year upside be attribute strong growth company pharmaceutical distribution segment world courier business revenue improve almost report quarter revenue also beat zack consensus estimate stock have zack rank hold corporation hold co price consensus ep surprise corporation hold co price consensus ep surprise corporation hold co quotesegmental distribution segment revenue segment be year year basis operate income be year year however segment be affected lower expect production pharmedium outsource facility notably operation facility be voluntarily suspend company follow few inspection fda quarter other segment include consult service abcs world courier mwi veterinary supply revenue segment come year year operate income segment be quarter year year strong performance world courier unit sluggishness abcs dampen segmental growth first quarter margin detailsin quarter review register gross profit year year basis percentage revenue gross margin be basis point bps prior year quarter operate expense first quarter fiscal be year year register operate income year year percentage revenue operate margin contract bps guidance raisedbase expectation recently legislate tax reform raise guidance fiscal company expect adjust earning share range previously range revenue growth fiscal be expect range higher previous range however company expect adjust operate expense increase range previous range adjust operate income growth be estimate range lower previous range january declare have complete acquisition largest independent wholesaler unite state cash deal be initiate november acquisition be expect be slightly accretive adjust earning share fiscal further deal be expect return cent adjust earning share fiscal year be expect strengthen company support community pharmacy drive long term durable value end first quarter fiscal solid note beating zack consensus estimate count strong guidance instill investor optimism stock strong performance pharmaceutical distribution segment world courier business hold promise recent takeover largest independent wholesaler unite state be positive flip side face headwind thank slowdown hepatitis revenue conversion brand drug lower price generic further temporary slowdown pharmedium growth be expect mar company bottom line cutthroat competition niche space add company wo key picksa few better rank stock report impressive earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently announce third quarter fiscal adjust earning share cent bottom line soar year year revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal narrower cent year quarter figure top line improve year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
259,PKI,feb issue update research report qiagen qgen free report stock carry zack rank hold netherlands base molecular diagnostic provider offer innovative technology product pre analytical sample preparation molecular diagnostic solution stock have be trading broader industry past month latest share price have lose compare decline broader industry company end fourth quarter solid note earning revenue beating zack consensus estimate quarter qiagen molecular diagnostic sale increase significantly dynamic growth quantiferon latent tb test also double digit cer growth revenue company companion diagnostic partnership sustain double digit cer growth consumable related qiasymphony automation system contribute top line moreover report quarter company surpass goal qiasymphony placement reflect strong demand system management now aim surpass cumulative qiasymphony placement end also company focus drive growth sample insight offering buoy optimism be also upbeat qiagen solid progress test menu expansion strategy regard january company ipsogen jak rgq pcr kit ipsogen jak assay receive fda approval additional use diagnosis neoplasms mpns also look forward implementation recently draw strategy boost top line contribution ngs portfolio meanwhile qiagen be expose stiff competition company be face intensify competition firm provide competitive pre analytical solution other product used qiagen customer market company product be very competitive price sensitive add concern also strong reliance collaboration decline hpv sale unite state be other negative key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
260,PKI,bruker corporation brkr free report report adjust earning share ep cent fourth quarter year figure also adjust ep beat zack consensus estimate couple cent revenue detailbruker report revenue fourth quarter year year top line surpass zack consensus estimate exclude positive effect acquisition favorable impact change foreign currency rate bruker report year year organic revenue growth bruker corporation price consensus ep surprise bruker corporation price consensus ep surprise bruker corporation currency adjust european revenue improve high single digit year year fourth quarter north america revenue decline mid single digit asia pacific organic revenue increase double digit china revenue rise mid single digit fourth quarter management company register organic revenue growth strength nano best bruker biospin group revenue decline low single digit organic basis due customer push out revenue nano group increase low teen organic basis significant growth semiconductor metrology business ray nano analysis product material research industrial academic research application calid revenue be low single digit organic basis strong performance mass spec optic product line be partially offset year year decline calid detection business best revenue rise organically margin trenda percentage revenue gross margin report quarter expand basis point bps selling general administrative expense increase research development expense rise year year overall adjust operate margin expand bps other charge rise year year financial positionbruker exit cash cash equivalent short term investment end precede year full year net cash used operate activity be compare year period glancein bruker revenue rise figure beat zack consensus estimate fiscal bruker year year organic revenue growth be growth acquisition be favorable effect change foreign currency rate be adjust ep be compare figure surpass zack consensus estimate guidancebruker issue guidance company expect revenue growth approximately include organic revenue growth approximately company expect year year increase adjust operate margin range bps fiscal bruker expect adjust ep range previous range zack consensus estimate be lower end company guidance takebruker exit fourth quarter solid note year year increase revenue earning expansion gross operate margin buoy optimism company strategic acquisition activity have be encourage be also upbeat company current focus product development higher flip side competitive landscape macroeconomic headwind continue challenge company zack rank key picksbruker carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
261,PKI,hologic inc holx free report report first quarter fiscal adjust earning share ep cent year year moreover adjust ep beat zack consensus estimate surpass company guidance cent report basis company record ep compare cent first quarter fiscal notably report figure include time tax provision net benefit courtesy tax reform revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company guidance solid contribution hologic molecular diagnostic breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesegment detailrevenue diagnostic segment total revenue decline year year cer first quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system continue solid uptake aptima woman health product cytology perinatal revenue also show rise cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest decrease cer operational updatein fiscal first quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit first quarter fiscal cash cash equivalent report end first quarter fiscal total long term debt be end report quarter compare year quarter company generate operate cash flow compare year cash flow guidancehologic have update fiscal financial guidance company currently expect adjust revenue grow range compare previously provide range cer current zack consensus estimate be guide range adjust ep be expect grow previously state range current zack consensus estimate adjust ep be peg guide range second quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg project range adjust ep be project cent reflect annualize growth current zack consensus estimate second quarter adjust ep be peg cent company guidance takehologic post better expect result first quarter fiscal term earning revenue growth geographical region buoy optimism however be disappoint decline revenue company diagnostic segment blood screening divestiture be also likely impede growth momentum company zack rank key pickshologic carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
262,PKI,surmodic inc srdx free report report adjust earning cent share first quarter fiscal lower year figure cent zack consensus estimate be loss cent revenue quarter fall miss zack consensus estimate stock have zack rank hold segment report revenue segment medical device diagnostic ivd medical devicein report quarter sale decline due lower hydrophilic royalty revenue royalty license fee revenue totale year year management decline royalty license fee revenue be cause lower royalty result expiration patent third generation hydrophilic coating unit generate operate loss report quarter compare unfavorably operate income year quarter operate income segment be affected plan increase investment related surmodic whole product solution strategy reduction royalty revenue well increase contingent consideration expense ivdin quarter review sale increase upside come back strong growth stabilization biofx microarray antigen product sale ivd operate income be current quarter compare first quarter fiscal surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quote margin detailsproduct gross margin contract basis point bps first quarter product sale compare year period margin quarter suffer expense irish facility infrastructure lower medical device product gross margin first quarter fiscal expense be net sale higher net sale year quarter company anticipate expense increase fiscal thank company whole product solution strategy investment advance transcend drug coater balloon human clinical trial preclinical work knee platform av fistula drug coat balloon project sg expense first quarter fiscal be revenue expand bps year year balance sheet cash flowat end first quarter company have cash investment surmodic generate cash operate activity company invest plant equipment continue expect fiscal year revenue range company expect fiscal earning share negative cent cent compare previous estimate adjust loss cent bottom linesurmodic end first quarter fiscal favorable note courtesy solid performance diagnostic segment segment have be gain ground back strong growth stabilization biofx microarray antigen product sale surmodic issue solid guidance fiscal company solid initiative strengthen research development program hold promise company witness significantly high operate loss specifically ireland product sale decline substantially owing shipment issue particularly medical device segment further foreign exchange wo related creagh medical buyout have be major dampener surmodic drug coat balloon face stiff competition niche space company margin be expect be pressure thank expense irish facility infrastructure lower medical device product gross margin key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
263,PKI,cvs health corporation cvs free report fourth quarter adjust earning share ep be year year adjust ep also beat zack consensus estimate cent time adjustment exclude impact income tax benefit result latest tax reform report ep continue operation come share surge year period full year adjust ep come improvement year adjust number net revenue fourth quarter increase year year exceed zack consensus estimate cvs health corporation price consensus ep surprise cvs health corporation price consensus ep surprise cvs health corporation quoterevenue year be improvement revenue also beat zack consensus estimate quarter detailspharmacy service revenue increase report quarter drive growth specialty pharmacy volume higher pharmacy network volume well brand inflation be however partially offset increase generic dispense continue price compression pharmacy network claim processed quarter climb day equivalent basis backed net new business growth also mail choice processed claim count be day equivalent basis continue adoption maintenance choice offering rise specialty pharmacy claim revenue cvs health retail ltc be marginal year year accord company increase same store prescription day equivalent basis brand inflation be partially offset continue reimbursement pressure increase generic dispense rate front end same store sale be year year be positively impact basis point seasonal cough cold front store sale be adversely affected soft customer traffic effort rationalize promotional strategy be partially offset increase basket size pharmacy same store sale increase report quarter sale be adversely affected approximately basis point bps due recent generic drug introduction apart marketplace change restrict cvs pharmacy participate certain network have bps negative impact same store prescription volume report quarter generic dispense rate proportion generic prescription total number prescription dispense increase approximately bps pharmacy service segment bps retail ltc segment gross profit improve however gross margin contract bps total operate margin quarter decline bps cvs health exit year cash cash equivalent short term investment compare end full year net cash provide operate activity be year period fourth quarter cvs health open new retail store close relocate retail location dec cvs health operated retail store include pharmacy target store state well district columbia puerto rico brazil company have revise outlook revision reflect effect tax reform achieve tax cut job act tcja management note cash benefit tcja company be able make strategic investment stimulate greater growth longer term accordingly company have increase adjust operate profit growth guidance range earlier state range earlier provide initial outlook cvs health note expect deliver net revenue growth year current zack consensus estimate full year revenue be peg first quarter company expect register adjust operate profit growth range takecvs health end year solid note better expect fourth quarter performance year year growth top line be drive strong pharmacy service segment benefit upside specialty service however year year retail ltc comparison be dull zack rank key pickscvs health have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
264,PKI,omnicell inc omcl free report have be gain investor confidence consistently positive result past year stock have rally mountain view base developer marketer end end automation solution medication use process have market cap company year project growth rate be favorable compare broader industry however estimate revision trend zack rank hold company current year have be mixed last day analyst revise estimate upward movement opposite direction however estimate revision earning increase share same time frame factor playwe note stock be progress well legged strategy cover market expansion delivery differentiate innovative solution expansion new market primarily outside unite state expansion strategic partnership acquisition new technology last report quarter company gain new prominent customer well significant strategic deal exist customer thereby progressed first leg strategy apart xt series momentum company be witness market momentum value validate entire omnicell platform strategic solution omnicell xr automate central pharmacy system be likely be available mid be already gain significant momentum market number contractual booking fourth quarter second leg expand new market be drive growth acute care segment company continue focus middle east south africa also see greater adoption technology other part world latest be australia internationally company have sign contract hcl hca healthcare pharmacy supply solution hospital third leg acquisition partnership be also progress successfully company most recent buyout be inpharmic mississippi base technology service company help omnicell expand capability performance center omnicell strong position sweden germany singapore middle east south africa china also buoy optimism company have be witness strong pipeline development country addition omnicell witness strong business trend europe have observed healthy acceptance medication adherence product meanwhile remain sideline past month omnicell have be underperform broader industry stock have decline versus industry fall moreover omnicell continue expect higher cost upcoming quarters stem integration aesynt ateb expense related recently launch xt series thereby add concern moreover omnicell be expose resilient hospital capital expenditure environment adversely affect adoption solution furthermore reimbursement mix have also affected endowment income further affect hospital spending capability company have win new deal larger hospital market be still susceptible economy credit condition key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
265,PKI,edward lifescience corporation ew free report have be healthy growth trajectory late positive tiding regulatory front strategic acquisition have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment edward lifescience have outperformed broader industry last month stock have gain ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare increase industry gain company have positive earning surprise last quarters also have long term expect earning growth rate headquarter irvine company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise share same time frame let find recent positive trend be sustainable edward lifescience fourth quarter performance be quite promising company beating zack consensus estimate revenue earning also raise guidance hint brighter prospect fact raise outlook be backed strong performance company product line market be also upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf thv segment edward lifescience recently acquire harpoon medical inc privately hold medical technology company focuse beating heart repair degenerative mitral regurgitation agreement harpoon medical flagship beating heart repair procedure mitral valve patient harpoon system be add edward lifescience surgical heart valve therapy portfolio treat structural heart disease other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
266,PKI,ecolab inc ecl free report report fourth quarter adjust earning share miss zack consensus estimate penny earning improve year quarter ecolab carry zack rank hold include net discrete tax benefit tax reform cent share ecolab register earning report basis adjust quarterly net sale be year quarter also net sale miss zack consensus estimate ecolab inc price consensus ep surprise ecolab inc price consensus ep surprise ecolab inc quotesegmental analysisglobal industrial segmentsale segment grow year year almost upside be drive major gain water food beverage life science unit europe north america latin america lead global industrial regional growth acquisition adjust fix currency operate income improve year year basis global institutional segmentsale increase lead strong growth specialty business line segment witness solid growth north america asia pacific acquisition adjust fix currency operate income remain flat year year global energy segmentsale rise owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income increase year year other segmentsale decline year year sale segment witness robust growth north america margin analysisas percentage revenue ecolab register adjust gross margin fourth quarter basis point bps year year basis adjust operate margin fourth quarter contract bps net revenue outlookecolab expect full year adjust earning range share year year percentage revenue adjust gross margin be expect range first quarter ecolab expect adjust earning range cent share previous range cent current outlook reflect increase year year adjust gross margin first quarter be expect be net revenue takeecolab end fourth quarter unfavorable note miss zack consensus estimate count strength pest elimination business other segment decline year year report basis ecolab operate highly competitive market mar prospect long haul believe volatility foreign currency exchange rate remain significant headwind company ecolab face pricing pressure energy segment be likely hurt profit brighter side strong guidance instill optimism stock further europe north america latin america lead global industrial regional growth quarter strength global institutional segment lead growth specialty healthcare business line be also positive robust product portfolio expand customer base be likely drive organic sale long haul key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
267,PKI,henry schein inc hsic free report report adjust earning share ep cent fourth quarter year year adjust ep remain line zack consensus estimate year year upside earning be drive strong revenue growth business segment adjust ep year be improvement year period also remain line zack consensus estimate revenue detailhenry schein report net sale fourth quarter year year marginally zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter net sale full year be improvement year number top line also exceed zack consensus estimate henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc quotein fourth quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service fourth quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be quarterly result also have negative impact additional week year period internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be extra week have negative impact quarterly sale performance internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit year cash cash equivalent compare end full year net cash provide operate activity be compare year period quarter review company buy back approximately share almost close fourth quarter company have authorize repurchase common stock guidancehenry schein raise ep guidance reflect impact tax reform legislation include estimate cent impact associate certain time cash bonus company currently expect ep range reflect growth report ep figure previous ep guidance range be zack consensus estimate adjust ep be guide range takehenry schein exit fourth quarter mixed note company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense increase ep guidance buoy optimism zack rank key pickshenry schein have zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
268,PKI,idexx laboratory inc idxx free report have be gain investor confidence consistently positive result stock have rally last year ahead gain broader industry rise moreover lead manufacturer product service primarily companion animal veterinary livestock poultry have market cap company year historical growth rate be also favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction estimate revision earning increase share same time frame style score idexx laboratory sport growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential regard idexx laboratory have favorable net margin net income sale industry negative company sale asset ratio versus industry signify be solid growth pick let find recent positive trend be sustainable idexx exit fourth quarter promising note strong year year growth organic revenue be encourage stellar performance be drive strong sale cag business fourth quarter cag organic revenue rise low double digit strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth be upbeat company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention regard be optimistic gain commercial launch catalyst sdma test north america january company point care customer be able add sdma essential element routine chemistry panel continue slew development january idexx enter global agreement diagnostic company apply biocode agreement idexx bring reference laboratory customer digital multiplex platform build apply biocode management aim commercial launch technology companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover strong top line growth quarter be drive considerable contribution rest business segment furthermore raise guidance earning share instill confidence stock be also upbeat company witness double digit organic revenue growth international business reflect continue consumable revenue gain support catalyst instrument base average testing utilization additionally company have strong cash balance allow carry share repurchase meanwhile idexx high reliance third party distributor be concern moreover competitive landscape domestic overseas market weigh company other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
269,PKI,phibro animal health corporation pahc free report report adjust earning share ep cent second quarter fiscal year year adjust ep surpass zack consensus estimate cent accord company year year improvement be primarily drive higher gross profit ratio reduce interest expense lower effective income tax rate report ep cent be year quarter lower net income majorly due rise income tax expense net salesin report quarter net sale totale year year improvement be drive sale growth animal health mineral nutrition performance product segment sale segmentsnet sale animal health segment increase report quarter volume increase nutritional specialty vaccine product group segment nutritional specialty product grow sale vaccine increase principally volume growth product poultry dairy industry phibro animal health corporation price consensus ep surprise phibro animal health corporation price consensus ep surprise phibro animal health corporation quote moreover sale medicated feed additive mfa other grow primarily buoy strength international business domestic net sale mfa other decline due reduce volume medically important antimicrobial unfavorable timing certain customer order international net sale increase drive growth most region include benefit recent buyout additional penetration cattle sector net sale mineral nutrition segment increase higher average selling price result increase underlie raw material commodity price moreover favorable product mix contribute overall revenue growth segment net sale performance product segment increase higher average selling price volume copper base product however lower average selling price personal care product have partially offset rise average selling price operational updatephibro second quarter gross profit increase year year gross margin contract basis point bps selling general administrative expense rise operate margin contract bps quarter financial update year date phibro generate cash flow operation compare year period capital expenditure amount period reflect reduction year period fy view raisedphibro have update guidance fiscal company expect generate net sale compare previous current zack consensus estimate fall guide range phibro raise adjust ep guidance state previously current zack consensus estimate be also company guide range takephibro end second quarter fiscal solid note company witness considerable improvement segment be also encourage raise fiscal guidance report quarter moreover company believe continuous investment portfolio enhancement develop organizational capability have start pay zack rank key picksphibro have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue increase year year constant exchange rate cer more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
270,PKI,feb issue update research report align technology inc algn free report stock carry zack rank hold notably align technology manufacture market clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage share company have be trading industry last year stock have rally compare industry growth company deliver encourage performance fourth quarter post better expect earning revenue be encourage company solid invisalign technology prospect growth north america internationally particularly asia pacific company have witness year year growth segment also expansion gross operate margin buoy optimism be also upbeat company distribution agreement glidewell dental distribute itero element intraoral scanning system latest glidewell io office solution north america flip side adverse foreign exchange translation continue raise concern align technology international operation also escalate cost expense be weigh margin moreover tough competitive landscape other macroeconomic headwind threat key pickssome better rank stock broader medical sector be bio rad laboratory bio free report resm rmd free report perkinelmer pki free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate resm have zack rank company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
271,PKI,feb issue update research report steris plc ste free report company have be actively try expand adjacent market strengthen core business acquisition dilution however company operate tough competitive landscape be concern stock carry zack rank hold developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have outperformed industry past year stock have gain compare industry rally steris exit third quarter fiscal mixed note earning beating zack consensus estimate revenue miss same be encourage favorable underlie market trend new product service offering company organic growth be strong specialty service life science apply sterilization segment be particularly upbeat steris acquisition first month fiscal buyout company aim strengthen healthcare product healthcare specialty service apply sterilization technology business furthermore finance cash hand credit facility borrowing company have incur acquisition cost net cash acquire include potential contingent consideration believe steris pursue back back acquisition long run order expand business customer base courtesy strong financial position be also encourage company recent organizational change serve customer better way also expect move enhance company cost structure further growth free cash flow reserve be indicative company strong cash balance meanwhile steris compete pharmaceutical research industrial customer several large company have extensive product portfolio global reach well number small company limit product offering operation few country company expect face intense competition new infection prevention sterile process contamination control surgical support product service enter market hamper steris growth considerably moreover number steris customer be undergo consolidation partly due healthcare cost reduction measure initiate competitive pressure well legislator regulator third party payor believe company fail check rate customer consolidation now adversely affect business well financial condition key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy becton dickinson company be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
272,PKI,cardiovascular system inc csii free report recently announce commercial launch diamondback coronary oas micro crown micro crown japan follow country pharmaceutical medical device agency pmda approval march device have be approve frontline treatment severe calcify lesion facilitate access artery percutaneous coronary intervention pci thereafter interestingly approval be give follow presentation favorable year datum coronary orbital atherectomy system study coast company note pcis year be project be extremely calcify japan market coronary intervention hold huge potential moreover micro crown have receive reimbursement approval be implement fully month cardiovascular system expect successfully complete initial micro crown stocking order third quarter fiscal medikit co ltd exclusive distribution partner japan recent developmentsin bid expand peripheral coronary intervention product portfolio add support complementary product cardiovascular system sign partnership january first company sign exclusive distributor agreement orbusneich orbusneich balloon product unite state company also enter original equipment manufacturer oem agreement integer holding itgr free report agreement cardiovascular system manufacture self brand zilient guidewire facilitate tip resilience crossability difficult arterial lesion cardiovascular system have be pursue product improvement evaluate new technology strengthen broaden portfolio powerful micro invasive tool company receive fda approval micro crown system facilitate stent delivery patient coronary artery disease cad market global market coronary heart disease be expect see huge demand back grow case chronic disease moreover go report publish technavio global market coronary heart disease be expect see cagr more consider company effort believe be well position gain favorable trend cad space share price system have be outperform broader industry past month stock have gain compare industry rise zack rank key system carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report bio rad laboratory have zack rank buy company have long term expect earning growth rate see complete list today zack rank strong buy stock here perkinelmer have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
273,PKI,maintain streak positive earning surprise athenahealth inc athn free report report adjust earning share fourth quarter beat zack consensus estimate cent further earning increase whopping year year basis watertown base maker bill medical practice management software post revenue beating zack consensus estimate revenue increase year year basis athenahealth flaunt zack rank strong buy glancein total revenue rise year year consolidated booking be business service segment register revenue net revenue implementation other segment report revenue net revenue athenahealth inc price consensus ep surprise athenahealth inc price consensus ep surprise athenahealth inc quote detailssegment report business service revenue year quarter however implementation other segment report revenue year year network expansionper management company expand network ambulatory hospital population health platform recently athenahealth surpass patient threshold now serve more healthcare provider company network have collector provider clinical provider communicator provider respectively year year basis athenaone hospital platform number discharge bed increase whopping year year population health platform number cover life increase year year buoy stellar network expansion company be expect fortify foothold revenue cycle management rcm space drive revenue earning long haul margin detailsa strong client base have be major growth driver company adjust gross margin fourth quarter be compare year quarter company see operate margin total revenue basis point year year notably adjust operate income report quarter increase year year be expect introduce fiscal guidance investor summit be schedule be hold feb meanwhile zack consensus estimate earning be peg year year zack consensus estimate revenue be peg bottom exit fourth quarter solid note earning revenue outpace zack consensus estimate believe application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system brand promise unbreak healthcare be fortify market position term exclusiveness service provide respective market strong client base have be key catalyst business service revenue witness year year growth same implementation other segment decline major concern athenahealth ehr solution face significant competition like allscript healthcare solution other further athenahealth fall short booking goal deteriorate client retention rate also add company wo other key picksa few top rank stock report impressive earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently announce third quarter fiscal adjust earning share cent bottom line soar year year revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal narrower cent year quarter figure top line improve year year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
274,PKI,jan issue update research report hill holding inc hrc free report stock carry zack rank buy batesville base company have be trading broader industry past year stock have so far gain comparison industry hill exit first quarter fiscal strong note better expect earning revenue company see solid year year increase revenue strong international growth primarily banking hill approach company be focuse product innovation latest launch be connex cardio ecg hill have update long range financial objective outlook consider gain new tax reform hill now expect adjust earning growth compound annual basis compare previous guidance moreover improvement gross adjust operate margin buoy optimism further accord management hill expect latest tax regulation have positive impact adjust effective tax rate earning begin first quarter fiscal hill merger acquisition activity be go strong company actively pursue buyout accelerate growth key clinical area viz patient mobility wound care prevention surgical safety efficiency clinical solution respiratory help apart welch allyn trumpf recent noteworthy acquisition include virtus aspen surgical mortara instrument flip side decline revenue patient support system segment be quite disappointing hill operate highly competitive space dominate large well small regional manufacturer also unfavorable currency movement continue be threat large chunk company revenue be generate international operation key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report resm rmd free report bio rad laboratory have zack rank company have long term expect earning growth rate see complete list today zack rank stock here perkinelmer have long term expect earning growth rate stock carry zack rank resm have long term expect earning growth rate stock carry zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
275,PKI,month have go last earning report perkinelmer inc pki free report share have lose past month underperform market recent negative trend continue lead next earning release be pki due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent report fourth quarter adjust earning cent share beating zack consensus estimate cent company base waltham report adjust revenue approximately beat zack consensus estimate revenue also surpass year figure segment analytical solution da revenue da totale fourth quarter year quarter perkinelmer have be focuse finalize organizational change associate life science business da unit come profit da segment company report fourth quarter adjust operate income year quarter percentage revenue adjust operate profit margin be basis point bps year year diagnostic segmentrevenue be compare year quarter reflect improvement organically divestment medical imaging business acquisition euroimmun medical laboratory diagnostic ag have be major driver segment perkinelmer announce completion buyout euroimmun approximately cash december euroimmun be autoimmune testing company emerge player infectious disease allergy testing meanwhile operate profit margin segment percentage revenue be bps year year financial detailsat end quarter operate cash flow continue operation be approximately include euroimmun deal related cost prepay royalty company end year approximately debt cash company issue adjust earning guidance perkinelmer expect adjust earning share further expect report revenue range include approximately foreign exchange tailwind approximately report revenue euroimmun perkinelmer project organic revenue growth have estimate be move then past month investor have witness downward trend fresh estimate have be revision lower current quarter perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote vgm scoresat time pki have subpar growth score however momentum be do bit better charting somewhat similar path stock be also allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested stock be suitable solely momentum base style score outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift interestingly pki have zack rank buy expect average return stock next few month
276,PKI,cardinal health inc cah free report report second quarter fiscal adjust earning share beat zack consensus estimate however exclude cent benefit legislate tax reform adjust earning be share meanwhile adjust earning year quarter be share revenue increase year year basis almost beat zack consensus estimate cardinal health inc price consensus ep surprise cardinal health inc price consensus ep surprise cardinal health inc stock have zack rank buy segmental revenue increase year year basis segment witness strong growth specialty business also gain large number pharmaceutical distribution customer however segment witness decline profit thank generic pharmaceutical pricing recent investment pharmaceutical platform lackluster generic program performance however solid performance specialty solution business partially offset negative impact segment medical segmentrevenue segment improve primarily higher contribution new exist customer medical segment profit increase courtesy higher contribution new exist customer acquisition patient recovery business share repurchase company board director approve new authorization repurchase company common share expire dec latest authorization cardinal health be authorize repurchase common share marginsas percentage revenue gross margin contract basis point bps net revenue however gross profit quarter be year year distribution selling general administrative sg expense increase year year basis benefit cent share lower federal rate due tax reform cardinal health raise fiscal outlook company expect adjust earning share continue operation range share higher previous range takecardinal health exit quarter solid note courtesy encourage performance medical segment pharmaceutical segment witness strong growth specialty business gain large number pharmaceutical distribution customer further company be banking strategic buyout joint venture supply agreement drive growth strong fiscal outlook buoy optimism flip side growth business profit pharmaceutical segment be hurt generic pharmaceutical pricing huge investment pharmaceutical platform lackluster generic performance be likely mar cardinal health operational efficiency upcoming quarter intense competition customer concentration be other bottleneck recently company recently close divestiture cardinal health china distribution other key picksa few other top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
277,PKI,feb issue update research report illumina inc ilmn free report zack rank hold stock last month san diego base company provide tool integrate system analysis genetic variation function have gain higher broader industry illumina exit fourth quarter solid note beating zack consensus estimate front additionally revenue earning improve year year basis apart improve margin scenario instilled investor confidence stock be also optimistic illumina expansion strategy enhancement portfolio sequence product development strategic partnership therapeutic diagnostic service provider regard january illumina sign commercial agreement distribute thermo fisher scientific ion ampliseq technology researcher conduct study illumina next generation sequence platform currently illumina be focuse product innovation research development well be evident recent launch iseq sequence system post promising fourth quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio meanwhile illumina face stiff competition sequence snp genotyp gene expression molecular diagnostic market several large player already enjoy significant market share intellectual property portfolio regulatory expertise also national institutes health nih funding issue raise concern key pickssome better rank stock broader medical sector be bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer pki free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company have zack rank company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
278,PKI,cardiovascular system inc csii free report report adjust loss share penny second quarter fiscal year quarter adjust earning cent figure be narrower earlier guide range loss share cent figure also compare favorably zack consensus estimate loss cent net system record revenue fiscal second quarter mark year year increase also figure be guide range however revenue miss zack consensus estimate cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quote segment detailscoronary device revenue increase year year date cardiovascular system have sell device lead institution unite statesmeanwhile peripheral device revenue rise year year basis company add new peripheral account coronary account fiscal second quarter margingross margin report quarter be basis point bps year year meanwhile selling administrative sg expense contract research development expense be resultantly adjust operate expense be management operate expense be lower earlier provide guidance due reduce incentive compensation payroll expense operate loss be operate income year quarter financial company exit second quarter fiscal cash cash equivalent compare end precede quarter company have long term debt system update fiscal revenue guidance range current zack consensus estimate fiscal revenue be peg company guide range company expect revenue range third quarter fiscal current zack consensus estimate be peg company guide range moreover company expect gross profit account revenue operate expense be estimate third quarter fiscal company expect incur net loss adjust earning share be expect be negative cent breakeven current zack consensus estimate be peg earning cent company guide range system exit second quarter fiscal solid year year increase coronary device peripheral device segment overall revenue increase year year basis strength company segment also expansion be gross margin buoy optimism company be putt effort product innovation investment flipside cardiovascular system face cutthroat competition niche space cardio vascular incur net loss recently report second quarter fact company have long history net loss inception zack rank key system have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
279,PKI,steris plc ste free report report third quarter fiscal adjust earning share ep exclude net tax benefit cent result tax reform report ep come adjust ep figure be year year be zack consensus estimate revenue detailsteris generate revenue year year meanwhile top line miss zack consensus estimate organic revenue growth constant currency be year year mainly drive high single digit low double digit growth majority segment company operate segment healthcare product healthcare specialty service apply sterilization technology life science revenue healthcare product remain relatively flat year year be largely due decline capital equipment revenue offset rise consumable revenue increase service revenue revenue healthcare specialty service segment fall report basis due linen divestiture however organic revenue grow reflect growth im north america steris plc price consensus ep surprise steris plc price consensus ep surprise steris plc quote revenue apply sterilization technology rise organic revenue grow increase demand core medical device customer revenue life science segment grow growth service revenue increase consumable revenue rise capital equipment revenue organic basis revenue increase year year marginsadjusted gross margin improve basis point bps year year report quarter account synergy divest low margin business favorable product mix pricing steris witness year year rise selling general administrative expense research development expense rise accordingly adjust operate margin expand bps year year basis report quarter financial detailssteris exit third quarter fiscal cash cash equivalent compare end second quarter fiscal company have long term debt end third quarter fiscal compare end second quarter fiscal year date company generate cash flow operation year period free cash flow period be compare prior year period guidancesteris continue expect organic revenue growth fiscal constant currency basis prior fiscal zack consensus estimate fiscal revenue be peg company have raise adjust ep outlook fiscal adjust ep be now project range comparison previously provide range zack consensus estimate fiscal adjust ep be peg guide range takesteris exit third quarter fiscal mixed note be encourage favorable underlie market trend new product service offering further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change be expect better align operation zack rank key pickssteris have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
280,PKI,cerner corp cern free report report adjust fourth quarter earning cent share cent year quarter figure also miss zack consensus estimate cent revenue rise year year marginally miss zack consensus estimate last month cerner have have favorable run bourse stock have return compare industry gain cerner corporation price consensus ep surprise cerner corporation price consensus ep surprise cerner corporation quote segment detailssystem sale fourth quarter rise year year basis be drive primarily growth license software support maintenance service account revenue worth year year basis line management expectation reimbursement travel sale amount compare year quarter booking time upside revenue be primarily attribute increase booking fourth quarter booking be year year basis company report full year booking record compare level marginsgross margin fourth quarter be flat year year operate margin report quarter be contract basis point bps year year basis downside be cause surge operate expense rise year year growth be drive personnel expense related revenue generate associate cash item financial positionoperate cash flow fourth quarter be compare year quarter cerner exit fourth quarter cash cash equivalent long term debt include capital lease obligation be slightly sequential basis glancein domestic revenue grow revenue rise full year revenue be compare adjust earning share be compare gross margin be contract bps full year system sale account total revenue support maintenance service contribute whopping reimbursement travel segment represent mere total revenue guidancecerner expect first quarter revenue zack consensus estimate same fall project range revenue be project range zack consensus estimate same lag project range first quarter adjust earning share be project range cent figure lag zack consensus estimate cent full year adjust earning share be estimate range figure be higher zack consensus estimate further company expect first quarter new business booking range takecerner end fourth quarter mixed note company see significant surge booking grow revenue however dwindle earning be concern moreover sale margin be partially affected thank lower margin technology resale result higher mix device resale management large complex opportunity pipeline drive booking report quarter be likely drive booking quarters ahead zack rank other stock considercerner carry zack rank buy few other top rank stock report solid result be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
281,PKI,medtronic plc mdt free report report third quarter fiscal adjust earning share ep beating zack consensus estimate penny earning rise year year adjustment quarter primarily include impact restructure charge intangible asset amortization divestiture related item acquisition related item adjust unfavorable foreign exchange impact penny adjust ep be adjustment company report net loss share compare cent previous year include net tax expense related tax reform total revenue report quarter gross constant exchange rate cer basis report basis top line surpass zack consensus estimate foreign currency fluctuation favorably impact medtronic third quarter revenue quarter review sale total revenue fall year year cer develop market revenue totale total revenue reflect increase cer report emerge market revenue total revenue amount cer report medtronic plc price consensus ep surprise medtronic plc price consensus ep surprise medtronic plc quote segment company currently generate revenue major group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv mitg now include surgical innovation si respiratory renal rgr division divestiture patient care deep vein thrombosis compression nutritional insufficiency enteral fee business rtg comprise spine brain therapy specialty therapy pain therapy segment diabetes group incorporate intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division cvg revenue improve cer report drive strong balanced growth division crhf sale totale year year cer report come back growth arrhythmia management lead high teen growth atrial fibrillation solution cer amplify penetration micra transcatheter pace system strong uptake tyrx absorbable antibacterial envelope apart strong demand company suite quadripolar cardiac therapy pacemaker crt growth mechanical circulatory support drive heart failure division revenue csh revenue be cer report back low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk moreover continue uptake resolute onyx drug eluting stent unite state japan revive coronary business apv revenue register growth cer report drive continue adoption valiant stent graft system peripheral be drive double digit growth percutaneous transluminal angioplasty drug coat balloon moreover solid contribution venaseal closure system drive high single digit growth endovenous mitg worldwide sale reach mark year year increase cer report basis high single digit growth si low single digit growth rgr cer rtg worldwide revenue be year year cer report low double digit growth brain therapy mid single digit growth specialty therapy high single digit growth pain therapy cer however revenue spine business remain flat cer year year basis moreover revenue diabetes group increase cer report marginsgross margin report quarter expand basis point bps rise gross profit adjust operate margin expand bps year year owing rise research development expense uptick selling general administrative expense other expense report quarter totale compare year quarter reiterate fiscal constant currency revenue ep guidance company maintain full year revenue growth projection range cer however company revise foreign currency fluctuation estimation be now project have positive impact fiscal result compare estimate earlier zack consensus estimate revenue remain fiscal adjust earning share growth be still expect range cer currency translation be likely have adverse impact cent compare earlier expectation negative effect cent zack consensus estimate fiscal earning be peg fourth quarter fiscal medtronic expect currency translation have favorable impact revenue currency translation be expect affect fourth quarter earning share cent takemedtronic exit fiscal third quarter solid note company demonstrated improve segmental performance cer growth business segment however escalate cost continue be concern moreover major business group contribute solid top line growth cer highlighted sustainability group region addition display successful integration achievement synergy target be also encourage company solid growth trend unite state well healthy global acceptance advanced therapy apart product innovation company be focuse geographical diversification business moreover company recent receipt fda approval riptide aspiration system neurovascular unit rtg business buoy optimism add valuable tool company acute ischemic stroke ais product portfolio zack rank peer have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
282,PKI,feb issue update research report myriad genetic inc mygn free report stock carry zack rank hold salt lake city ut base molecular diagnostic provider have be outperform broader industry past month company have rally industry decline myriad genetic exit second quarter fiscal promising note company particularly observed strong growth genesight testing revenue company molecular diagnostic portfolio have be gain prominence medtech space late be particularly upbeat newly launch range product myriad genetic have be record strong volume endopredict genesight test prolaris testing space volume continue grow double digit fiscal second quarter particular myriad genetic be focuse drive revenue commercialize innovative product include vectra da prolaris mypath melanoma myriad genetic companion diagnostic endopredict myplan lung cancer test earlier management expect product generate revenue more fiscal moreover myriad genetic have be consistently gain reimbursement approval report quarter company announce finalization lcd noridian endopredict thereby expand total coverage market also prolaris test be evaluation revise nccn guideline have be cover medicare patient intermediate risk also order gain reimbursement coverage vectra da genesight testing platform company have be undertaking certain measure furthermore raise fy guidance instill confidence be upbeat growth new product volume expand reimbursement new product increase international rna kit revenue meanwhile myriad genetic face competition key bracanalysis market company expect competition intensify owing advancement technology believe competitive headwind reduce price expensive test provide company impede margin improvement well moreover company receive considerable portion revenue pay portion expense foreign currency be risk exchange rate fluctuation foreign currency dollar key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
283,PKI,jan issue update research report integra lifescience holding corporation iart free report stock carry zack rank hold past year integra lifescience have be trading broader industry stock have gain compare gain industry integra lifescience have be witness key development overseas front international sale specialty surgical increase last report quarter drive strength door repair tissue ablation franchise asia pacific europe accord company acquisition codman effectively double company international business segment orthopedic tissue technology international sale increase double digit largely incremental revenue derma science moreover consistently strong performance orthopedic tissue technology segment buoy optimism notably company regenerative technology be largest franchise orthopedic tissue technology last report quarter company register mid single digit growth franchise primarily addition derma science strong growth inpatient skin portfolio moreover integra lifescience introduce several product have expand solution portfolio unite state hernia repair market european breast reconstruction market spur growth be also encourage company pillar strategy optimize execute accelerate growth accord management help company optimize infrastructure deliver commitment improve plan communication grow launch product internal development geographic expansion strategic acquisition however integra lifescience face significant competition surgical implant medical instrument market company need be innovative product front fend competition moreover consolidation industry lead intense pricing pressure further company generate significant revenue international business increase vulnerability adverse currency movement key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report resm rmd free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank resm have long term expect earning growth rate stock carry zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
284,PKI,abiom inc abmd free report report third quarter fiscal adjust earning cent share easily beating zack consensus estimate cent moreover adjust earning share grow whopping year year basis revenuesin report quarter revenue increase roughly year year basis outpace zack consensus estimate upside be support robust performance impella heart pump product line company witness month impressive impella performance quarter quarter review product revenue totale reflect increase compare prior year quarter funded research development revenue accounting rest total revenue decline year year impella abiom flagship product line have continue be growth catalyst reflect stellar performance report quarter unite state pci cardiogenic shock indication establish new quarterly record company impella adoption increase total high risk pci emergency patient outside unite state revenue impella heart pump totale be year year further abiom open new site impella rp total hospital set record patient support abiom inc price consensus ep surprise abiom inc price consensus ep surprise abiom inc margin report quarter be expand basis point bps year quarter have be favorably impact higher production level company produce record number pump operate margin be expand impressive bps year year basis upside be attributable strong revenue growth have partially offset increase research development selling general administrative expenditure financial positionin third quarter abiom generate cash operate activity end third quarter cash cash equivalent marketable security totale company currently have debt be not currently cash income tax payer company officially close purchase danver massachusett global headquarters guidance raisedbase strong third quarter performance company increase fiscal revenue guidance again earlier expectation zack consensus estimate fall project number fourth quarter revenue be estimate approximately year year basis zack consensus estimate fourth quarter revenue fall anticipate figure guidance operate margin fiscal have also be raise approximately earlier expectation take abiom exit third quarter fiscal better expect result revenue margin quarter company witness breakthrough term record revenue earning growth impella product pipe line continue be forerunner aid company gain solid global foothold also company be progress field heart recovery management be optimistic capture market opportunity be also impressed company strong margin performance company balance sheet be debt free fortify financial position end report quarter however cutthroat competition niche space continue be woe zack rank other stock considerabiom carry zack rank buy few other top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
285,PKI,pacific bioscience california inc pacb free report report loss cent share fourth quarter penny narrower zack consensus estimate also figure be narrower year quarter report loss cent strength china asia contribute company bottom line improvement report period full year report loss share be cent wider year tally cent fourth quarter revenue exceed zack consensus estimate dip year year basis notably dna sequence market be highly competitive due presence several establish player cutthroat competition niche space be primary reason year year top line decline segment detailsproduct revenue rise almost service other revenue deteriorate year earlier quarter almost total product service other revenue fourth quarter be higher prior year number pacific bioscience california inc price consensus ep surprise pacific bioscience california inc price consensus ep surprise pacific bioscience california inc quote consumable revenue quarter review be year year basis mark metric eighth consecutive quarter growth continue consumable sale momentum upside be drive increase utilization company grow install base sequel system instrument revenue fourth quarter be year year basis higher shipment instrument take place latter part early company have record contractual revenue quarter margin detailsin fourth quarter pacific bioscience generate gross profit percentage revenue gross margin quarter be basis point year year operate expense fourth quarter totale compare year year basis expense quarter totale year selling general administrative expense period be compare fourth quarter company incur operate loss quarter wider loss year financial updatecash investment end be compare end outlookbanking better expect fourth quarter show pacific bioscience expect revenue grow year figure translate approximately total revenue term company anticipate first quarter revenue be slightly lower report count fourth quarter due seasonality bioscience end fourth quarter promising note consumable revenue platform act significant positive pacific bioscience quarter sale momentum china continue remain strong company recent receipt order sequel system premier sequence service provider bgi outlook look encourage well major concern dna sequence market breed stiff competition several establish player dominate market aggressive rivalry niche space be headwind also higher operate expense be likely mar prospect company have zack rank hold company report solid earning resultsa few better rank stock report solid earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently announce third quarter fiscal result adjust earning share cent bottom line soar year year revenue report quarter rise year year basis perkinelmer release fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal narrower year figure cent top line improve year year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
286,PKI,edward lifescience corporation ew free report fourth quarter adjust earning share ep come cent exclude net expense share impact tax reform report ep come cent adjust ep figure beat zack consensus estimate cent however adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business full year adjust ep come beating zack consensus estimate moreover figure beat year number sale detailsfourth quarter sale improve moreover figure beat zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation net revenue totale outpace zack consensus estimate figure also improve year number revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance surgical heart valve therapy critical care product line too edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quote segment detailsin fourth quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt sale totale year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system solid uptake core product outside unite state critical care sale be report quarter represent increase fourth quarter solid growth product category be drive strong growth company core product mainly unite state china marginsin fourth quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf be however partially offset shutdown company manufacturing plant switzerland sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment expenditure increase year year owing continue investment transcatheter aortic valve mitral valve program adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit cash cash equivalent short term investment compare end long term debt totale compare report previous year cash flow operate activity be exclude capital spending free cash flow be quarter average diluted share outstanding be guidance raisededward lifescience have raise sale expectation high end previously project range zack consensus estimate full year revenue be well guide range adjust ep expectation have also be raise previous range zack consensus estimate full year adjust ep stand low end company guide range first quarter company project sale zack consensus estimate revenue be company project range company estimate adjust ep meanwhile zack consensus estimate adjust ep be be also company forecast range takeedward lifescience exit fourth quarter solid note strong transcatheter valve sale domestic market well overseas be major positive company also perform well gross margin front management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy however tough competition cardiac device market reimbursement issue continue challenge zack rank key picksedward lifescience have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank strong buy stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
287,PKI,share perkinelmer inc pki free report rally new week high oct close tad lower represent strong year date return approximately better same time frame perkinelmer provide scientific instrument consumable service pharmaceutical biomedical environmental testing chemical general industrial market worldwide company currently have zack rank hold majority last month company share price have considerably outperformed broader industry stock have rally month slightly higher industry gain just notably perkinelmer have market cap take stable performance stock consideration expect perkinelmer scale higher come quarters company long term growth also hold promise spectrum broad perkinelmer expand product portfolio be help market share boost organic growth first half year organic growth have be company year year basis short span time perkinelmer new product gain significant traction consumer believe product continue boost company market share area diagnostic research environment estimate revision trend solid estimate revision trend perkinelmer be favorable moment full year analyst moved north compare movement opposite direction last month result full year estimate inched share current quarter analyst moved north compare movement opposite direction last month zack consensus estimate current quarter earning rise cent share same time frame perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc drive growth acquisition strategic partnership have be key catalyst perkinelmer year earlier year company announce plan acquire euroimmun medical laboratory diagnostic ag approximately cash deal be expect close fourth quarter buyout expand perkinelmer reach autoimmune allergy diagnostic market acquisition also reinforce company capability pertain new infectious disease chinese market management acquisition be expect add cent cent adjust earning guidance raise perkinelmer revise adjust earning guidance full year company now expect adjust earning share band previously provide range key picksa few better rank stock broader medical sector be sonova hold sonvy free report idexx laboratory inc idxx free report luminex corporation lmnx free report sonova luminex have zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate luminex come positive earning surprise last quarter stock have long term expect earning growth rate trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
288,PKI,vwr corporation announce open new kit center skalice czech republic eve company be take avantor vwr new square foot facility be strategically locate be helpful company business high prospect emea europe middle east africa region notably new center particularly help expand therapak acquire vwr exist footprint europe advanced facility comprehensive kit service regional well global customer location wise new center assist company vwrcatalyst offer grow apart proximity site major industrial freight carrier hub enhance service level compare vwr current model facility be fully operational oct notably vwrcatalyst clinical biorepository service lend complete solution global regulate research product development client pharma biopharma manufacturing clinical trial industry earlier vwrcatalyst acquire laboratory medical equipment ancillary supplier mesm international biorepository service organization epl archive regard note last couple year vwr emea apac asia pacific segment have be experience increase comparable net sale backed several strategic initiative implement recent time include series plan significantly upgrade information technology infrastructure optimize distribution network modify marketing scheme recently report second quarter organic basis net sale emea apac improve go forward management expect emea apac segment continue run strong historical progress however presence large number player have make medical device market intensely competitive general vwr compete player thermo fisher scientific tmo free report agilent technology inc free report perkinelmer inc pki free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
289,PKI,aug issue update research report waltham base perkinelmer inc pki free report company provide scientific instrument consumable service pharmaceutical biomedical environmental testing chemical general industrial market worldwide company currently have zack rank hold perkinelmer expand product portfolio be help company market share worldwide short span time new product have gain significant traction consumer believe product continue boost company market share area diagnostic research environment moreover perkinelmer be well position benefit investment area cancer immunotherapy well rise trend outsource instrument maintenance scientific service long term acquisition strategic partnership have be key catalyst perkinelmer year earlier year company announce plan acquire euroimmun medical laboratory diagnostic ag approximately cash deal be expect close fourth quarter acquisition euroimmun medical laboratory diagnostic expand perkinelmer reach autoimmune allergy diagnostic market acquisition also reinforce company capability pertain new infectious disease chinese market management acquisition be expect add cent cent adjust earning perkinelmer continue acquire large number company improve revenue opportunity add integration risk frequent acquisition also negatively impact balance sheet form high level goodwill intangible asset frequent acquisition be also distraction management impact organic growth stock performance share price movement past year have be unsatisfactory company represent return almost bit lower broader industry return almost company have be witness weakness academic market outside unite state furthermore lackluster performance europe impact company third party logistic second quarter estimate revision trend have be favorable perkinelmer last month current quarter estimate moved north compare movement opposite direction full year estimate moved north same time frame have have significant impact magnitude estimate current quarter estimate increase full year estimate inched same time frame key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
290,PKI,waltham base perkinelmer inc pki free report worldwide provider product service solution diagnostic research laboratory service market report second quarter adjust earning cent share line zack consensus estimate company report adjust revenue approximately come zack consensus estimate however come year quarterly revenue segment analytical solution da revenue totale second quarter compare year quarter marked rise organically meanwhile operate profit margin percentage revenue second quarter be prior year quarter level diagnostic segment segment revenue be second quarter compare year quarter imply increase organically meanwhile operate profit margin percentage revenue segment second quarter be year quarter margin detailsadjust gross margin percentage revenue be quarter basis point bps year year downside be result impact acquisition divestiture complete adjust selling general administrative sg expense percentage revenue be bps year quarter research development expense percentage revenue rise bps quarter result company overall adjust operate margin continue operation come net revenue rise bps year year basis perkinelmer inc price consensus ep surprise perkinelmer inc price consensus ep surprise perkinelmer inc quotefinancial detail first half perkinelmer operate cash flow continue operation be compare prior year period company finished quarter approximately debt guidance company revise adjust earning guidance full year perkinelmer now expect adjust earning share band previously provide range key have zack rank hold better rank stock broader medical sector include edward lifescience corporation ew free report abiom inc abmd free report dextera surgical inc notably edward lifescience sport zack rank strong buy abiom dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month abiom yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
291,PKI,boston scientific corporation bsx free report post adjust earning share ep cent fourth quarter year quarter figure remain line zack consensus estimate fall company guide range cent adjust ep adjustment take consideration estimate net income tax charge related deem repatriation unremitted earning foreign subsidiary partially offset benefit related re measurement company defer taxe arise lower corporate tax rate adjustment company report loss cent share compare ep cent year period full year adjust ep come increase year number however be line zack consensus estimate full year adjust ep also remain company project band revenue detailrevenue fourth quarter be year year report basis operational basis constant exchange rate cer tally remain line company earlier announce preliminary sale result exceed zack consensus estimate revenue be report basis operational basis count boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoteorganic revenue growth fourth quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically fourth quarter company achieve operational growth unite state organically europe asia middle east africa region emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively fourth quarter second largest contributor boston scientific top line be rhythm management comprise cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm decline defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin fourth quarter expand basis point bps year year rise cost product sell adjust operate margin improve bps report quarter quarter selling general administrative expense go research development expense rise royalty expense decrease quarter guidanceboston scientific have provide guidance company project current year earning range annualize growth report basis increase organic basis cer include contribution approximately bps symetis zack consensus estimate current year revenue be peg guide range adjust ep guidance be issue range zack consensus estimate be guide band company also provide first quarter financial outlook adjust earning be expect band cent share revenue consensus mark ep stand cent revenue takeboston scientific post mixed fourth quarter performance earning line zack consensus estimate revenue ahead mark however balanced growth business line geography be impressive also gradually improve foreign exchange scenario have also start contribute company overall topline performance promising view be more encourage indicative overall bullish trend continue term boston scientific be leave stone unturned strengthen core business invest new technology well global market accounting higher sale geography fourth quarter be also optimistic company gain number product approval domestic overseas market recent development worth mention be fda approval company vercise deep brain stimulation system treat symptom parkinson disease spectra wavewriter spinal cord stimulator system simultaneously provide paresthesia base sub perception therapy company have also invest millipede privately hold company have develop iris transcatheter annuloplasty ring system treat severe mitral regurgitation zack rank key picksboston scientific carry zack rank hold few better rank stock report solid earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent bottom line soar year year revenue report quarter rise year year basis perkinelmer release fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal narrower year figure cent top line improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
292,PKI,headquarter waltham perkinelmer inc pki free report provide scientific instrument consumable service pharmaceutical biomedical environmental testing chemical general industrial market worldwide company be expect release second quarter fiscal result aug close bell perkinelmer report first quarter adjust earning share cent beating zack consensus estimate penny notably adjust earning surpass management guide range cent cent company report adjust revenue comfortably beat zack consensus estimate interestingly revenue be management guide range let take look thing be shape prior second quarter earning announcement factor upbeat second quarter perkinelmer project revenue range represent organic revenue growth approximately notably include foreign exchange headwind second quarter adjust earning share be forecast range cent cent expansion asia perkinelmer acquire goa india base tulip diagnostic private ltd undisclosed amount tulip be acquire early january be bullish buyout help perkinelmer tap opportunity emerge market diagnostic takeover be also likely strengthen perkinelmer foothold infectious disease testing space foreign exchange volatility increase exposure international market enhance risk foreign exchange volatility fluctuation currency exchange rate adversely impact company international sale due sluggish european economy revenue earning be likely be affected adversely company do not hedge exposure currency fluctuation estimate revision perkinelmer estimate revision trend remain stable moment current quarter analyst moved south compare upward revision last month current quarter earning estimate stand cent share earning whispersour proven model do not conclusively show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp perkinelmer be most accurate estimate zack consensus estimate stand cent share uncover best stock buy sell re report earning esp filter zack rank perkinelmer currently carry zack rank favorable zack rank increase predictive power esp company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision perkinelmer inc price ep surprise perkinelmer inc price ep surprise perkinelmer inc quotestock warrant lookhere be few company want consider proven model show have right combination element post earning beat quarter haemonetic corporation hae free report have earning esp zack rank see complete list today zack rank stock here halyard health inc have earning esp zack rank bio rad laboratory inc bio free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
293,PKI,conm corporation cnmd free report report fourth quarter adjust earning cent share beating zack consensus estimate cent moreover earning improve year year basis management upside be drive strong performance general surgery orthopedic segment revenue surpass zack consensus estimate further revenue surge year year basis fourth quarter domestic sale total revenue improve year year international sale represent total revenue increase year year basis conm corporation price consensus ep surprise conm corporation price consensus ep surprise conm corporation quoteover last year conm have have favorable run bourse stock have return compare industry rally segment surgery revenue segment totale year year business domestic category decline management be optimistic exit quarter growth mark first upside witness decline consecutive quarters general surgery segment deliver revenue worth report quarter year year quarter surgery consistent performer worldwide constant currency cc basis general surgery grow post eighth straight quarter positive gain previous quarter segment deliver growth year year basis cc sale segment totale additionally domestic general surgery grow back solid growth advanced surgical endoscopic technology deliver decent performance fourth quarter full year continue innovation courtesy management steady focus innovation fiscal new product have be introduce transcend previous goal total number product innovation last year be company consistently direct focus research development international business high report eighth consecutive quarter positive return international general surgery report growth cc meanwhile international orthopedic surgery report growth cc international business conm display stellar performance yet fiscal year marginsadjusted gross margin expand basis point bps net revenue management year year improvement be attributable favorable foreign exchange rate favorable impact product mix operate margin also expand bps be partially offset increase expense research development financial positioncash flow operation be prior year quarter free cash flow fiscal be prior year quarter notably company long term debt decline year year basis guidance company expect full year sale growth range cc adjust earning share be project range fiscal research development expense be expect range percentage sale further company project operate cash flow be expect result free cash flow fy fiscal revenue totale prior year quarter domestic revenue increase year year back strong performance general surgery international revenue improve cc drive growth general surgery orthopedic adjust earning share full year be prior year quarter revenue orthopedic surgery segment totale prior year segment contribute full year revenue revenue general surgery totale prior year segment contribute full year revenue takeconm have deliver stellar performance fourth quarter beating earning revenue estimate performance company business segment have be commendable orthopedic surgery rebound quarters decline solid focus innovation continue drive sale gain leverage international market raise guidance shrink debt instill optimism however higher research development expenditure be likely be concern continue affect operate margin intense competition niche space add conm wo stock worth lookconm carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank strong buy stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
294,PKI,qiagen qgen free report fourth quarter adjust earning share ep come cent exclude tax charge cent share impact tax reform notably roughly cent share charge include cash item be derive revaluation defer taxe other tax provision report loss come cent share adjust ep figure be year year figure beat zack consensus estimate penny constant exchange rate cer company report adjfull year adjust ep come compare year quarter figure also surpass zack consensus estimate revenue detailnet sale actual rate fourth quarter grow year year basis cer also top line surpass zack consensus estimate qiagen price consensus ep surprise qiagen price consensus ep surprise qiagen quote full year net sale grow same cer year quarter figure surpass zack consensus estimate region wise sale americas revenue grow cer revenue europe middle east africa asia pacific japan increase respectively sale top emerge market exhibit growth year year cer quarter review segment detailqiagen primarily generate revenue molecular diagnostic apply testing pharma academia represent net sale respectively report quarter molecular diagnostic sale be cer sale derive apply testing rise cer pharma sale rise cer fourth quarter academia sale improve backed grow demand operational updateadjusted operate income exclude restructure charge increase year year fourth quarter also adjust operate margin expand basis point financial updateqiagen exit full year cash cash equivalent precede quarter net cash operate activity be year moreover company report full year free cash flow compare year period qiagen have announce new commitment return shareholder open market repurchase return shareholder end notably share be repurchase frankfurt stock exchange organic growth net sale be expect be cer exclude business portfolio change well acquisition stat dx launch plan second half company expect total adjust net sale be zack consensus estimate net sale be peg qiagen expect underlie growth adjust ep approximately cer be however expect decline due dilution cent cer owing tax reform adjust tax rate anticipate dilution cent development qiastat dx system accretion penny share share repurchase plan zack consensus estimate adjust earning be peg first quarter adjust net sale growth be expect zack consensus estimate net sale stand be guide range moreover first quarter adjust ep be project cent zack consensus estimate adjust earning be peg cent guide range takeqiagen end fourth quarter solid note be impressed year year growth segment company also deliver strong performance respect operate margin meanwhile commitment return more shareholder increase repurchase reflect solid cash position market be also look forward recently inked agreement qiagen buy privately hold developer next generation multiplex diagnostic fully integrate step molecular analysis certain well know syndrome used novel system base real time proven qiagen chemistry pcr technology flip side competitive landscape strong reliance collaboration remain major overhang zack rank key picksqiagen have zack rank sell few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent rise year year revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
295,PKI,thermo fisher scientific inc tmo free report report better expect performance fourth quarter adjust ep come beating zack consensus estimate year quarter figure report basis fourth quarter ep marked decline year year bottom line figure include time tax provision associate recent enactment tax reform legislation unite state full year adjust ep come year period ahead zack consensus estimate quarter ep also exceed company provide guidance range revenue quarter come year year top line also outpaced zack consensus estimate full year revenue be year period surpass zack consensus estimate moreover revenue count stand company guide band quarter detailorganic revenue fourth quarter grow year year acquisition increase revenue currency translation positively impact total revenue thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quote thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment total revenue improve year year analytical instrument segment sale rise represent acquisition fei company revenue laboratory product service segment surge reflect buyout patheon august specialty diagnostic segment record rise gross margin fourth quarter be basis point bps year year improvement gross profit adjust operate margin contract bps rise selling general administrative expense increase research development expense company exit year cash cash equivalent compare end full year net cash provide operate activity be compare year period company provide financial outlook earning conference call bottom linethermo fisher end fourth quarter promising note adjust earning revenue beating zack consensus estimate be encourage company solid international performance strong year year growth asia pacific emerge market china south korea middle east also series product launch major progress precision medicine initiative benefit company performance thermo fisher acquisition fei company have already start boost analytical instrument portfolio also company deploy strategic acquisition add lead biopharma contract development manufacturing service patheon significantly enhance company value proposition biopharma customer patheon have start contribute company laboratory product service segment zack rank key picksthermo fisher have zack rank hold better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning prior year quarter revenue report quarter increase year year constant exchange rate cer perkinelmer release fourth quarter adjust earning cent company report adjust revenue approximately top year quarter accuray announce loss cent second quarter fiscal cent narrower year figure total revenue gain year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
296,PKI,maintain streak positive earning surprise stryker corporation syk free report report fourth quarter adjust earning share beating zack consensus estimate penny revenue outpaced zack consensus estimate notably revenue improve year year adjust earning share increase year quarter upside primarily be attribute organic sale growth report quarter organic growth unite state be year year basis same ous be management fourth quarter result be drive research development innovation well stellar performance company mako total knee application stryker corporation price consensus ep surprise stryker corporation price consensus ep surprise stryker corporation quote last year stryker have favorable run bourse stock have return compare industry rally segment revenue segment totale year year constant currency cc revenue increase cc segment deliver organic growth cc courtesy strong performance unite state notably region witness organic growth quarter such gain indicate robust demand company print product foot ankle portfolio mako platform medsurg sale segment totale year year basis cc revenue increase cc internationally medsurg report constant currency growth organic sale growth indicate strong performance europe australia neurotechnology spine segment deliver sale worth year year cc revenue improve cc neurotechnology spine witness growth cc organic growth year year basis show strong demand product target coil ais cmf company neuropowered instrument further spine business unite state also post positive number bolster high demand ivs print interbody tritanium product quarter highlightsmako momentum continue fourth quarter mako total knee platform drive stryker earning mako robot installation totale globally unite state additionally company have first robot sale japan approval mako be expect end surgeon have be trained report quarter integration mako moreover mako total knee procedure be more competitive surgeon used triathlon total knee implant first time mako utilization rate have surge more year year basis company exit year mako robot install hospital represent customer base edge fourth quarter stryker continue invest internal innovation expense totale sale report quarter full year basis marginsadjusted gross margin fourth quarter be flat year year management gross margin be affected productivity issue associate continue recovery puerto rico manufacturing facility operation facility be disrupt thank natural calamity further unfavorable pricing integration risk dent margin operate margin quarter be net sale basis point year quarter glanceon full year basis revenue grow adjust earning increase orthopedic segment report net sale medsurg account total sale neurotechnology spine contribute total revenue fy guidancestryker expect net sale be positively impact courtesy favorable foreign exchange rate adjust earning be expect range first quarter earning guidance be company anticipate organic sale growth range management announce capital expenditure range compare approximately financial positionstryker continue maintain strong balance sheet cash cash flow operation be approximately total debt end year amount takestryker corporation exit fourth quarter full year impressive earning revenue figure company solid product portfolio outstanding mako total knee performance initiative buoy optimism however high debt sage product recall issue be concern zack rank key picksstryker carry zack rank hold few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter improve year year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
297,PKI,hill holding inc hrc free report report first quarter fiscal adjust earning share ep cent reflect increase year quarter adjust earning surpass zack consensus estimate be well company project range cent strong bottom line performance be backed solid core revenue growth continue margin expansion strategic investment drive growth cent benefit related tax reform marked consecutive quarter double digit earning growth company revenue detailsrevenue first quarter increase year year cer top line also exceed zack consensus estimate momentum core business mortara acquisition value add new product geographically revenue grow revenue outside unite state increase cer core revenue growth be cer hill holding inc price consensus ep surprise hill holding inc price consensus ep surprise hill holding inc quote segmental performancein first quarter patient support system revenue drop year year cer segment domestic revenue decline however adjust divestiture core revenue increase nominally prior year revenue front line care segment include welch allyn respiratory care mortara increase cer apart gain mortara performance be drive contribution new product strong growth thermometry blood pressure monitoring device double digit growth respiratory care business surgical solution segment revenue increase cer international growth drive strong momentum middle east europe revenue increase negative hurricane impact growth be backed record placement integrate table motion contribution product iled new ts mobile operate table marginsreport gross margin fiscal first quarter be bps year year increase cost revenue company witness gross margin expansion account increase revenue adjust gross margin grow bps back company consistent initiative portfolio diversification benefit cost sourcing efficiency product launch gain mortara adjust operate margin improve bps outlookin view promising first quarter performance hill have raise fiscal guidance have also provide second quarter estimate full year company continue expect revenue growth report basis cer exclude foreign currency mortara divestiture other strategic asset company continue expect core revenue growth hill expect adjust earning share range zack consensus estimate fiscal earning be peg revenue second quarter hill expect revenue growth report basis approximately cer core revenue be expect increase year year company expect adjust earning share zack consensus estimate second quarter earning stand revenue takehill exit fiscal first quarter strong note earning revenue beating zack consensus estimate company see solid year year increase revenue strong international growth company be also focuse product innovation research development hill have update long range financial objective outlook company expect positive impact adjust effective tax rate hill now expect drive adjust earning compound annual basis previous guidance however decline revenue patient support system segment be quite disappointing also foreign exchange remain concern zack rank key pickshill have zack rank hold few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning prior year quarter revenue quarter increase year year constant exchange rate cer perkinelmer report fourth quarter adjust earning cent adjust revenue approximately surpass year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter increase year year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
298,PKI,abaxis inc abax free report report third quarter fiscal adjust earning share cent beating zack consensus estimate moreover adjust earning rise year cent total revenuein fiscal third quarter abaxis record revenue reflect increase year top line also surpass zack consensus estimate foreign currency exchange fluctuation have favorable impact top line segment detailrevenue north america accounting total revenue rise report quarter revenue international market accounting rest improve abaxis operate main segment veterinary medical other report quarter veterinary sale account total sale medical contribute remain be generate other veterinary market revenue improve year year drive uptick veterinary consumable revenue veterinary instrument revenue be year year revenue medical market be same quarter last year lead strength piccolo instrument well medical rotor also revenue north american medical division totale year year global basis abaxis sell piccolos quarter compare year abaxis inc price consensus ep surprise abaxis inc price consensus ep surprise abaxis inc quote abaxis exhibit strong consumable growth year year quarter consumable product line total rotor revenue be year quarter global basis abaxis sell rotor unit quarter review unit year quarter hematology reagent rapid assay stat cartridge coagulation cartridge urine analysis strip also drive growth veterinary consumable revenue solid contribution feline test test canine specific lipase revenue rapid assay be major contributor top line report quarter moreover total instrument sale rise rise sale haematology stat coagulation piccolo instrument also impressive revenue vetscan ua hand hold urine chemistry analyzer launch last september contribute significantly top line operational updatesgross profit third quarter rise gross margin contract basis point bps research development expense increase year year sale marketing expense rise general administrative expense also rise resultant operate income be quarter operate margin decline bps financial updateabaxis exit fiscal third quarter cash cash equivalent short term investment compare fiscal second quarter takeabaxis exit fiscal third quarter promising note however decline gross operate margin be concern meanwhile year year increase revenue buoy optimism be upbeat company solid consumable instrument sale growth strength medical veterinary market segment meanwhile be encourage note company be initiate new sale marketing strategy regard company recently receive approval usda center veterinary biologic combination test heartworm lyme ehrlichia anaplasma vetscan flex rapid test moreover company plan sell introduce product vmx conference february abaxis plan additional launch fiscal include urine sediment analyzer accord company product drive growth long haul zack rank key picksabaxis have zack rank hold few better rank stock broader medical sector be resm rmd free report perkinelmer pki free report accuray aray free report company carry zack rank buy see complete list today zack rank strong buy stock here resm post second quarter fiscal adjust earning prior year quarter revenue report quarter increase year year constant exchange rate cer fourth quarter adjust earning cent company report adjust revenue approximately surpass year quarter accuray report loss cent second quarter fiscal cent narrower year figure total revenue increase year year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
299,PKI,perkinelmer inc pki free report report fourth quarter adjust earning cent share beating zack consensus estimate cent base waltham lead medtech company report adjust revenue approximately beat zack consensus estimate revenue also surpass year quarter figure stock have zack rank buy glanceadjust earning share be compare adjust revenue year be compare perkinelmer successfully launch number product result solid organic revenue growth further divestiture medical imaging business close euroimmun transaction be noteworthy perkinelmer inc price consensus ep surprise perkinelmer inc price consensus ep surprise perkinelmer inc quotesegment analytical solution da revenue da totale fourth quarter year quarter perkinelmer have be focuse finalize organizational change associate life science business da unit come profit da segment company report fourth quarter adjust operate income year quarter percentage revenue adjust operate profit margin be basis point bps year year diagnostic segmentrevenue be compare year quarter reflect improvement organically divestment medical imaging business acquisition euroimmun medical laboratory diagnostic ag have be major driver segment perkinelmer announce completion buyout euroimmun approximately cash december euroimmun be autoimmune testing company emerge player infectious disease allergy testing read more perkinelmer close euroimmun acquisition meanwhile operate profit margin segment percentage revenue be bps year year margin detailsadjust gross margin percentage revenue be quarter basis point bps year year downside be cause acquisition divestiture execute company expect significant gross margin expansion next year perkinelmer continue be track achieve operate margin net revenue year financial detailsat end quarter operate cash flow continue operation be approximately include euroimmun deal related cost prepay royalty company end year approximately debt cash guidance company issue adjust earning guidance perkinelmer expect adjust earning share further expect report revenue range include approximately foreign exchange tailwind approximately report revenue euroimmun perkinelmer be project organic revenue growth geographically perkinelmer expect mid single digit organic revenue growth americas europe mid high single digit organic revenue growth asia gross margin be likely expand bps year year basis first quarter perkinelmer project report revenue approximately represent mid single digit organic revenue growth adjust earning share be estimate range cent key picksother top rank stock broader medical sector be amedisys am free report bio rad laboratory bio free report abiom abmd free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate amedisys have long term expect earning growth rate stock carry zack rank abiom have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
300,PKI,jan perkinelmer inc pki free report share hit new week high close session nominally lower same day company issue dividend cent shareholder company share have return last year higher index gain also share have outperformed industry rally stock have market cap consider expect perkinelmer scale new high upcoming quarters further company have impressive long term earning growth rate look encourage project sale growth be first quarter perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote factor drive perkinelmerlet find be possible growth propeller qsight triple quad lc ms ms drive growth perkinelmer deliver comprehensive suite scientific informatic software solution aggregate datum actionable insight automate scalable way company launch new mass spectrometry platform qsight triple quad lc ms ms clinical market third quarter receive very positive response customer notably qsight be also register class instrument fda further instrument ce mark european market have also be accomplish enable be used clinical application newborn screening company other product include industry lead chemdraw software electronic lab notebook include cloud base element saas offer enterprise notebook solution tibco spotfire platform scientific datum analytic perkinelmer expand portfolio be help company market share worldwide acquisition recently company complete previously announce acquisition euroimmun medical laboratory diagnostic ag cash buyout be expect extend perkinelmer reach autoimmune allergy diagnostic market acquisition be likely enable company cure new infectious disease management be optimistic acquisition drive company growth fiscal notably acquisition tulip diagnostic recent past have be beneficial company revenue growth robust fundamental growth last year company have be witness high revenue growth multiply cagr adjust earning share witness cagr perkinelmer zack consensus estimate fourth quarter earning be peg cent year year zack consensus estimate revenue be peg year year basis meanwhile company also deliver positive earning surprise last quarter solid organic growth dampening continue headwind radionucleotide business perkinelmer continue experience favorable market trend first time more year perkinelmer witness positive organic growth region world third quarter look specifically end market pharma biotech diagnostic be expect see strong sale quarters ahead guidance raise earlier management confirm company have be advance favorably original guidance cite begin fiscal regard company raise adjust earning share guidance band compare previous range reflect company be upbeat deliver positive financial result quarters come stock worth lookperkinelmer carry zack rank buy other top rank stock broader medical space be bioverativ inc centene corporation cnc free report molina healthcare inc moh free report stock sport zack rank strong buy see complete list today zack rank stock here bioverativ have impressive expect growth rate first quarter stock have gain last year industry gain centene have project long term growth rate last month stock have rally impressive surpass industry rally molina healthcare expect long term growth rate last month stock have gain perform industry make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
301,PKI,perkinelmer inc pki free report recently announce completion buyout euroimmun medical laboratory diagnostic ag approximately cash latter be autoimmune testing company emerge player infectious disease allergy testing feel acquisition be strategic move perkinelmer lubeck germany base euroimmun have approximately employee serve customer more country financial acquisition euroimmun medical laboratory diagnostic expand perkinelmer reach autoimmune allergy diagnostic market buyout also enhance perkinelmer capability china new infectious disease market management acquisition be expect add cent cent share adjust earning management expect addition euroimmun drive expense margin company be consistently try drive inorganic growth acquisition company recently complete buyout tulip diagnostic private limit company base goa india total consideration diagnostic segment get now have advanced detection capability imaging assay development prospect deliver better more complete solution customer fact post acquisition perkinelmer complete global diagnostic portfolio get boost segment now include solution focuse reproductive health autoimmune infectious disease allergy testing gene analysis genomic offering oncology other molecular test wide range instrument reagent assay platform software offering regard company diagnostic segment grow organically year year basis last quarter believe latest development further boost growth segment stock price performance perkinelmer have be favorable last year stock have gain outperform broader industry gain almost current level compare favorably return zack rank key carry zack rank hold few better rank medical stock be athenahealth inc athn free report align technology inc algn free report luminex corporation lmnx free report notably athenahealth align technology sport zack rank strong buy luminex carry zack rank buy see complete list today zack rank stock here athenahealth have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year luminex have long term expect earning growth rate stock have gain past month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
